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Abstract 
Arthritis is a common disease characterised by chronic inflammation as well as bone and 
cartilage destruction. Proinflammatory cytokines such as interieukin-17 (IL-17), aT cell- 
derived cytokine, and Oncostatin M (OSM) a microphage cytokine, are elevated in 
rheumatoid arthritis (RA). The aim of this study was to characterise the effects of IL-17 
and OSM on the expression of receptor activator of NF-kappaB ligand (RANKL) and its 
decoy receptor osteoprotegerin (OPG) by mesenchymal lineage cells in vitro, in particular 
synovial fibroblasts and the human osteosarcoma cell line (MG-63 and SaOS-2) that are 
potentially involved in this process as they regulate osteoclastogenesis. In addition, the 
ability of IL-17 to support osteoclastogenesis in vitro was assessed. 
Human synovial fibroblasts (SFB) from RA and OA patients were contrasted with cell lines 
MG-63 and SaOS-2 and were treated with IL-17 and/or OSM for up to 48 hr. The 
expression and production of RANKL and OPG over a time course was assessed in these 
cells. To investigate osteoclastogenesis, peripheral blood mononuclear cells (PBMCs) were 
cultured with IL-17 either alone or with Macrophage colony stimulating factor (M-CSF). 
Osteoclastogenesis was analyzed after 21 days by tartrate-resistant acid phosphatase 
(TRAP), positive multinucleated cell counts, and resorption of ivory slices. 
This study demonstrated a direct role for IL- 17 in bone and cartilage catabolism through the 
induction of RANKL and OPG mRNA levels at 6 hr and 48 hr in SFB RA and OA, MG-63 
and SaOS-2. Furthermore the combination of IL-17 and OSM showed that the expression 
of RANKL and OPG was down-regulated. Co-incubation of IL-17 with or without M-CSF 
significantly enhanced TRAP+ve multinucleated cell formation. Furthermore, cultures of 
PBMC with IL-17 on ivory slices showed significantly increased resorption and when co- 
cultured with synovial fibroblasts from RA and OA patients further significant resorption. 
The addition of OPG to IL-17 cultures significantly inhibited the formation of resorption 
lacunae. The effect of IL-17 on bone resorption in vitro is mostly RANKL-dependent. 
This finding may lead to the conclusion that IL-17 significantly induces osteoclastogenesis 
in vitro. Therefore, IL-17 represents a key cytokine involved in the exacerbation of 
inflammatory joint disease, and is an important target for anti-cytokine therapies. Also 
these results provide proof of the concept that OPG production can result in effective 
therapies. 
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1 General introduction 
1.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease that links the immune system with 
bone and cartilage destruction. RA is a chronic, systemic, inflammatory disease that 
mainly affects the synovial membranes of multiple joints of the body. As the disease is 
systemic, there are many extra-articular features of the disease as well. The skeletal 
abnormalities in RA are characterised by progressive articular cartilage destruction and 
bone erosions as well as local and systemic osteoporosis. There is also major 
development of new vessels and indications of systemic inflammation, for example, up- 
regulated acute phase proteins. In more severe cases there is contribution of vessels 
and other organs (Feldmann M. et al., 1996). A diseased joint showing the major cell 
types and sites ofj oint destruction is illustrated in Figure 1.1 
Characteristic histopathological features of RA are hyperplasia of synovial lining cells 
with a dense microvasculature and infiltration by blood-derived cells, essentially 
memory T cells, plasma cells and macrophages, all cells that show signs of activation 
(Rehman Q. and Lane NE 200 1; Suzuki Y. et al., 200 1; Janossy G. et al., 198 1; Cush JJ. 
and Lipsky PE. 1988). RA, in common with many autoimmune diseases, is more often 
diagnosed in women, suggesting a role for sex hormones in this disease (Feldmann M. 
et al., 1996). This leads usually to progressive destruction of cartilage and bone, which 
occurs after attack of these tissues by the cellular synovial tissue and is believed to be 
mainly mediated by cytokine induction of destructive enzymes, predominantly matrix 
metalloproteinases (MMPs). 
It has long been hypothesized that proinflammatory cytokines excessively produced in 
areas of active inflammation may transfer signals from immune cells to osteoclasts, 
which constitute the specialised cells of bone resorption (Rehman Q. and Lane NE. 
2001). Human osteoclast (hOC) and human osteoclast-like cells (hOCL) synthesize and 
secrete high constitutive and inflammation-stimulated levels of the chemokine 
interleukin-8 (IL-8). Consequently, hOC-derived IL-8 could act as an important 
regulatory signal for bone, vascular, and immune cell recruitment and activation during 
normal and pathological bone remodeling (Rothe L. 1998; Hofbauer LC. et al., 2001). 
A recent study demonstrated that the bone-resorbing activity of multinucleated cells 
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derived from rheumatoid synovial tissue was much higher than that of osteoarthritic 
synovial tissue, and was related to disease activity (Suzuki y. et al., 2001). In addition, 
multinucleated giant cells are uncommon in the rheumatoid synovium, but some of the 
synovial lining cells appear to become multinucleated (Muller-Ladner U. et al., 1998). 
Human macrophages obtained at arthroplasty and human monocytes cultured with RA 
synovial fibroblasts have been shown to differentiate into osteoclastic bone-resorbing 
cells (Kotake S. et al., 1996; Suzuki. Y. 2001; Toyosaki-Maeda T. et al., 2001). 
However, the pathogenesis of tissue destruction in RA and the cellular and molecular 
context of this process, in particular the details of cross-talk between the immune system 
and bone metabolism, remain elusive. Functional interdependence between the immune 
and bone systems is reflected in a number of regulatory molecules such as receptor 
activator of NF-kB ligand/receptor activator NF-kB/osteoprotegerin 
(RANKL/RANK/OPG) (see table 1-1 for pseudonyms of these agents). These cytokines 
have crucial roles in the development and function of osteoclasts, dendritic cells, and T 
and B lymphocytes, as well as in thymus and lymph node organogenesis. The cytokines 
produced by immune cells may affect bone cell function and vice versa, but the full 
complexity of these interactions awaits further investigation. Therefore, disturbances of 
the immune system may affect bone metabolism, and vice versa (Kotake S. et al., 2001; 
Grevice D. et al., 2001 ). 
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7,1 
OPG', Osteoprotegerin (OPG or 
Osicocla'stogenesis inhibitory factor. (O'CIF 
RANK, -Receptor activator of NF-kB (RANK )or , 4,1 1 0ý 
Ostoclast differentiation and activation receptor (OD 
RANKL Receptor activator of NF7kB ligand (RANKL) br. - , , 
il'-,, %', 4r- (0 Osteoclast differiintiaiioý fiýtoýr 
" 0 ii liga steoprotege n nd L) or. 
' TNF-related activation-induced cytokine (TRANCE)", ,,, , 
" ` "' % TRAF ý ," "" I 
Tum'Or factor necrosis factor receptor7. 'associated - ' , ) , _ , ., Iý'. e , . 
TRAIL, " 
., 
TNF-related apoptosis-inuucing ligand 
Table 1.1. Commonly used synonyms of bone regulating factors (Hofbauer, et al., 
2000). 
1.2 Bone 
In life, bone is a rigid yet dynamic organ that is continuously remoudelled. Bone 
microstructure is patterned to provide maximal strength with minimal mass, as 
determined by the mechanical needs of the organism. Once formed, bone undergoes a 
remodelling process that involves breakdown (resorption) and build-up (formation) of 
bone, and this occurs in microscale throughout the skeleton. Imbalances of remodelling 
can result in gross perturbations in skeletal structure and function, and potentially to 
morbidity and shortening of lifespan (Boyle W, J., 2003). 
Bone can develop by one of two routes. Mesenchymal cells can differentiate directly to 
bone, as occurs in the flat bones of the craniofacial skeleton; this process is termed 
intramembranous ossification. Alternatively, cartilage can provide a blueprint or 
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template for bone morphogenesis, as occurs in the majority of the 200 + bones in the 
human skeleton. The cartilage blueprint is ephemeral and is replaced by bone in a 
process termed endochondral ossification (Reddi AH. 1981). Bone is also continuously 
modelled during growth and development and remodelled throughout the life of the 
organism in response to physical and biochemical signals. The physical signals include, 
but are not limited to, gravity, electricity, magnetism and ultrasound. Bones are a 
superb example of design architecture and engineering. They consist of cortical or 
compact bone and cancellous or trabecular bone. The outer cortical and inner trabecular 
bone network permits mechanical function and adaptation to changing mechanical 
environment and signals. Osteoporosis is a systemic skeletal disease of low bone mass, 
loss of the network of trabeculae, and deterioration of microarchitecture in bone 
trabeculae especially in postmenopausal women (Riggs and Melton, 1992). In 
developing bone, osteoblasts of mesenchymal lineage initially form woven bone that is 
subsequently modeled by osteoclasts of the hematopoietic monocyte-macrophage 
lineage (Marks SC. 1989), leading to the formation of lamellar bone with its 
characteristic concentric rings with a central blood vessel. The osteocytes and 
osteoblasts in the bone form syncytium by gap junctions and connecting canalicular cell 
processes (Vukicevic et al., 1990). The primordial signals for the lineage of bone- 
forming osteoblasts are the family of bone morphogenic proteins (Reddi, 1997). 
Further studies have demonstrated that bone modelling during development and 
remodelling throughout life are dependent upon factors that regulate the number and 
activity of both bone-forming osteoblasts and bone-resorbing multinucleated osteoclasts 
(Chambers, T. et al., 2000; Teitelbaum S. L. 2000; Boyle W, J., 2003). Deciphering the 
biochemical and molecular mechanisms that manage bone cell precursor recruitment, 
differentiation, and activity is, therefore, important for understanding both normal and 
pathological processes in bone. Bone remodelling is tightly regulated by local (ie. 
autocrine and/or paracrine) and endocrine factors. The endocrine regulation of bone 
resorption has been well known for many years. Many osteotropic hormones such as 
loc, 25 dihydroxy vitamin D3 (vitD3), parathyroid hormone (PTH), and calcitonin 
preferentially modulate the process of bone resorption and control bone remodelling 
(Teitelbaum SL. 2000). 
Many adult skeletal diseases are due to excess osteoclastic activity, leading to an 
imbalance in bone remodelling which favours resorption (Rodan GA. and Martin T. J. 
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2000). Excessive osteoclast activity is observed in many osteopenic disorders 
characterized by increased bone resorption and crippling bone damage, Such diseases 
include osteoporosis, periodontal disease, multiple myeloma, metastatic cancers, post- 
menopausal osteoporosis, Paget's disease, lytic bone metastases and RA. Local or 
generalized bone loss has also been reported in chronic infections [hepatitis, human 
immunodeficiency virus (HIV)], leukamia, auto-immune and allergic disease, and RA, 
suggesting that an activated immune system can affect bone physiology (Reddy SV and 
Roodman GD. 1998; Kotake S et. al., 1999). However, it is only recently that bone 
formation has been shown to be under endocrine control (Ducy P. et al., 2000). 
For individuals with osteoporosis, bone fractures represent life-threatening events, and 
today there are enormous numbers at risk worldwide. Recent breakthroughs in our 
understanding of osteoclast differentiation and activation have come from the analysis 
of a family of biologically related tumour necrosis factor (TNF) receptor (TNFR)ffNF- 
like proteins: osteoprotegerin (OPG), receptor activator of nuclear factor (NF)-kB 
(RANK) and RANK ligand (RANKL), which together regulate osteoclast function 
(Khosla, S. 2001). The study of this pathway is providing a deeper understanding of 
how diverse physiological and pathophysiological signals exert their effects on the 
RANK signalling pathway to induce osteoclastogenesis, bone resorption and skeletal 
remodelling, and so control bone mass. 
1.3 The osteoblast 
Osteoblasts are believed to be derived from mesenchymal cells, which further 
differentiate into osteocytes once embedded in calcified tissues (Rodan GA. 1992; Suda 
T. et al., 1992; Aubin JE. 1998). Functionally, osteoblasts are the cells within bone that 
lay down the extracellular matrix and regulate its mineralization. Morphologically, 
these cells are cuboidal in shape and located at the bone surface together with their 
precursors, where they appear as a tight layer of cells. Osteoblasts are highly anchorage- 
dependent and rely on a number of cell-matrix and cell-cell contacts, via a multiplicity 
of transmembrane proteins (connexins, cadherins, integrins) and specific receptors (for 
growth factors, hormones, cytokines) to continue cellular function and responsiveness to 
metabolic and mechanical stimuli (Ferrari SL. et al., 2000, Lecanda F. et al., 1998). 
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The lifespan of an osteoblast ranges between 3 days in young rabbits up to 8 weeks in 
humans, during which time it lays down 0.5-1.5 pni of osteoid per day (Jowsey J 1977, 
Owen M. 1972). Ultimately, some osteoblasts may become "trapped" in their own 
calcified matrix, changing their phenotype and developing into osteocytes. These cells 
continue to survive, but considerably reduce their cell organelles and the production of 
matrix proteins. They remain attached with other similar cells but also with bone-lining 
cells (inactive osteoblasts) at the bone's surface, creating an extensive network of 
intercellular communication. There is accumulating evidence for a functional role of 
these cellular connections in sensing the need for, and directing the site of, new bone 
turnover (Donahue HJ. et al., 1995; Mosley JR. 2000). 
In cell culture, osteoblasts are almost identical to fibroblasts. The only morphological 
feature specific to osteoblasts is positioned outside the cell, in the form of a mineralized 
extracellular matrix. However, there are two genes expressed in osteoblasts selectively 
as evidence to date that bone matrix mineralization is orchestrated by osteoblasts, and 
conversely, only osteoblast-specific transcription factors have been identified: one 
encoding cbfal, a transcription factor and the other encoding osteocalcin, a secreted 
molecule that inhibits osteoblast function (Ducy P. et al., 1996,1997; Zambotti A et al., 
2002). A recent study revealed that bone morphogenic protein-7 (BMP-7), part of the 
transforming growth factor beta (TGF-P) protein superfamily, is a growth and 
differentiation factor that causes a shift in the differentiation pathway from myoblastic 
to osteoblastic phenotype in C2C12 mouse myoblast precursor cells in vitro. BMP-7 
induces the expression of osteoblastic differentiation markers (Gu K. et al. , 2004). 
1.4 The osteoclast 
1.4.1 The origin, differentiation and molecular 
characteristics of the osteoclast 
Osteoclasts are bone-resorbing polykaryons (often in the range 4-20 nuclei) that form 
fusion of mononuclear precursors and are capable of resorbing mineralised tissues. 
They are morphologically characterizied by well-developed Golgi complexes around 
each nucleus, abundant lysosomal vesicles, vesicular trafficking, and a highly polarized 
structure. Perhaps the most recognisable osteoclast features are the ruffled border 
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(striking finger-like protrusions formed by membrane and cytoplasmic undulations) and 
the sealed zone (the region of close apposition of the osteoclast ventral membrane to the 
bone surface) (Aubin JE. 2000). 
The osteoclast progenitors are of hemopoietic origin, such as colony forming unit- 
granulocyte macrophage (CFU-GM) or more differentiated monocytic cells (Udagawa, 
N. et al., 1990). The precursor cells differentiate into mature osteoclasts at the site of 
bone resorption under the control of osteotropic hormones, local factors produced in the 
microenvironment, and osteoblastic stromal cells (Suda, T. et al., 1992; Suda, T. et al., 
1995). Osteoclast progenitors are present in hemopoietic tissue. Bone marrow-derived 
osteoblastic stromal cells play an important role in the modulation of the differentiation 
of osteoclast progenitors in two different ways: one is through cell-to-cell recognition, 
and the second through production of soluble mediators such as cytokines and growth 
factors which are produced in the microenvironment mainly by osteoblast lineage cells 
but also by immune cells, endothelial cells and megakaryocytes (Chambers TJ. 1992; 
Suda T. et al., 1992; 1995; 1999; Takahashi N. et al., 1988). In addition, Feuerbach, D. 
and Feyen JH. (1997) suggested that vascular cell adhesion molecule I (V-CAM-1) is 
involved in the interaction between stromal cells and osteoclastic precursor cells during 
osteoclastogenesis, presumably most importantly during early stages of the formation of 
osteoclasts. Moreover, co-culturing of B9/BMI cells and bone marrow-derived 
endothelial cells (BMECs) promotes osteoclast differentiation, and this effect was 
blocked when these cells were separated from one another as the BMECs expressed 
factors on their surface. 
Addition of OPG to the co-culture system of B9/BM1 murine bone marrow metastasis 
and bone marrow-derived endothelial cells (BMECs) in the presence of vitamin D3 and 
M-CSF promoted differentiation of primary osteoclast progenitors to osteoclasts. OPG 
completely blocked osteoclast induction as did addition of anti-CD44 antibody (Okada 
T. et al., 2003). In other words, osteoblastic cells are supporting cells that are able to 
provide a suitable microenvironment for osteoclast differentiation in bone (Suda T. et 
al., 1992). 
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1.4.2 Osteoclast phenotype 
The phenotype of osteoclasts is quite different from that of macrophages. 
Macrophages are non-specific esterase (NSE) positive, Fc receptor positive, C3 
receptor positive, and they phagocytose foreign bodies. In contrast, osteoclasts are 
tartrate-resistant acid phosphatase (TRAP) positive, express the calcitonin receptor 
(CTR), the vitronectin receptor (ocvP3, a member of the integrin family of cell 
adhesion receptors), carbonic anhydrase II, cathepsin K and vacuolar proton- 
translocating ATPase (V-ATPase) (Rehman Q and Lane NE 2001). However, the 
remarkable essential feature of the active osteoclast is its ability to resorb bone. 
Moreover, numerous vacuoles, endoplasmic reticulum. and mitochondria are found in 
the cytoplasm of osteoclasts with a ruffled border-like structure and peripherally 
oriented filaments. V-ATPase and cathepsin K have also been demonstrated in 
multinucleated-like cells from synovial lining cells (Okahashi N. et al., 1997; 
Hummel KM. et. al., 1998; Gravallese EM. et. al. 2000; Suzuki Y. et al., 2001). 
1.4.3 Mechanism of bone resorption 
The osteoclast is responsible for bone resorption, which involves several cellular and 
molecular processes. When osteoclasts transform from the resting (non-polarised) state 
to the polarised (resorbing) state, a striking alteration occurs in the organisation of their 
cytoskeleton. The osteoclasts adhere to the surface of bone via integrin molecules, 
mostly through the vitronectin receptor and develop specialised structures called 
podosomes in the clear zone that consists mainly of F-actin. After these cytoskeletal 
changes, osteoclasts exhibit a specific bone-resorbing activity that involves acid 
demineralisation of bone by a proton transporter AT? ase (V-ATPase) and degradation 
of the bone matrix by proteinases. While a number of proteases are known to exist in 
osteoclasts, recent studies have demonstrated that the acidic cysteine proteinase, 
cathepsin K, and a neutral proteinase (MMP-9) play a crucial role in osteoclast-mediated 
matrix degradation. Both protons and these enzymes are secreted into the sealed space 
beneath the ruffled border to degrade bone (Flanagan AM. et al., 1992; Blair HC. 1998; 
Suzuki Y. et al., 2001; Boyle WJ. et al., 2003). The survival of the mature osteoclast, 
and its participation in successive rounds of bone resorption, is regulated in part by 
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hormones and cytokines (Rodan, G. A. 1998). RANKL and IL-I increase the survival 
time of the mature osteoclast in vitro and in vivo, and this may be due to the ability of 
these factors to induce nuclear factor kB (NF-kB) activity (Jimi E. et al., 1999; Lacey D. 
et al., L 2000). 
1.4.4 Regulation of osteoclast formation 
(osteoclastogenesis) 
Osteoclast formation has been studied intensively in rodent cell systems, in which cells 
of the stromal cell/osteoblast lineage have been shown to promote the differentiation of 
osteoclast precursors (Flanagan AM. et al., 1992; Chambers TJ. and Collins DA. 1992; 
Suda T. et al., 1992). Recently, culture systems have been devised for the study of 
human osteoclast differentiation. Together, these experimental systems have been 
invaluable tools in investigating the activity of molecular promoters or inhibitors of 
osteoclast formation and function. Addition of a number of hormonal and cytokine 
factors has been found to promote formation and differentiation to fully functional 
murine osteoclasts from precursor cells (Anderson DM. et al., 1997; Wong BR. et al., 
1997a, b; Yasuda H. et al., 1998; Itonaga 1, et al., 2000; Boyle WJ. 2003). 
Many local factors as well as hormones play a role in osteoclast differentiation. These 
can be classified into three categories in terms of their signal transduction: vitD3 
receptor-mediated signals; protein kinase A-mediated signals: parathyroid hormone, 
parathyroid hormone-related protein and prostaglandin E2 (PTH, PTI-IrP, PGE2 and IL- 
I); and gp130 -mediated signals [IL-6, IL-11, Oncostatin-M (OSM), and leukaemia 
inhibitory factor]. In addition, certain adhesion molecules such as intercellular adhesion 
molecule (ICAM) and vascular cell adhesion molecule (VCAM), can act as osteoclast- 
inducing factors. Moreover M-CSF/CSF-1, a product of osteoblast/stromal cells, 
regulates differentiation of osteoclast progenitors into mature osteoclasts (Chambers TJ. 
And Collins DA. 1992; Feuerbach D and Feyen JH. 1997; Suda T. et al., 1997; Suda T. 
et al., 1998; Jimi E. et al., 1999; Nakashima, et al., 2000; Norgard M. et al., 2003; Boyle 
WJ. et al., 2003). In contrast, calcitonin, interferon-y, GM-CSF, IL-4, IL-13, TGF-P1 
and 3-methylcholanthrene (3MC) inhibit osteoclast formation (Hattersley G and 
Chambers TJ. 1991; Rodan GA. 1992; Kasono K. et al., 1993; Kudo 0. et al., 2002; 
Ikeda T. et al., 1998; Ura K. et al., 2000; Naruse M. et al., 2004). However, another 
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report suggested that TGF-P enhances osteoclast formation by abrogating the 
suppressive effect of the non-adherent PBMCs, therefore maintaining the osteoclast 
forming potential of the osteoclast precursor population. The effect of TGF-P is 
context-dependent on the cytokine milieu of the microenvironment and/or the state of 
activation of the cell being targeted by TGF-P. The recent discovery of RANKL has led 
to a greater understanding of the mechanisms that regulate osteoclast formation (Massey 
HM, et al., 2001). 
Cellular interactions between osteoblast/stromal lineage cells and hematopoietic 
osteoclastic progenitors maintain osteoclastogenesis (Suda T. et al., 1999). In addition, 
Nakagawa N. et al., (1998) reported the essential role of RANKL and RANK in the 
development of osteoclasts. RANKL is preferentially expressed on osteoblast/stromal 
lineage cells whereas its receptor RANK is preferentially expressed on osteoclast 
lineage cells and dendritic cells. However, RANK is the signaling receptor essential for 
RANKL-mediated osteoclastogenesis (Nakagawa, N. et al., 1998). Binding of RANKL 
to RANK activates NF-kB and c-jun N-terminal protein kinase (JNK), which are 
associated with osteoclastic differentiation and activation (Jimi, E. et al., 1999, 
Nakashima, et al., 2000). Osteoclastogenesis also occurs under the control of bone 
marrow stromal cells (Suda T. et al., 1992). Most of these cytokines produced by 
stromal cells in bone marrow appear to be essential for osteoclastogenesis. 
At least 24 genes loci have been shown to positively and negatively regulate 
osteoclastogenesis and osteoclast activation, based on naturally occurring mutations or 
targeted knockout mutations in rodents and humans (McLean W. et al., 2001). 
Disruption of these genes blocks the development and/or function of the mature 
osteoclast, resulting in abnormally high levels of mineralized bone and cartilage, a 
condition called osteopetrosis. As a class of mutations, these genes exert their effects 
at various stages of osteoclast development and activation. Some genes act during the 
formation and/or survival of the osteoclast precursor cell (PU-1 and op/CSF-1), 
whereas other genes mediate either the ability of the precursor cell to undergo 
differentiation (RANK, p5O/p52 rel and c-fos) or the adherence and lytic function of 
the mature osteoclast (src, oc/Tcirg and CATK). Continued analysis of the unknown 
loci in this group of genes is likely to further define important control mechanisms 
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within the osteoclast and the osteoclast regulatory networks (Marks SC and Popoff SN. 
1989; Wagner EF. et al., 2001). 
1.5 Cytokines 
All cytokines have certain properties in common. They are all small molecular weight 
peptides or glycopeptides. Many are produced by multiple cell types such as 
lymphocytes, monocytes/macrophages, mast cells, eosinophils, even endothelial cells 
lining blood vessels. The immune system has many different types of cells acting 
together to counteract unwanted infections and altered cells. Cytokines play a central 
role in the modulation of the immune system. They orchestrate the cellular and 
humoral adaptive immune responses and also play a significant role in innate 
immunity. They are produced by a variety of cells, have varied functions and form a 
complex interactive system. Cytokines often act together and enhance the effects of 
one another (synergy) or may also act as antagonists. Each individual cytokine can 
have multiple functions depending upon the cell that produces it and the target cell(s) 
upon which it acts via specific receptors (called pleiotropism). Binding initiates signal 
transduction and can lead to gene activation, mitosis and cell division, cell growth and 
differentiation, cell migration or programmed cell death (apoptosis). Also, several 
different cytokines can have the same biological function (called redundancy).. 
Cytokines can exert their effect through the bloodstream on distant target cells 
(endocrine), on target cells adjacent to those that produce them (paracrine) or on the 
same cell that produces the cytokine (autocrine). Physiologically, it appears that most 
cytokines exert their most important effects in a paracrine and/or autocrine fashion. 
Their major functions appear to involve host defence or maintenance and repair of the 
blood elements. Thus cytokines may induce, amplify, prolong and terminate 
inflammation (Rogler G. and Andus T. 1998). The effects of cytokines are not limited 
to immune cells but include cells of the epithelium, endothelium, mesenchyme and 
extracellular matrix including bone and cartilage cells. 
Cytokines are categorized by their major specific function(s). There are four major 
categories of cytokines. Interferons are so named because they interfere with virus 
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replication. The colony stimulating factors are so named because they support the 
growth and differentiation of various elements of the bone marrow. The tumor 
necrosis factors (TNF) are so called because injecting them into animals causes a 
hemorrhagic necrosis of their tumors. The largest group is the interleukins, so named 
because their fundamental function appears to be communication between (inter-) 
various populations of white blood cells (leucocytes -leukin). They are produced by a 
variety of cell types such as monocytes/macrophages, T cells, B cells and even non- 
leucocytes. 
1.5.1 RANKL, RANK and OPG 
1.5.1.1 RANKL 
1.5.1.1.1 Identification and characterization 
RANKL expression is restricted primarily to stromal/osteoblastic cells and lymphocytes 
and has been demonstrated in CD3+ T cells. The ability of activated T lymphocytes to 
support osteoclast formation may provide a mechanism for the potentiation of osteoclast 
formation and bone resorption in disease states such as RA (Horwood NJ. et al., 1999; 
Anderson DM. et al., 1997; Lacey DL. et al., 1998; Yasuda H. et al., 1998). In addition, 
RANKL expressed by synovial fibroblasts is believed to be involved in rheumatoid 
bone destruction by inducing osteoclastogenesis (Takayanagi H. et al., 2000). In extra- 
skeletal tissues, RANKL mRNA and protein is detected in brain, heart, kidney, skeletal 
muscle and skin during mouse development, suggestive of the possibility of various 
other functions of the molecule. RANKL is also developmentally regulated, as 
evidenced by its expression in the intestine, liver and lung in newborn mice but not in 
the adult (Kartsogiannis. V. et al., 1999). Additionally, RANKL has been detected in 
various stromal cell lines (ST-2, MC3T3-El, hMs, primary human marrow stromal 
cells), osteosarcoma cell lines (ROS, MG-63), primary murine osteoblasts, and a murine 
monocytic cell line RAW 264.7 (Anderson MD. et al., 1997; Wittrant Y. et al., 2004). 
RANKL is a stimulatory factor for dendritic cells and is an essential cytokine signal for 
various osteoclast functions. A recent study demonstrated that both B and T 
lymphocytes might act through the RANKL/RANK/OPG cytokine system, which has 
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been independently discovered within immune and bone systems. These cytokines 
have crucial roles in the development and function of osteoclasts, dendritic cells, and 
T- and B-lyrnphocytes, as well as in thymus and lymph node organogenesis (Wong BR. 
et al., 1997; Anderson DM. et al., 1997; Yasuda H. et al., 1998; Lacey DL. et al., 1998; 
Grevice D. et al., 2001). Moreover RANKL, RANK, and OPG were detected in the 
superficial zone of normal cartilage. However, RANKL does not activate human 
articular chondrocytes (Komuro, H. et al., 2001). 
Human RANKL is a polypeptide of 317 amino acids that is a type 11 transmembrane 
glycoprotein which possesses a long extracellular stalk region followed by a receptor- 
binding core domain as shown in Fig 1.2 (Yasuda H. et al., 1998). Murine RANKL 
encodes a 316 amino acid, 35kDa protein (45kDa after N-terminal glycosylation) that 
shares 83% sequence homology with human RANKL (Wong BR. et al., 1997). 
RANKL is related to the TNF-related apoptosis inducing ligand (TRAIL; 20-34% 
homology), the CD40 ligand (38% homology), and to the Fas ligand (19% homology) 
(Lacey, et al., 1998). RANKL lacks a signal peptide and has a cytoplasmic domain at 
the N-terminus (residues 1-48), a transmembrane domain (residues 70-317), and an 
active ligand site (residues 158-317) sequence that are present in TNF ligand family 
members (Anderson DM. et al., 1997; Yasuda H. et al., 1998). 
TNI E 
N112 J. -CO011 
1 48 316 
Fig 1.2. Schematic structure of RANKL. RANKL is an OPG-binding protein. 
Domains: C, cytoplasmic; 'FM, transmembrane-, L-, extracellular. (Yasuda. It.. et at.. 
1998). 
RANKL exists in two biologically active forms; a cellular membrane bound form (40- 
45 kDa) and a soluble form (31 kDa) derived post translationally by cleavage at position 
104 or 145 (Lacey DL. et al., 1998). A variety of transmembrane proteins are 
synthesised as a membrane-bound protein, which are cleaved into a soluble form by 
ectodomain shedding (Schlondorff J. and Blobel CP. 1999; Walsh MC. and Choi Y. 
2003). Since an inhibitor for metalloproteases prevents the conversion of membrane- 
bound RANKL to its soluble form, metalloproteases appear to play a role in cleaving 
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membrane-bound RANKL (Lurn L. et al 1999). TNF-oc converting enzyme (TACE), a 
sheddase that cleaves membrane-bound TNF-oc, has been identified as a member of the 
disintegrin and metalloprotease (ADAM) family (Black R. et al., 1997). Membrane 
bound RANKL is cleaved into its soluble form by TACE (also called ADAM-17) 
(Black R. et al., 1997 and Nakashima T. et al., 2000). RANKL is more potent when 
membrane-bound, but finther investigation will be required to elucidate any true 
physiological difference. The protein in its soluble form may have different functional 
properties from that of the membrane-bound one, which is exemplified in Fas-mediated 
apoptosis elicited by Fas 1. Membrane-bound Fas I efficiently induces target cell 
apoptosis, whereas the apoptotic activity of soluble Fas I (sFas 1) was significantly lower 
than that of membrane-bound Fas I (Nakashima T. et al., 2000). However, the 
functional difference of both soluble and nonsoluble RANKL is not entirely clear 
(Walsh MC. and Choi Y 2003). Characterization of the functions of RANKL and its 
receptors have contributed significantly to the emergence of a new field of study, osteo- 
immunology, directed at examining the interplay between active immunity and 
maintenance of bone homeostasis (Walsh MC. and Choi Y. 2003; Jones DH. et al. , 
2002). 
Human RANKL was mapped to chromosome l3q14 while mouse TRANCE was 
located to the portion of mouse chromosome 14 syntenic with human chromosome 
13ql4. A recombinant soluble form of RANKL composed of the entire ectodomain 
induced JNK activation in T cells but not in B cells or in bone marrow-derived dendritic 
cells. These findings propose a role for TNF-related ligand in the regulation of the T 
cell-dependent immune response (Wong BR. et al., 1997). RANKL augments the 
ability of dendritic cells to excite naive T-cell proliferation in a varied lymphocyte 
reaction, and enhance the survival of RANK+ T cells generated with IL-4 and TGF-P. 
Therefore, RANK and RANKL seem to be necessary regulators of interactions between 
T cells and dendritic cells (Anderson DM. et al., 1997). 
1.5.1.1.2 Expression of RANKL 
RANKL is an essential factor for osteoclast formation, fusion, activation, and survival. 
In addition to the cell-bound RANKL form, activated T lymphocytes produce the 
secreted RANKL form (Figl. 3). Manabe, et al., (2001) demonstrated that 13- 
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lineage cells are a major source of endogenous RANKL in bone marrow and support 
osteoclast differentiation in vitro. Moreover, the levels of RANKL mRNA are-4ýest 
in skeletal (trabecular bone, bone marrow) and in lymphold tissues (lymph node, 
thymus, spleen, fetal liver, peyers patches) that are active in mediating the response. 
However, lower levels of RANKL are found in heart, skeletal muscle, lung, stomach, 
placenta and the thyroid gland (Lacey DL. et a)., 1998). In addition, a recent study 
with animal models suggests the involvement of RANKL in the pathogenesis of 
periodontal disease (Mog] M. et al., 2004). 
Stromal/Osteoblast cell 
, 
Vnactivated RANKU 
OPG complex 
)ý OPG 
0 RANKL 
Y RANK 
0 M-CSF 
A c-FMS 
Cell to Cell 
contact 
4ý Differentiation 
and activation 
Osteoclast Precursor Mature Osteoclast 
Fig-1.3 Regulation of osteoclastogenesis by the interaction of RANKL, OPG and 
them receptor RANK and M-CSF and its receptor c-FMS in the bone 
microenvironment. RANKL can bind to the receptor in a soluble sRANKL or cell- 
bound (cRANKL) form (Fcng X et al., 2002; Hofbauer LC. et al., 2000). 
1.5.1.1.3 Biological effects of RANKL 
Both forms of RANKL act through binding to and activating RANK. This is a cell- 
bound receptor of the TNFR superfamily that is located on osteoclast precursor cells, 
mature osteoclasts, and dendritic cells (Kong Y-Y. et al., 1999). Similarly to other 
cytokine systems [IL-1, TNF-oc], the stimulatory effects of RANK by RANKL are 
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through binding to it (Lacey DL. et al., 1998). The up-regulation of RANKL protein 
production capable of regulating aspects of early uncommitted precursor differentiation, 
fusion and activation, leads to osteoclast maturation and functions, while up-regulation 
in OPG protein production leads to osteoclast apoptosis as shown (Fig-1.4). 
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Fig-1.4 Osteoclast formation and function are regulated by RANKL/OPG. 
Includingg initiation of differentiation, fusion of preosteoclasts to form active mature 
osteoclasts, M-CSF is required only for initiation of differentiation of osteoclast 
precursors (Hofbauer LC. et al., 2000). 
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The balance of bone resorption depends on the local RANKL: OPG ratio, which is 
enhanced in bone metastases and humoral hypercalcernia of malignancy. Abnormalities 
of the RANKL/OPG system have been implicated in the pathogenesis of various 
primary and secondary bone malignancies (Hofbauer LC. et al., 2001), and excessive or 
defective production of RANKL, RANK and OPG display the extremes of skeletal 
phenotypes, osteoporosis and osteopetrosis. RANKL and OPG production in stromal 
cells and osteoblast-like cells are modulated by many osteotropic agents, including 
cytokines, growth factors, peptide and steroid hormones and vitamins (Lacey DL. et al., 
1998) as shown in (table 1-2a and b). 
Evidence indicates that RANKL and RANK are essential for bone metabolism, and play 
a critical role in the orderly development and function of the immune system. RANKL 
promotes osteoclast formation and activation, and inhibits osteoclast apoptosis (Yasuda 
H. et al., 1998; Fuller, et al., 1998). The subsequent increased number and activities of 
osteoclasts, promoted by RANKL have been shown to cause profound bone resorption 
and bone loss in vitro and in vivo (Lacey DL. et al., 1998; Fuller K. et al., 1998). In 
contrast, RANKL deficiency is associated with generalised osteopetrosis due to 
impaired osteoclastic bone resorption (Kong Y-Y. et al., 1999). OPG has been observed 
to completely antagonise the effects induced by RANKL both in vitro and in vivo. Over 
expression or exogenous administration of OPG increased bone mass and prevented 
bone loss associated with estrogen deficiency (Fuller K. et al., 1998). 
RANKL produced by osteoblastic lineage cells and activated T lymphocytes is the 
essential factor for osteoclast formation, fusion, activation, survival in vivo (Hofbaure 
LC. et al., 2001; Kong YY. et al., 1999) and increasing dendritic cell survival by 
blocking apoptosis (Anderson MD. et al., 1997). The phenotype of RANKL-deficient 
mice is characterized by a lack of lymph nodes and hypoplasia of thymus and peyer's 
patches, indicating that RANKL is essential for normal embryological development of 
lymphoid tissue (Kong YY. et al., 1999). 
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I 
F ffecs on RANKU ! Effect on 
IL-1cc 
TNF-cc 
TNF-P 
PGE2 
IL-I I 
IIA 
11-47 
IIA + oc-CD3 (T Cells) 
CD40L (dendritic cells) 
OSM 
BMP2 
TGFP 
TGFP + a-CD3 (T Cells) 
Calcium 
IGF-I 
Cyclosporin A 
Tacrolimus 
Tonomycin (T Cells) 
PMA (T Cells) 
Vasoactive intestinal peptide 
Indian hedgehog 
LPS 
Table 1.2a Shows the regulation of RANKL and OPG by regulatory factors 
and cytokines based on (Hofbauer LC, 2000; Kong Y-Y, 2000 and Walsh M. and 
Choi Y. 2003). T up-regulates; ý down-regulates; - not detennined. 
19 
Chapter- I Introduction 
E,,,: fj kc ýo ? E,,:, ffeit OPG iýc 'ii A"KL 
4ýr 
PTH 
Vitamin D3 lct, 25-(OH)2D3 
170-Estradiol 
Glucocorticoid 
Estrogen 
Table 1.2b Shows the regulation of RANKL and OPG by Calcitropic 
Hormones based on (Hofbauer LC, 2000; Kong Y-Y, 2000 and Walsh M. and 
Choi Y. 2003). T up-regulates; ý down-regulates; - not determined. 
1.5.1.2 RANK 
RANK belongs to the TNFR superfamily. Since the molecular identification of RANK, 
an abundance of reports have been published documenting its biological function and 
signalling mechanisms. 
RANK is a type I transmembrane protein and human RANK (616 amino acids) has a 
signal peptide (28 amino acids), an N-terminal extracellular domain (184 amino acids), 
a short transmembrane domain (21 amino acids), and a large C-terminal cytoplasmic 
domain (383 amino acids). The gene encoding RANK has been localised to human 
chromosome l8q22.1 (Anderson DM. et al., 1997; Hofbauer, et al., 2000; Walsh MC 
and Choi Y. 2003). The extracellular domain of RANK contains four cysteine-rich 
pseudorepeats and two N-glycosylation sites, a characteristic feature of members of the 
TNFR superfamily, including OPG. RANK has a 40% homology with CD40, although 
RANK was originally described as a receptor. on osteoclasts and dendritic cells 
(Anderson DM. et al., 1997). RANK mRNA expression has been detected in a variety 
of tissues including skeletal muscle, liver, small intestine, colon, thymus, and adrenal 
gland, as well as osteoclastic, lymphocytic, and nonlymphocytic cells. The distribution 
of RANK is restricted to osteoclasts, dendritic cells, B- and T-cell lines. Among bone 
cells, RANK is found only in osteoclast lineage cells. In dendritic cells RANK 
expression is stimulated by CD40 ligand (Anderson DM. et al., 1997; Hofbauer, et al., 
2000). 
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The important role of RANK and its ligand RANKL in the formation of osteoclasts was 
clearly recognized by genetic studies in which both RANK and RANKL knockout mice 
displayed a prominent osteopetrotic phenotype and inflammation that may explain part 
of the abnormal phenomena in diseases such as RA characterized by both inflammation 
and destruction (Dougall WC. et al., 1999). Cytokines play a central role in the 
perpetuation of synovial inflammation. The persistence of the chronic inflammatory 
response in conjunction with ongoing joint destruction (a finding in many patients with 
RA despite the use of effective anti-inflammatory agents and disease-modifying drugs) 
probably appears as a direct result of sustained recruitment, inappropriate retention and 
impaired apoptosis (Morovic-Vergles J. 2003). Osteoclast-like cells are formed in co- 
culture of peripheral blood mononuclear cells and rheumatoid synovial fibroblasts 
obtained by continued sub-cultures in the presence of vitD3 and M-CSF. The 
multinucleated cells showed all the phenotypical and functional characteristics of 
osteoclasts including the expression of TRAP, vitronectin receptors, receptors for 
human calcitonin and the ability to resorb bone. Synovial macrophages are capable of 
differentiating into osteoclasts in the presence of rheumatoid synovial fibroblasts which 
can support differentiation of monocytes/macrophages, implicating that osteoclasts 
generated within the synovial membrane are probably involved in bone destruction in 
RA (Takayanagi H. et al., 1997). Synovial cells are capable of differentiating to 
osteoclast-like cells under some circumstances, including culturing with M-CSF and 
RANKL. This suggests that bone erosion seen in RA may result from RANKURANK 
system activation by activated T cells. This opens up the possibility that OPG may have 
therapeutic effects mediated by blockade of the RANKURANK system (Saidenberg 
Kerrnanac'h N. et al., 2002). An initial study demonstrated that short term Fc-OPG 
treatment has powerful anti-erosive effects, principally on bone, even though synovitis 
is not affected. These findings indicate the potential utility of disrupting RANK 
signaling to preserve skeletal integrity in inflammatory arthritis (Romas E. et al., 2002). 
In addition, RANK and RANKL along with OPG have functions to do with lymph node 
organogenesis, dendritic cell survival and early lymphocyte differentiation (Takahashi 
N. 1999). 
Moreover, RANKL and RANK are expressed in mammary gland epithelial cells, and 
play a role in lactation (Fata, J. E et al 2000). Modulation of these systems provides a 
unique opportunity to design novel therapeutics to inhibit bone loss in arthritis, 
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periodontal disease, and osteoporosis (Theill LE. 2002). While the detailed molecular 
mechanism for each of the diverse functions of RANK is expected to be unravelled in 
the near future, there has already been extensive progress in elucidating RANK 
signalling pathways in a few specific cell types, especially osteoclasts and osteoclast 
precursor cells (Blair HC. and Athanasou NA. 2004). 
1.5.1.2.1 Biological effects and signal transduction 
RANKL binds to its receptor, RANK with high specificity and affinity. This activates a 
cascade of intracellular events, including interaction with TRAF family members, 
activation of the transcription factor NF-kB, and stimulation of the JNK pathway 
(Suada, T. et al., 1999). RANK interacts with various TRAFs through distinct motifs 
and activates NF-kB via a novel TRAF6 interaction motif, which then activates NF-KB- 
inducing kinase (NIK), thus leading to NF-kB activation. RANK most likely activates 
JNK through a TRAF2-interacting region (Darnay BG. et al., 1999; Darnay BG and 
Aggarwal BB. 1999). Moreover, RANKL activates the antiapoptotic serine/threonine 
kinase (protein kinase B Akt/PKB)) (via a signaling complex involving c-Src and 
TRAF6. An insufficiency in c-Src or accumulation of Src family kinase inhibitors 
blocks RANKL-mediated PKB activation in osteoclasts. c-Src and TRAF6 interact with 
each other and with RANK upon receptor engagement. TRAF6 enhances the kinase 
activity of c-Src leading to tyrosine phosphorylation of downstream signaling molecules, 
for example c-Cbl. These data provide evidence of cross-talk between TRAF proteins 
and Src family kinases (Wong BR. et al., 1999). RANKL also induces the expression of 
c-Fos, a component of the dimeric transcription factor activator protein-1 (AP-1). AP-1 
is composed mainly of Fos (c-Fos, FosB, Fra-I and Fra-2) and Jun proteins (c-Jun, JunB 
and JunD). c-Fos has an essential role with TRAF6 in osteoclastogenesis in both the 
differentiation and maturation of osteoclasts by establishing a link between RANK 
signalling and the expression of AP-1 proteins in osteoclast differentiation (Matsuo K. 
et al., 2000). 
TRAF adaptor proteins appear to play an important role in the signal transduction 
pathway induced by RANK. TRAFs 1,2,3,5 and 6 were shown to bind through the 
conserved TRAF domain to RANK in vitro and in transfected cells. TRAF binding 
domains are functionally important for the RANK-dependent induction of NF-kB and 
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JNK activities. Site-directed mutagenesis demonstrated that these TRAF binding sites 
exhibited selective binding for different TRAF proteins. In particular, TRAF6 interacts 
with membrane-proximal determinants distinct from those binding TRAFs 1,2,3 and 5. 
Among the TRAF proteins, TRAF6 appear to be crucial for RANK signalling in 
osteoclasts (Galibert L. et al., 1998; Kim HH. et al., 1999). Furthermore, results from 
experiments where RANK knockout cells were manipulated to express RANK mutants 
lacking the TRA176-binding region provided evidence for TRAF6 in RANK-directed 
cytoskeletal association and the resorptive functions of osteoclasts (Damay BG. et al., 
1999; Armstrong A. P. et al., 2002). TRAFs may act by transmitting the RANK signal 
to downstream targets that consist of NF-kB and JNK. Indeed, over-expression of 
TRAFs 2,5 and 6 stimulate the actions of NF-kB and JNK and the activation of JNK 
and extracellular signal-regulated kinase (ERK), but not that of p38, and appear to be 
involved in AM activation by RANK. Thus, RANK may utilize both JNK and ERK 
pathways to signal to the AM transcription factor as shown in Fig 1.5 (Hofbauer LC. 
and Heufelder AE. 2001; Lee Z. H. et al., 2000; Walsh MC, Choi Y. 2003). 
1.5.1.2.2 RANK signalling by way of NF-kB activation 
RANK signaling leads to a strong increase in the activation of NF-kB. NF-kB activity 
seems to be critical for osteoclast differentiation (osteoclastogenesis) as shown in mice 
deficient in both NF-kB proteins p5O and p52. The surprising result was that these 
animals developed osteopetrosis because of a defect in osteoclast differentiation, 
suggesting redundant functions of NF-kB I and NF-kB2 proteins in the development of 
this cell lineage (Iotsova, V. et al., 1997). NF-kB is retained in the cytoplasm as a 
complex with the inhibitory kB (IkB) protein in unstimulated cells. Stimuli that activate 
NF-kB induce the activation of IkB kinases (IKK), resulting in the phosphorylation and 
subsequent proteasome-mediated degradation of IkB. 
NF-kB then enters the nucleus where it binds to DNA target sites and exerts its 
transcriptional activity. Events that have been shown to occur after RANK stimulation 
in differentiated osteoclasts or osteoclast precursor cells include the phosphorylation and 
degradation of IkBa and the nuclear translocation and DNA binding of the NF-kB 
proteins p50, p52 and p65 (Jimi E. et al., 1999; Abu-Amer Y. et al., 2001). IKK 
functions as a complex composed of two catalytic components, IKKa and IKKP, and a 
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regulatory protein, IKKy. IKKa and IKKO are essential for the proinflammatory 
cytokine-induced activation of NF-kB (Li Z. W. et al., 1999). Therefore, IKKP might 
mediate RANK activation of NF-kB through IkB degradation. The activation of NF-kB 
inducing kinase (NIK) and IKKa is essential for the processing of the NF-kB2 precursor 
(plOO) to p52 (Senftleben U. et al., 2001) and for the phosphorylation of Ser536 in the 
transactivation domain of p65 (Jiang X. et al. , 2003). It has been shown that TRAF6- 
deficient spleen cells were defective in the RANKL-induced degradation of IkBP 
(Kobayashi N. et al., 2001). Furthermore, the recruitment of TAKI to TRAF6 in 
RANK-transfected 293 cells and the interference of NF-kB activation by kinase- 
defective TAKI in RANKL-treated RAW 264.7 cells were recently demonstrated. 
Thus, TAK I appears to be a likely downstream target of TRAF6 in the RANK to NF-kB 
signaling pathway in osteoclasts (Mizukami J. et al., 2002). 
1.5.1.2.3 RANK signalling and MAPK cascades 
The activation of mitogen-activated protein kinases (MAPKs) through RANK signalling 
has been well characterized. It has been established that members of all three MAPK 
families, ERK, JNK and p38, are activated by RANK in osteoclasts or osteoclast 
precursors (Jimi E. 1999; Lee SE. et al., 2002). Additionally, p38 and ERK play roles in 
osteoclast differentiation at least in art by participating in RANKL signalling (Lee SE. et 
al., 2002). Spleen cells derived from TRA176-deffient mice failed to activate JNK and 
p38 in response to RANKL, suggesting that TRAF6 is critical to RANK signalling 
through these MAPKs (Kobayashi N. et al., 2001). In differentiated osteoclasts, 
association of ERKI/2 and NF-kB regulate different aspects of osteoclast activation: 
ERK is responsible for osteoclast survival, whereas NF-kB regulates osteoclast 
activation for bone resorption (Miyazaki T. et al., 2000). Recently, osteoclast progenitor 
cells derived from JNKI knockout, but not from JNK2 knockout, mice were shown to 
have a reduced (but not ablated) level of RANKL-stimulated osteoclastogenesis, 
suggesting that JNKI, and not JNK2, is important for efficient osteoclast differentiation 
(David J. P. et al., 2002). The inhibition of the TRAF2-mediated activation of JNK by a 
kinase-inactive form of mitogen-activated protein kinase I (MEKK1) may suggest the 
potential involvement of this mitogen-activated protein kinase kinase kinase 
(MAPKKK) in RANK signalling (Song HY. et al., 1997). Ras has been implicated in 
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the activation of ERK via a signal transduction pathway involving CD40, a TNF family 
receptor that shares similar signalling characteristics as RANK (Kashiwada M. et al., 
1998). The TAKI/TAB2 activity that induces JNK and p38 activation was shown to be 
located downstream of TRAF6 in the RANK signalling pathway (Mizukami J. et al., 
2002). Downstream targets of ERKs and JNKs include AP-1 transcription factor, a 
dimer composed of a Fos and a Jun family protein. ERK can induce and activate c-Fos, 
while JNK can increase AP-1 transcriptional activity through the phosphorylation of c- 
Jun (Cano E. and Mahadevan LC., 1995). Mice deficent in c-Fos developed 
osteopetrosis due to a failure to commit to osteoclast lineage, underscoring the 
fundamental role of AP-1 in osteoclast development (Grigoriadis AE. et al., 1994). 
1.5.1.2.4 RANK signalling through the P13WAkt pathway 
In osteoclasts, RANK induces the activation of Akt, which is blocked by the P13K 
inhibitor LY294002 (Wong B. R. et al., 1999, Lee S. E. et al., 2002). Furthermore, 
LY294002 reduces the RANK-mediated survival response of osteoclasts (Wong BR. et 
al., 1999). The P13K inhibitor also displays a potent inhibitory effect on osteoclast 
differentiation (Lee SE. et al., 2002), which may result from a reduced survival of 
osteoclast precursor cells during differentiation. It has been shown in osteoclasts that 
RANK elevates Sre kinase activity and that RANK activation of Akt is blocked by a Src 
family kinase inhibitor or the genetic deletion of c-Src (Wong BR. et al., 1999). Thus, 
Src may play a role as mediator of RANK via P13K/Akt signals. Among the many 
molecules downstream of Src, PM and c-Cbl have been implicated in osteoclast 
adhesion signalling and bone resorption function. Src and P13K may function at the 
point where RANK and adhesion signals converge, transmitting the signals for proper 
actin cytoskeletal organization that facilitates the resorptive activity of osteoclasts 
(Duong LT. et al., 1998, Tanaka S. et al., 1996). 
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Fig 1.5 A model for RANKL-mediated signal transduction. Soluble or membrane-bound 
RANKL binds its soluble decoy receptor, OPG, or its functional receptor, RANK. Ligation of 
RANK leads to binding of the adapter TRAF6 at the proximal portion of the RANK 
intracellular domain. RANK signalling activates the mitogen-activated protein kinase 
(MAPK) JNK pathway, and the transcription factor AP- I through the kinase TGF-P activated 
kinase (TAKI). The PKB/Akt is activated by RANK through a distinct TRAF6-dependent 
mechanism. TRAF6 forms a complex with the scaffolding protein Cbl, and phosphoinositide 
. 3-kinase 
(Pl_')K), which recruits c-Src to the receptor. Activation of PKB/Akt through 3 
phosphorylation of membrane phosphatidylinositides by P13 )K requires the kinase activity of c- 
Src. Additional downstream targets of RANK include NF-kB and p38. Activation of RANK 
downstream targets results in upregulation of various pro-survival and activating factors 
important for osteoclasts, as well as differentiating factors for osteoclast precursors, including 
c-Fos. Adapted from (Walsh MC, Choi Y. 2003 )). 
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1.5.1.3 OPG/OCIF 
The functional integrity of the skeleton depends upon bone remodelling, the cycle of 
controlled resorption of bone by osteoclasts, and new bone formation by osteoblasts. 
An imbalance between bone resorption and bone formation results in osteoporosis. A 
step forward in our understanding of how osteoclastogenesis is regulated was the 
identification of OPG, a soluble protein that blocks osteoclast formation in vitro and 
bone resorption in vivo. OPG is a secreted TNFR-related protein that regulates bone 
density and bone mass in animals (Simonet, WS. et al 1997; Yasuda H. et al., 1998), 
and upon systemic administration can block pathologic bone resorption in various 
animal models (Simonet WS. et al 1997; Morony, S. et al., 1999). 
The gene encoding OPG was first identified and cloned from rat intestinal cDNA during 
a screening project targeting TNFR superfamily (TNFRSF) homologues. However, 
OPG is a novel member of the TNFR superfamily. In vivo, hepatic expression of OPG 
in transgenic mice results in a profound yet non-lethal osteopetrosis, coincident with a 
decrease in the later stages of osteoclast differentiation. These same effects are 
observed upon administration of recombinant OPG into normal mice. In vitro, 
osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by 
recombinant OPG. Furthermore, OPG blocks ovariectomy-associated bone loss in rats. 
OPG can act as a soluble factor in the regulation of bone mass and imply a utility for 
OPG in the treatment of osteoporosis associated with increased osteoclast activity 
(Simonet WS. et al., 1997). 
OPG is synthesized as a propeptide (401 amino acids) from which the signal peptide (21 
amino acids) is cleaved, thus generating the mature protein [380 amino acids (44 kDa)]. 
In contrast to all other TNFR superfamily members, OPG lacks transmembrane and 
cytoplasmic domains and is secreted as a soluble protein (Hofbauer LC. et al., 2000). 
The N-terminus of OPG contains four domains (DI-D4) with cysteine-rich motifs 
involved in the formation of tethered loops and is most closely related to TNFR-2 and 
CD40. The C-terminus contains two death domain-homologous (DDH) tandem regions 
(D5 and D6) that are closely related to Fas and TNFR-1, and a domain (D7) with a 
heparin-binding site and a cysteine residue (position 400) required for homodimer 
formation. The integrity of all four cysteine-rich motifs (DI-D4) appears to be required 
for the biological activity of OPG. Furthermore, when fused to the transmembrane 
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region of Fas, the C-terminus (D5-D7) can mediate cytotoxicity directly; see (Fig 1-6) 
(Yasuda H. 1998; Yamaguchi k. et al., 1998; Hofbauer LC. et al., 2000). 
OPG is synthesized as a monomer (55-62 kDa), assembled, and then secreted as a 
disulfide-linked homodimeric glycoprotein with 4-5 potential N-glycoslation sites (110- 
120 kDa) (Tsuda E. 1997; Simonet WS. et al., 1997; Kwon BS. et al., 1998). Tomoyasu 
A. et al., (1998) suggested that monomeric OPG is derived from the homodimeric OPG 
by lacking several amino acids including Cys 379 , which is involved in intermolecular 
disuffide bone, in the - C-terminal region. The human OPG gene has been mapped to 
chromosome 8q23-24 and contains five exons distributed over 29 kilobases (kb). Of 
interest, exon4 that encodes most of the first DDH region, is a partial duplication of 
exon5. Three major OPG mRNA species exist; there is one abundant 2.2 to 3.0-kb 
species and two minor species of 4.2-4.4 kb and 6.5-6.6 kb, respectively. The two 
largest species are splice variants that contain either the entire intron 2 (6.5-to 6.6-kb 
species) or the 3' half of intron 2 (4.2- to 4.4-kb species) (Hilton MJ. et al. 2001; 
Morinaga T. 1998; Yamaguchi K. et al., 1998; Hofbauer LC. et al., 2000). 
INIBBITION OF CYTOTOXICITY IIEPARIN BINDING 
OSTEOCLASTOGENESIS (When Fused to Fas) DIMERIZATION 
1234567 Domain 
cooll NH2 W(DCUj)(]DGja C400 SP 
C195 C202 C277 C319 
Sil 
CYSTEINE-RICII DOMAINS DDIII DD112 
Fig 1.6 Representation of structure-functional relationship of OPG. 
OPG domains and their biochemical and functional properties are indicated. 
Closed box, signal peptide (SP); open boxes with vertical bars, cysteine-rich 
domains; hatched box, DDH regions; open square, domain 7. OPG is 
present as a monomer with a molecular mass of 60 kDa and a homodimer of 
120 kDa in conditioned media of human fibroblasts. Monomeric OPG is 
derived from the homodimer by lacking several amino acids including 
Cys379 which is involved in intermolecular disulfide bond in C-terminal 
region (Tsuda E. et al., 1997; Yasuda, H. et al 1998; Tomoyasu, A. et al., 
1998; Schoppet, M. et al., 2002; Yamaguchi, K., et al., 1998. 
Another identical form to OPG which inhibits osteoclast-like cell formation was found 
in condition media of human embryonic lung fibroblasts IMR-90, and has been termed 
osteoclastogenesis inhibitory factor (OCIF). It is a heparin-binding basic glycoprotein 
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and has been isolated as a monomer with an apparent molecular weight of 60 kDa and a 
homodimer of 120 kDa. The N-terminus of OCIF is blocked and the determination of 
internal amino acid sequences revealed that OCIF has no homology to other known 
proteins. OCIF inhibited in a dose-dependent manner osteoclastogenesis elicited 
through three distinct signalling pathways stimulated by vitD3, PTH and IL-1 1, 
respectively. OCIF neither inhibits bone resorption by mature osteoclasts nor exerts any 
other biological activities (Tsuda E. et al., 1997). Additionally, TNF receptor-related 
molecule I (TRI) identified as a member of TNFR superfamily shows activities 
associated with osteoclastogenesis inhibition and fibroblast proliferation. TRI was 
identified from a search of an expressed sequence tag database, and encodes 401 amino 
acids with a 21-residue signal sequence. Unlike other members of TNFR, TRI does not 
contain a transmembrane domain and is secreted as a 62 kDa glycoprotein. TRI gene 
maps to chromosome 8q23-24.1 and its mRNA is abundantly expressed in primary 
osteoblasts, osteogenic sarcoma cell lines and primary fibroblasts. The receptors for 
TRI were detected on a monocytic cell line (THP-1) and in human fibroblasts. 
Recombinant TRI induced proliferation of human foreskin fibroblasts and potentiated 
TNF-induced proliferation in these cells. In a co-culture system of osteoblasts and bone 
marrow cells, recombinant TRI completely inhibited the differentiation of osteoclast- 
like multinucleated cell formation in the presence of several bone-resorbing factors. 
TRI also strongly inhibited bone-resorbing function on dentine slices by mature 
osteoclasts and decreased Ca release in fetal long-bone organ cultures. Anti-TRI 
monoclonal antibody promoted the formation of osteoclasts in mouse marrow culture 
assays. These results indicate that TRI has broad biological activities in fibroblast 
growth and in osteoclast differentiation and its functions (Kwon BS. et al., 1998). 
OPG has a wider tissue distribution and is expressed more abundantly than RANKL. 
High levels of OPG mRNA have been detected in lung, heart, kidney, liver, stomach, 
intestine, skin, brain and spinal cord, thyroid gland and bone (Simonet WS. et al., 1997; 
Yuri TJ. et al. 1998). OPG mRNA levels have been detected in a variety of osteoclastic 
lineage cells, including marrow stromal cell lines, osteoblastic cell lines, and the 
osteosarcoma cell line MG-63, fibroblastic cells and human periodontal ligament cells 
(Anderson DM. et al., 1997; Lacey DL. et al., 1998; Hofbauer LC. et al., 1999; Zhang 
D. 2004). In addition, high OPG mRNA levels have also been detected in endothelial 
cells and aortic smooth muscle cells. Also, OPG is expressed in arterial smooth muscle 
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cells and endothelial cells, whereas RANKL and RANK are not expressed in vascular 
tissues under physiologic conditions (Simonet WS. et al., 1997; Min H. et al., 2000). 
Moreover, RANKL and OPG are differentially expressed in calcific aortic stenosis 
(AS). In cultured human aortic valve myofibroblasts, RANKL promotes matrix 
calcification and induces the expression of osteoblast-associated genes, indicating a 
transition towards an osteogenic phenotype which, suggests that the RANKL-OPG 
pathway may regulate valvular calcification in calcific AS (Kaden JJ 2004). 
OPG mRNA and protein in osteoblastic lineage cells are increased by the cytokines IL- 
loc, IL-lP, TNF-oc, TNF-P, and by the antiresorptive agents estrogen and TGF-P. OPG 
mRNA levels of murine marrow stromal cell lines are increased by treatment with 
calcium chloride. By contrast, OPG mRNA and protein levels are decreased by 
glycocorticoids, PGE2 and by the estrogen receptor antagonist IC1182,780. 
Transcriptional regulation of the OPG gene, specifically in response to TGF-P, appears 
to be mediated by Smadl and the osteoblast-specific transcription factor, cbfal 
(Thirunavukkarasu K. et al., 2001; Wan M. et al., 2001). However, both RANKL and 
OPG are regulated by various hormones (glucocorticoids, vitD3, estrogen) and cytokines 
TNFa, IL-1, -4, -6, -11 and -17) see (table 1-2a and 1-2b). Various mesenchymal 
transcription factors such as cbfa-1, peroxisome proliferetor-activated receptor gamma, 
and Indian hedgehog have also been implicated (Hofbauer LC. et al., 2001). 
1.5.2 Interleukin-17 and its receptor (IL-17R) 
1.5.2.1 IL-17 
Interleukin-17 (IL-17) is a novel proinflammatory cytokine, secreted exclusively by 
human [CD4+ RO+] T cells (THI and TH2) in healthy subjects [as well as by CD4+ 
CD8+ cells from mice] (Yao Z. et al., 1995; Shin HC. et al., 1999). IL-17 is a mixture 
of disulfide linked, homodimeric glycosylated and nonglycosylated polypeptides. Its 
gene has been mapped to a single site on human chromosome 2q3I (Yao Z. et al., 1995; 
Rouvier E. et al., 1993). IL-17 cDNA has been isolated and cloned from cytotoxic T 
lymphocyte antigen 8 (CTLA-8) (Rouvier E. et al., 1993; Yao Z. et al., 1996) and 
exhibits an overall sequence identity of 72% at the a level with open reading frame 13 
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from the T lymphotropic Herpesvirus saimiri and 63% with mouse IL- 17 (mIL- 17). The 
human IL-17A gene product is a protein of 155 amino acids with a molecular weight 
ranges from 28 (the glycosylated form) to 15 kDa (the nonglycosylated form), and is 
secreted as a disulfide linked homodimer of 30-35 kDa (Fossiez F. et al., 1996; Yao Z. 
et al., 1995 ). 
Five related cytokines were identified, through database searches and degenerate RT- 
PCR, that share 20-50% homology to IL-17 and a conserved C-terminal region, but 
have N-terminal segments that differ IL-1713, C and E have significantly different 
biological profiles from IL-17A (Li H. et al., 2000; Shi et al., 2000; Lee J. et al., 2001). 
IL-17A has been identified as the original member of the IL-17 cytokine family. The 
mutual features of the IL-17 cytokine family include conserved cysteines which, in IL- 
17F, have been shown to exhibit the features of a classic cysteine knot structural motif 
found in BMPs, TGF-P, nerve growth factor (NGF) and platelet-derived growth factor 
BB (PDGF-BB) (McDonald NQ. and Hendrickson WA., 1993). IL-17F, like IL-17A, is 
produced primarily in activated T-cells (Hymowitz SG et al., 2001). In contrast, IL-17B 
is expressed in pancreas, small intestine and stomach. IL-17C is very rarely expressed. 
IL-17D is preferentially expressed in skeletal muscle, brain, adipose tissue, heart, lung, 
and pancreas (Starnes T. et al., 2002) whereas IL- I 7E mRNA was detected at very low 
levels in several peripheral tissues. IL-17E induces activation of NF-kB and stimulates 
production of the proinflammatory chemokine IL-8 (Lee J. et al., 2001). Their functions 
partially overlap those of IL-17A, although they have not been as thoroughly 
investigated (Shi Y. et al., 2000; Starnes T. et al., 2001, Spriggs MK. et al., 1997; 
Moseley TA. et al., 2003). IL-17B and IL-17C have -27% related amino acid identity 
and stimulate the release of TNF-oc and IL-I P from the monocytic cell line, THP-1 (Shi 
Y. et al., 2000; Spriggs MK. et al., 1997). Li H, et al., (2000) demonstrated that IL- I 7B 
and IL-17C differ in their patterns of expression and proinflammatory responses, and 
may be transduced through a similar set of cell surface receptors. 
IL-17 stimulates cells such as epithelial, endothelial and fibroblastic cells to secrete a 
large variety of proinflammatory molecules, including IL- 10, TNFa and inducible nitric 
oxide synthase (Miljkovic Dj et al., 2003; Jouzeau JY et al., 2002; Miljkovic D. et al., 
2004). In addition, IL-17 has been found to induce the expression of potent modulators 
of bone resorption through NF-kB, and enhance the expression of ICAM-1, and 
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granulocyte macrophage colony-stimulating factor (GM-CSF) in fibroblasts, skeletal 
myoblasts and muscle tissue (Yao Z. et al., 1995; Chevrel G. et al., 2003). Thus, IL- 17 
can be found in the pannus of inflamed synovium, in rheumatoid suffers (Chabaud M. et 
al., 1998; 1999). IL-17 appears to provide a direct linkage between T-cell activation and 
the inflammatory response. IL-17 can, alone and synergistically in combination with 
other proinflammatory cytokines, promote chondrocyte mediated MMP dependent type 
II collagen release from cartilage. Furtherinore, in vivo, IL-17 has a direct catabolic 
effect on cartilage in addition to stimulatory effects on macrophages and synoviocytes, 
making it a potentially important cytokine in the pathogenesis of arthritis. The raised 
levels of proinflammatory cytokines in rheumatoid synovial fluids suggest that IL-17 
may act as a potent upstream mediator of cartilage collagen breakdown in inflammatory 
joint diseases (Dudler J et al., 2000; Koshy PJ et al., 2002; Chabaud M. et al., 2001). In 
addition, IL-17 may affect bone metabolism in pathological conditions characterized by 
the presence of activated T cells and TNFa production such as RA and loosening of 
bone implants (Van bezooijen RL. et al., 1999 Chabaud M. et al., 2001; Kotake S. et al., 
1999; Chabaud M and Miossec P. 2001). However, in vivo blockade of IL-17 by muIL- 
17R: Fc treatment attenuated AIA and reduced joint damage, suggesting that IL- 17 plays 
an important role in the inflammation and joint destruction of AIA. IL-17 may be a 
potential therapeutic target for inflammatory diseases in humans, such as rheumatoid 
arthritis (Bush KA. Et al., 2002). 
1.5.2.2 IL-17 Receptor 
The cell surface receptor for IL-17 is widely expressed in many tissues and cell types. 
The presence of IL-17R has been demonstrated on the surface of various cells of human 
origin, such as MG-63, HOS osteosarcoma cell lines, cells from peripheral blood 
mononuclear cells (I-Ionorati MC. Et al., 2003) and human foreskin fibroblast cells 
(Thiele K. et al., 2000). In addition, synovial and chondrocytes expressing IL-17R are 
found in the majority of patients with different type of arthritis (Honorati MC. et al., 
2001). Also, IL-17R mRNA was expressed by mouse osteoblastic cells (Fossiez F. et 
al., 1998; Van bezooijen, et al., 1999) and were found in chondrocytes and synovial 
fibroblasts from OA patients (Honorati MC. et al., 2002). 
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The open reading frame for IL-17R has been characterised as an extremely long type I 
transmembrane glycoprotein of approximately 130 kDa 864 amino acids in total. It 
includes an N-terminal signal peptide with a cleavage site after amino-acid 31 followed 
by a 29 1 -amino acid extracellular domain, a21 -amino-acid transmembrane domain and 
521 amino-acid cytoplasmic tail. IL-17 Receptor is not a member of the 
immunoglobulin family of receptors and is unique in possessing a long cytoplasmic 
domain that has no sequence homology with any other growth factor receptors. IL-17R 
has tyrosine kinase (TK) activity associated with it. The extracellular domains are not 
related to any of the known cytokine receptor families. Through human chromosomal 
mapping techniques, the IL-17R is localised to chromosome 22qll. 22-qll. 23. 
Expression of IL-17R is almost ubiquitous (Yao Z. et al., 1995). 
1.5.2.3 The biological function of IL-17 
Although limited in number, studies now suggest that IL-17 may be a major vehicle by 
which T cells communicate with other cells of the hematopoietic system. In particular, 
fibroblasts, when cultured in the presence of IL-17, are able to sustain CD34+ 
hematopoietic progenitor cells and direct their maturation towards neutrophils (Fossiez, 
F. et al., 1996). The exact pathway(s) involving IL-17 is not clear. However, IL-17 has 
been demonstrated to induce IL-6, IL-8, G-CSF and PGE2 production by fibroblasts, 
epithelial and endothelial cells, and some of these cytokines are known to impact on 
hematopoiesis (Fossiez, F. et al., 1996). IL-6, for instance, induces hematopoietic 
progenitor cells to form granulocyte/macrophage colonies (Ikebuchi, K. et al., 1987), 
while G-CSF, both in vitro (Berliner, N. et al., 1995) and in vivo (Roberts, A. W. and D. 
Metcalf 1994) accelerates the formation of neutrophils. IL-8, in contrast, seems to down 
modulate the effects of myelopoietic-promoting cytokines, suggesting that IL-17 may 
ultimately be found to have the ability to modify or impact all general phases of a 
hematopoietic response. Thus, it appears that IL-17 can now be considered the newest 
T-cell-derived hematopoietic cytokine, joining IL-3 (Dilloo D. et al., 1996; Huhn, R. D. 
et al., 1996), IL-4 and IL-5 (Takatsu K. et al., 1994; Kim MR. et al., 2002), as either 
regulators or co-regulators; of hernatopoiesis (Fossiez, F. et al., 1996). 
It is not yet clear how widespread the expression of IL-17 is. Early reports implicated 
T-lymphocytes as the major source of IL-17 (Fossiez, F. et al., 1996; Yao, Z. et al., 
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1995), particularly activated memory CD4+ T cells (Fossiez, F. et al., 1996). More 
recent studies have suggested a different and more restricted expression pattern in mice. 
Expression of mouse IL-17 by various activated T cells could only be detected using 
PCR analysis. Using Northern analysis only a subset of T cells, abTCR+CD4-CD8- T 
cells were found to express IL-17 at physiologically significant levels (Kennedy, J. et 
al., 1996). These cells are among the first to be activated during immune responses and 
are capable of producing large amounts of cytokines characteristic of Th2 type 
responses (IL-4, IL-5, IL-10 and IL-13) as well as factors usually associated with CD8+ 
T cells (IFN-y, TNF-0, RANTES and Fas ligand) (Kennedy, J. et al., 1996). Although 
these results suggest that IL-17 is not expressed by a wide variety of cell types, it is 
possible that other cells may express higher levels of IL-17 when appropriate activation 
conditions are found. 
IL-17 is as a pro-inflammatory cytokine, and has been implicated in a number of 
diseases including RA (Chabaud M. et al., 2001; Miossec P. et al., 2000), allergic skin 
immune responses (Albanesi C. et al., 2000), psoriasis (Teunissen MB, et al., 1998), 
organ transplant rejection (Antonysamy MA. et al., 1999; Van Kooten C. et al., 1998), 
multiple sclerosis (Matusevicius D. et al., 1999) asthmatic airways (Molet S. et al., 
2001) and the inflammation process in strokes (Li HL. et al. , 2001) As well as being 
produced by tumor infiltrating lymphocytes, and increasing tumorogenicity of human 
cervical tumors (Fridman WH. and Tarour E., 1998; Tartour E. et al., 1999). IL-17 
reportedly induces hematopoietic cytokines such as GM-CSF, LIF and IL-6 (Yao Z. et 
al., 1997). IL- 17 can, therefore, be said to act as an element of the cytokine network that 
bridges the immune system to hematopoiesis (Fossiez F et al., 1996). 
It is apparent that IL-17 has a pleiotropic effect upon a number of cell types associated 
with inflammation and bone destruction. Proliferation of T cells is enhanced in the 
presence of IL-17 co-stimulated with suboptimal amounts of phytohemagglutinin 
(PHA), and IL-17 has also been shown to stimulate the maturation of bronchial cells and 
recruitment of neutrophils (Fossiez F. et al., 1996). IL-lP and TNFa are Th-1 type 
cytokines that stimulates IL-17 production by human macrophages and corneal 
fibroblasts and also increase the effects of these cytokines on synoviocytes through 
synergistic mechanisms (Maertzdorf J. et al., 2002). IL-17 is known to up-regulate the 
production of MMPs, such as gelatinase-3 (MMP-9) in macrophages, IL-6 and PGE2. 
In addition, IL-10 and TNFa mRNA are also controlled by IL-17. The anti- 
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inflammatory cytokines IL-4 and IL-10 completely reverse IL-17-stimulated IL-10 
release in human macrophages. IL-10 exerts a significant suppressive effect on IL-17 
inducing TNF-a release that suggests a pivotal role for IL-17 in initiating and/or 
sustaining an inflammatory response in human macrophages (Jovanovic DV. et al., 
1998). In contrast, Shin HC, et al., (1999) demonstrated that IL-17 and IFN-y mRNA 
were both inhibited in the presence of PGE2 or the adenylate cyclase (cAMP) analogue 
(dibutryl-cAMP), while the anti-inflammatory cytokine IL-10 was highly increased in 
human memory T cells. 
1.5.2.4 Signal transcluction by IL-17 
IL- 17 activates the transcription factor NF-kB and JNK. The upstream signalling events 
are largely unknown but Schwandner R. and Yamaguchi K. (2000) reported that the 
requirement of TRAF6 in IL-17-induced NF-kB and JNK activation in embryonic 
fibroblasts (EFs). In addition, IL-17 promotes cartilage breakdown (bovine articular 
chondrocytes) by inducing MMPs and aggrecanases by stimulating the phosphorylation 
of ERK, p38 and JNK via MAP kinases, AP- I and NF-kB mediators (Sylvester J. et al., 
2004). IL-17 induces NF-kB protein-DNA complexes consisting of P65/P5O 
heterodimers in the rat intestinal epithelial cell line IEC-6, correlating with the induction 
of CXC and CC chemokine mRNA expression. In IEC6-cells, synergism of IL-17 with 
IL-lP induces NF-kB by IL-17 through TRAF6, but not TRAF2. In addition, to 
activation of NF-kB, IL-17 regulated the activation of ERK, JNK, and p38 MAPK in 
IEC-6 cells (Awane M. et al., 1999), whereas the IL-17-mediated activation of ERK 
MAPK was mediated through Ras and JNK activation was dependent on functional 
TRAF6. However, TRAM and IL-17R are coexpressed in 293 cells and TRAM 
coimmunoprecipitates with IL-17R. Therefore, IL-17R and TRAM are crucial 
components in IL- 17 signalling leading to proinflammatory responses (Schwandner R et 
al., 2000). 
IL-17F (ML-1) is able to induce the expression of IL-6, IL-8 and ICAM-1 in primary 
bronchial epithelial cells (Kawaguchi M. et al., 2001) and the activation process is 
mediated, via the phosphorylation of ERKI/2, but not p38 (Kawaguchi M. et al., 2002). 
Another study indicates a role for Rafl-MEK-ERKI/2 pathway in IL-17F (ML-1) 
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induced C-X-C chemokine expression (Kawaguchi M. et al., 2003). These signalling 
cascades can all be triggered by IL-17, TNF-alpha and IL-1 beta in (intestinal epithelial 
cells, fibroblasts, and bronchial cells) as shown by Fig-1-8 (Awane M. et al., 1999; 
Schwander R. et al., 2000). In addition, the effect of IL-17 on p38 MAPK appears to be 
necessary for the regulation of IL- 18, growth-related protein GRO-alpha and GRO-beta 
expression from fibroblast-like synoviocytes (SFQ isolated from rheumatoid arthritis 
(RA) patients. These data support the hypothesis that IL-17/IL-17R may play a 
significant role in the pathogenesis of RA contributing to an unbalanced production of 
cytokines as well as participating in connective tissue breakdown (Kawaguchi M. 2003; 
Kehlen A. et al., 2002). 
1.5.3 Oncostatin M (OSM) 
Oncostatin M (OSM) is an approximately 28 kDa glycoprotein produced by activated 
monocytes and macrophage/T lymphocytes and is related to the family of cytokines that 
include leukaemia inhibitory factor (LIF), IL-6, IL-11, cardiotrophin-I and ciliary 
neurotrophic factor. These cytokines share a common signal transducer receptor 
component, gpl30, and have overlapping biological activities (Rose TM. and Bruce AG 
1991). It is a pleiotropic cytokine that exerts numerous effects in many different cell 
types, and modulates the growth and differentiation of several normal and tumour cell 
lines. It also stimulates expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) 
and plasminogen activator in synovial fibroblasts (Wang H. et al., 1997) and up- 
regulates MMP-9 in human smooth muscle cells through the MEK-ERK but not STAT3 
pathway (Nagata T. et al., 2003). 
Activated T lymphocytes and macrophages are able to produce OSM and the level of 
OSM mRNA is higher in RA patients than OA patients (Wang H, 1997; Hirano, et al., 
1994). In addition, Lisignoli G. et al. , (2000) reported that OSM was found only 
in 
mononuclear cells in RA. OSM has potentially important functions in the modulation 
of chemokine and MMP production by synovial cells of the joint (Langdon, et al., 
1997). 
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Fig 1.8 The signal transduction pathway of IL-17 through its receptor. Ligation of 
IL-17R leads to binding of the adapter TRAF6 at the proximal portion of the IL-17R. 
IL-17R signalling activates the Ras MAPK JNK pathway, and the transcription I-actor 
AP-1 through the MAP-kinase and JNK which interacts with TRAF6. Additional 
downstream targets of IL-17R include NF-kB and p)8 through activation of IKB and 
MAPK. Activation of IL-17 downstream targets results in upregulation of various pro- 
survival and activating factors important for osteoclasts, as well as differentiating 
factors for osteoclast precursors. 
Studies have demonstrated that IL-17 and other proinflammatory cytokines can, in 
combination with OSM, promote a synergistic, chondrocyte-mediated MMP-dependent 
release of type 11 collagen from cartilage (Koshy PJ et al., 2002). Recently Hui W et al., 
(200-3)) demonstrated that OSM + TNF-a represents a potent proinflammatory cytokine 
combination that markedly induces MMP production in both cartilage and synovium, 
thus promoting joint destruction. Another in vivo study suggests that TNFalpha and 
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other proinflammatory cytokines are involved in the up-regulation of the coordinated 
degradation of cartilage aggrecan and collagen in RA. Further, OSM may act 
synergistically with other proinflammatory cytokines in up-regulating the production of 
MMPs by chondrocytes in rheumatoid joints (Manicourt DH. et al., 2000). Additionally, 
OSM and IL-I together induced membrane-associated metalloproteinase that cleaves 
aggrecan. This activity is rapidly induced after stimulation with IL-1 + OSM and is not 
inhibited by TIMP-1 and -2 but is inhibited by synthetic MMP inhibitors. This same 
combination of cytokines also upregulates the collagenases with the subsequent release 
of collagen fragments, and there is a close correlation between the amount of collagen 
released and collagenase activity produced (Cawston T et al., 1999). Levels of all these 
proinflammatory cytokines are raised in rheumatoid synovial fluids, and data suggest 
that IL-17 may act as a potent upstream mediator of cartilage collagen breakdown in 
inflammatory joint diseases (Koshy PJ. et al., 2002; Cawston TE et al., 1998). 
OSM induces the expression of Tissue factor (TF), a transmembrane glycoprotein, that 
initiates the extrinsic coagulation cascade. This indicates that OSM may play a key role 
in promoting TF expression in vascular smooth muscle cells (SMCs) within 
atherosclerotic lesions (Nishibe T. et al., 2001). OSM also promotes the expression of 
urokinase plasminogen activator, basic fibroblast growth factor, granulocyte colony- 
stimulating factor and GM-CSF (Brown TJ. et al., 1991; Hamilton JA. et al., 1991). In 
human fibroblasts, OSM modulates not only MMPs but also tissue TIMPs (Nemoto 0. 
et al., 1997; Korzus E et al., 1997). In addition, Rowan AD (2001) reported that OSM 
synergizes with IL-lalpha to induce chondrocyte-mediated cartilage collagen breakdown 
and collagenase production. Furthermore, OSM was demonstrated to stimulate 
angiogenesis in vivo and was shown to be present in human aortic aneurysms (Modur V. 
et al., 1997; Vasse M. et al., 1999). OSM is produced by activated 
monocytes/macrophages and T lymphocytes, cell types found frequently at sites of 
inflammatory wound repair (Nishibe T. et al., 2001). 
OSM also stimulates osteoclast formation and function (Richards CD, et al., 2000). The 
role of OSM and its interactions with RANKL, RANK and OPG were studied in 
neonatal mouse calvaria. Human OSM and murine OSM (mOSM) enhanced the mRNA 
expression of RANKL and OPG in mouse calvaria, but had no effect on the expression 
of RANK (Richards CD. et al., 2000; Palmqvist P. et al., 2002). In addition, human 
LIF, hOSM, and mOSM also stimulated Ca 2+ release and enhanced the mRNA 
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expression of RANKL and OPG in mouse calvaria. Also, hIL-6 plus shIL-6R and 
mOSM increased RANKL and OPG proteins in mouse calvaria cells (Palmqvist P et 
al., 2002). In contrast, another study described OSM as a bone-remodelling factor 
stimulating osteoblast activity. OSM induced proliferation, collagen synthesis, and IL-6 
secretion by osteoblasts, whereas it inhibited alkaline phosphatase activity and bone 
resorption. In vitro, OSM enhanced the effect of BMP-2 on osteoblast differentiation. 
Immunohistochemistry demonstrated the expression of RANKL and RANK in the 
periosteurn but osteoclasts were not detected at sites of bone apposition. OSM favours 
bone apposition at periosteal sites instead of resorption in vivo. This effect was not 
dependent on, or inhibited by, IL-6 (Jay PR. et al., 1996; de Hooge AS. Et al., 2002). 
1.6 Mechanism of bone destruction in RA 
The paralleled roles of RANKL and OPG in regulating bone metabolism and the 
immune system are mediated by the expression of RANK by osteoclasts and dendritic 
cells. The cross-talk of T lymphocyte-derived RANKL and osteoclasts within the bone 
microenvironment have made RANKL an obvious candidate cytokine that promotes the 
skeletal complications of RA. Several in vivo studies using established animal models 
of RA provide support for this hypothesis (Kong YY. et al., 1999; Romas E. et al., 2000; 
Haynes DR. et al., 2001). Kong and associates have clearly demonstrated that RANKL 
mRNA is produced by synovial fibroblasts and activated T lymphocytes in affected 
lesions of rats with adjuvant arthritis. These animals displayed severe bone loss due to 
enhanced osteoclast formation and joint erosions within one week after subcutaneous 
administration of Mycobaterium tuberculosi (Kong YY. et al., 1999). 
In another rodent model of RA (induced by intradermal injection of type II collagen) 
RANKL expression was detected in mononuclear cells and chondrocytes within areas of 
inflammation, and actively resorbing osteoclasts were located at sites where RANKL 
production was most abundant (Romas E. et al., 2000). In addition, targeted over 
expression of the antiresorptive cytokine IL-4 markedly suppressed RANKL production 
in collagen-induced arthritis, and protected these mice from developing bone loss and 
cartilage damage (Lubberts E. et al., 2000). 
39 
Chapter-I Introduction 
There is mounting evidence supporting an essential role of RANKL in human RA. 
Gravallese EM. et al., (2000) demonstrated that both RANKL mRNA and protein are 
abundantly produced by activated T lymphocytes infiltrating the synovium, but are 
absent in synovial tissue derived from patients with other forms of arthritis and in 
healthy subjects. Expression of RANKL mRNA and protein was confirmed in vitro 
with cultured fibroblasts and T lymphocytes derived from synovial specimens of 
patients with RA (Gravallese EM. et al., 2000). Therefore, the systemic bone sparing 
effects of immunosuppressants such as cyclosporin A in patients with RA may be 
through inhibition of T cell activation, resulting in decreased RANKL production 
(Ferraccioli G. et al., 1996). In addition, Kong YY. et al., (1999) and Gravallese EM. et 
al., (2000) demonstrated that activated T lymphocytes and synovial fibroblasts in vitro 
were inhibited by administration of OPG. Furthermore, IL-17 concentrations were 
elevated in synovial fluid in human RA, and were found to be among the most potent 
stimulators of RANKL production (Kotake S. et al., 1999). The sequential action of IL- 
17 and RANKL is supported by the finding that osteoclastogenesis induced by IL-17 
was completely inhibited by administration of OPG (Ferraccioli G. et al., 1996). 
However, as previously described RA is an autoimmune disease characterized by a 
severe lymphocyte penetration into the synovial cavity resulting in the secretion of a 
multiplicity of cytokines, which eventually leads to destruction of joint tissues. Among 
the infiltrating cells are activated T cells, which produce specific cytokines capable of 
osteoclast progenitor cell expansion, fusion, and activation. Cultures of activated 
human T cells and human osteoblasts were used to study the possibility that 
lymphokines may act on osteoblasts to produce the osteoclastogenic factors IL-17, IL-6 
and RANKL (Rifas L. and Avioli LV. 1999). IL-17, produced by activated T cells in 
the synovial tissues, enhances the production of PGE2 synthesis in the osteoblast/stromal 
cells in adjacent bone. The presence of PGE2 in these cells causes RANKL up- 
regulation which leads to RANK activation. M-CSF produced by osteoblast/stromal 
cells is also an essential soluble factor for osteoclast survival in mice cells. Elevation of 
IL- 17 in RA synovial tissue may induce osteoclastogenesis, leading to joint damage Fig 
1-9 (Kotake, et al., 1999). 
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Fig-1.9 Osteoclastogenic mechanism mediated by activated T cells and osteoblasts. 
(taken from Kotake, et al., 1999). 
1.7 Overall summary 
RA is an autoimmune disease characterised by chronic inflammation of multiple 
synovial joints leading to progressive joint destruction and bone resorption. T cell 
recruitment and activation is believed to be a pivotal part of RA and leads to the 
accumulation of cytokines such as IL- 17 and OSM in the joint space. The precise role 
of T cells in normal bone homeostasis is not fully understood but the T cell-derived 
cytokine IL-17 is known to support osteoclastogenesis. This is believed to be mediated 
through the up regulation of RANKL expression and production by marrow stromal and 
osteoblast cells. A recent study proposed that activated T cells regulate bone loss and 
joint destruction in adjuvant arthritis (Kong YY et al., 1999). Kotake, et al., (1999) 
demonstrated that activated T cells and synovial fibroblasts express RANKL and M- 
CSF which, may directly stimulate osteoclast differentiation. survival and activation. 
Activated T cells further influence local RANKL expression through the production of 
IL- 17. which stimulates osteoblasts and synovial fibroblasts. 
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1.8 Alm of the study 
The overall aim of this project is to characterise the pro-osteolytic response of synovial 
cells to the T cell-derived cytokine IL-17 and OSM a macrophage and activated T cell 
on the expression of RANKL and OPG. In addition, the ability of IL-17 to support 
osteoclastogenesis in vitro. 
1.9 The Specific objectives of this thesis are: 
9 To determine the temporal pattern of RANKL expression and production by 
synovial cells treated with IL-17 and OSM and contrast this with the 
expression in osteoblasts. 
To determine the temporal pattern of OPG expression and production by 
synovial cells treated with IL-17 and OSM and contrast this with the 
expression in osteoblasts. 
To determine whether the temporal pattern of RANKL and OPG expression 
by synovial cells is altered when treated with IL- 17 in combination with OSM, 
and to contrast this with the expression in osteoblasts. 
To investigate the formation multinucleated cells from PBMCs in response to 
IL-17. 
To investigate the effects of IL-17 on osteoclastogenesis. 
* To investigate the possibility that IL-17 treated synovial cells are capable of 
mediating bone resorption independently of RANKL. 
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2 General Materials and Methods 
2.1 Materials 
2.1.1. Cell, tissue culture reagents and plastic ware 
Tissue culture solutions were Dulbecco's modification of Eagle's medium (DMEM) 
with 1000 mg/L glucose and pyridine, and 25mM HEPES, Alpha minimal essential 
medium (oc-MEM) with Glutamax-1 without ribonucleosides and deoxyribonucleosides, 
RPMI 1640 media, Fetal calf serum (FCS) (Life Technologies). Penicillin, streptomycin 
and L-glutamine were obtained from Life Technologies Ltd. Collagenase (type I from 
Clostridiurn histolyticum), and trypsin (type III, from bovine pancreas), Dulbecco's 
phosphate buffered saline (PBS), dimethyl sulfoxide (DMSO), gentamycin solution, 
nystatin suspension and Histopaqe 1077 were obtained from Sigma-Aldrich Company 
Ltd. Tissue culture 48-well plates and 162 cm 2 75 CM2 and 25 CM2 vented cell culture 
flasks were obtained from Corning/Costar UK Ltd. (High Wycombe, UK). Cell 
scrapers were obtained from Greiner Labortechnik (Gloucester, UK). Universals (5 and 
20 ml) were obtained from Bibby Sterilin Ltd (Stone, Staffs, UK). Syringe filters (0.2 
ýtm) were from Pall Gelman Sciences (Northampton, UK). Sterile disposable scalpel 
blades were from Swann-Morton (Sheffield, UK). Flat-bottomed 96 well plates were 
from Dynatech Laboratories (Billington, UK). 
2.1.2 Cytokines 
Recombinant human IL-17 was obtained from R&D systems Europe Ltd UK. Human 
recombinant oncostatin M (OSM) was kindly donated by Prof J. Heath, Department of 
Biochemistry, University of Birmingham, UK. OSM stock was at 10 ýIg/ml in 
phosphate-buffered saline (PBS) with 0.1% bovine serum albumin (BSA) stored at - 
801C. IL-17 was at 20 ýtg/ml in PBS containing 0.1 % (w/v) BSA, stored at -20T. 
Recombinant human RANKL, OPG and M-CSF were purchased from PeproTech EC 
Ltd (PeproTech House UK). RANKL, OPG and M-CSF stocks were at 20 ýtg/ml, 50 
pg/ml and 20 pg/ml, respectively, in distilled water. Immediately prior to use the 
cytokines were diluted in culture medium and sterile filtered through a 0.2 ýtm filter. 
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2.1.3 Cell lines 
The osteosarcoma cell lines used in this project were SaOS-2 cells and MG-63 cells 
both from European collection of cell cultures (ECACC) The European Tissue Culture 
Society (ETCS) UK Branch. 
2.1.4 Molecular biology reagents 
Formamide, 3-(N-morpholino) propanesulphonic acid (MOPS), diethyl pyrocarbonate 
(DEPC), 37% (VN) formaldehyde and P-mercaptoethanol were obtained from Sigma- 
Aldrich Company Ltd. RNeasy Mini kits and Plasmid Maxi kits were purchased from 
Sigma. RNA ladder (1- 10 kD), agarose (electrophoretic grade) and salmon sperm DNA 
(10 mg/ml) were obtained from Life Technologise Ltd. [a- 32p]-dCTP, Ready-To-Go 
DNA labelling beads and ProbeQuant G50 micro-columns were purchased from 
Amersham. Pharmacia Biotech UK Ltd. GeneScreen plus membrane was obtained from 
NEN life Science products, Inc. (Hounslow, UK). All RNA work was performed under 
RNase-free conditions using RNase-free reagents and materials. All reagents required 
for RNA work were molecular biology grade. DEPC water was prepared by the 
addition of DEPC to d. H20 to a final concentration of 0.1% (v/v). This was left 
overnight, then autoclaved for at least 20 min to remove traces of the DEPC. 
Furthermore, all glassware was oven-baked at 200'C, for at least 3 hr and cooled to 
room temperature, prior to use 
2.1.6 Complementary DNA probes 
Complementary DNA (cDNA) clones for human RANKL and OPG were cloned and 
sequenced from the PCR products. Glyceraldehyde-3 -phosphate dehydrogenase 
(GAPDH) cDNA was originally isolated by Fort et al. (1985). The size of OPG clones 
was (2.5 kb) human cDNAs and GAPDH clones was (2.2 kb) human cDNAs, in 
Northern blot analysis. 
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2.1.6 Other reagent 
All other chemicals and biochemicals were commercially available analytical grade 
reagents obtained from Sigma-Aldrich Company Ltd UK., Gibco Life Technologies UK, 
R&D or Promega UK (Southampton). 
2.2 Cells and cell culture 
2.2.1 Synovial fibroblasts 
Solutions 
Culture medium 
DMEM, 2mM L-glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin, 20pg/ml 
nystatin and 100 pg/ml gentarnicin. 
Dulbecco's phosphate buffered saline (L)PBS) 
DPBS containing 100 U/ml penicillin, 100 pg/mI streptomycin. 
Method 
Synovial tissue was obtained from patients undergoing joint replacement surgery at the 
Freeman Hospital Newcastle upon Tyne or the Queen Elizabeth Hospital, Gateshead, 
and stored at 4"C in DPBS containing I OOU/ml penicillin and 100 [Lg/ml streptomycin. 
Tissue was used up to 5 days after removal from the patient. The culture conditions 
were based on the method of Dayer et al. (1976). Fat and fibrous connective tissue was 
carefully dissected away and the remaining synovium washed twice in DPBS and 
finely chopped. The synovium. fragments were digested for 2 to 3 hours at 37'C in 
DMEM supplemented with 2 mg/ml of bacterial collagenase, which had been filtered 
through a 0.2 pm filter. After incubation in an orbital shaker (I 10 rpm), the tissue 
fragments were dispersed by gentle pipetteing with a Pasteur pipette and filtered with 
cell strainer 100 pm Naylon BD Falcon (Becton Dickinson Labware USA). The cell 
suspension was centrifuged for 5 min at a relative centrifugal force of (200g) at room 
temperature. The cell pellet was resuspended in DMEM containing 20% FCS. The 
cells were plated into T75 cm 2 tissue culture flasks (10 ml/flask). The following day, 
medium was removed from each of the flasks and replenished with fresh medium. The 
passage zero (pO) cells typically took 7-15 days to reach 90-95% confluence. Synovial 
fibroblasts were split 1: 2, and grown up to passage 4 or 5 (p4 or p5) before use in 
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experiments. Before cytokine stimulation, cells were washed twice in DPBS and left 
for 24 hr in 10 ml of 0.5% FCS cultured medium/flask. 
2.2.2 Cell lines 
Solutions 
Culture medium 
DMEM, containing 10% (v/v) FCS, 2 mM L-glutarnine, 100 U/mI penicillin, 100 Pg/mI 
streptomycin, 20 pg/mI nystatin and 100 pg/mI gentarnicin. a-MEM containing 10% 
(v/v) FCS, 2mM L-glutarnine, 100 U/mI penicillin, 100 pg/mI streptomycin, 20 Pg/mI 
nystatin. 
Dulbecco's phosphate buffered saline (L)PBS) 
DPBS containing 100 U/mI penicillin, 100 pg/mI streptomycin. 
Method 
Human osteosarcoma cell line SaOS-2 was cultured in ccMEM, and MG-63 cells were 
cultured in DMEM. The cells were grown until they reached confluence at 37T, 5% 
C02. Before experiments the cells were serum-reduced in medium containing 0.5% 
(v/v) FCS overnight. Then fresh medium with cytokines at different concentrations 
was added and the cells further incubated for different time periods. 
2.3 RNA extraction 
In experiments with osteosarcoma cell lines and human synovial fibroblasts, gene 
expression was assessed by analysis of mRNA levels. Total RNA was extracted from 
cells using Trizol reagent (Life Technologies) which is an improvement to the single- 
step RNA isolation method developed by Chomczynski and Sacchi (1987). 
Method 
Culture supernatants were decanted from the cells grown in a monolayer, and total 
RNA was extracted from the cells. Trizol reagent (2 ml) was added to each T75 cm 2 
flask, worked over the cell monolayer and a scraper used to collect the lysate which 
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was then transferred to a 1.5 ml eppendorf tube. Chloroform (0.3 ml) was added; the 
tube inverted several times and placed at room temperature for 10 min. After 
centrifugation at 13000xg for 10 min at 4*C each tube has three distinct phases. An 
upper RNA containing layer which was carefully transferred to a new tube leaving < 
0.1 ml of this layer to avoid DNA contamination from the interface. The lower phase, 
containing protein was stored at -20*C until required. Isopropanol (0.6 ml) was added 
to the aqueous phase containing RNA and placed at -20*C overnight (an alternative is 
to keep at -80T for 2 hr). The RNA was spun at 13000xg for 15 min at 4"C, and the 
supernatant carefully discarded so as not to disturb the pellet. The pellet was washed 
with 0.7 ml of 70% ethanol and centrifuged at 13000xg for 5 min at 4*C. The ethanol 
was removed and the pellet air-dried until translucent (around 5 min). The pellet was 
reconstituted in 15 ýfl DEPC-1120. The absorbance of the RNA was measured using a 
GeneQuant II spectrophotometer (Amersham. Pharmacia Biotech Ltd UK) at 
260/280run. The RNA was stored at -80*C until required. 
2.4 Reverse transcri ptase-polym erase chain reaction (RT- 
PCR) 
Principles of RT-PCR sensitive methods for the detection and analysis of rare mRNA 
transcripts or other RNAs present in low abundance are an important aspect of most 
cell/molecular biology studies. RNA cannot serve as a template for PCR, so it must first 
be reverse transcribed into cDNA. Gattei V ET AL., (1997) described a combined 
technique (now commonly known as RT-PCR) in which reverse transcription (RT) is 
coupled with PCR amplification of the resulting cDNA. RT-PCR provides the 
possibility to assess gene transcription in cells or tissues. PCR and RT-PCR techniques 
have been instrumental in dental research. PCR and RT-PCR show many advantages 
including high specificity, sensitivity, and speed. 
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2.4.1 DNase treatment 
All RNA was treated with DNase I to ensure there was no genomic DNA 
contamination. For 3 pg of RNA, 1 pl of I Ox DNase I reaction buffer and I ýd of 
DNase 1 (2.5 U/pl) (Amplification grade from Invitrogen (Gibco BRL) Life 
technologies UK) were added, and then DEPC-treated H20 to a 10 PI final volume. 
After incubation for 15 min at room temp, I ýd of 25 mM EDTA was added and then 
heated to 65*C for 10 min to inactivate the DNase. Each tube containing II ýfl was 
then split in half and 44.5 jil-distilled water was added to negative controls for RT- 
PCR reactions a further 5 [d DEPC-H20 was added and mixed well. 
2.4.2 cDNA synthesis 
RNA was reverse transcribed into complementary DNA (cDNA) using the Superscript 
kit (Invitrogen (Gibco BRL) Life technologies UK). Between 3-5 ýtg of the total 
RNA was used as template from each sample for cDNA synthesis by SuperScripJMII. 
OligOdT12-19 (0-5 pg) was added; the volume was made up to 10.5 Pl. The mixture was 
incubated at 70*C for 10 min then placed on ice. 5x first strand buffer 4 gl, 2 PI DTT, 
I pI of 10 mM dNT? S, I pl RNase inhibitor (40 U/pl) and I pI Superscript Il reverse 
transcriptase (200 U/pl) (Sigma) were added. The final volume (20 pl) was incubated 
at 42'C for I hr. The cDNA was diluted to 50 pI and stored at -20*C. 
2.4.3 Conventional PCR analysis 
Complementary DNA was amplified by PCR using primer pairs to generate products 
corresponding to specific gene as listed in Table 2-1. Primers were designed against 
human sequences for RANKL, OPG, GAPDH, IL-17 and IL-17R in the 
EMBUGenBank database. 
Ile amplification mixture contained IU of Taq DNA polymerase (Life Technologies), 
200 ng each of the 5' and 3' primers, 0.2 mM dNTPs (dATP, dCTP , dGTP and dTTP), 
1-5 MM MgC12,2 gl of lOx reaction buffer, and DEPC-H20 to 25 gl and 2 gl of 
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template cDNA. A negative control reaction was run with each experiment and 
contained all the reagents except the cDNA template. PCR was performed for 35 cycles 
for GAPDH, RANKL, OPG, IL- 17, and 38 cycles for IL- I 7R. 
GAPDH AF019047 GGT GAA GGT CGG AGT CAA CGG 542-1024 483 
GGT CAT GAG CCC TTC CAC GAT 
IL-17R U94332 GGC TAA ACT GCA CGG TCA AG 287-722 436 
TAT TCC TGG TCA GGG TCA AC 
RANKL U32659 GCA CAT CAG AGC AGA GAA AG 124-682 386 
AGT AAG GAG GGG YYG GAG AC 
OPG U58917 TGC CCT GAC CAC TAC TAC AC 172-502 400 
CAA ACC TGA AGA ATG CCT CC 
IL-17 M33197 GAA TCA CAA TCC CAC GAA ATC C 69-589 520 
GCC AAG TGT TAC CTC TGA AGC 
Alkaline phosphatase NM 000478 GGA CAT GCA GTA CGA GCT GA 1251- 281 
GGT GCA GAA GTG TAA ACC AC 1551 
Table 2.1 the Conventional PCR primers sequence for RANKL, OPG, GAPDH) 
IL-17 and IL-17R. 
A PTC-100 Thermal Cycler (MJ Research (Genetic Research Instrumentation Gene 
House. UK) was programmed to perform the following PCR program. After an initial 
step at 95*C for 3 min to break down the complex tertiary structure of cDNA, each cycle 
consisted of 30 seconds denaturation at 94T, annealing depends on the melting 
temperature of each primer pair (for RANKL; 60*C, OPG and GAPDH, 5511C IL-17R, 
61"C) for 30 seconds then extension at 72*C for 30 seconds. This was followed by an 
additional extension step at 72*C for 5 min. In all cases, the primers were mRNA- 
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specific in that the recognition sites of the upstream and downstream primers resided in 
separate exons in the genomic sequence. Primer sequences and predicted PCR product 
sizes are shown in table 2-1. Amplification products were identified by electrophoresis 
on a 1% (w/v) agarose gel. Amplified products corresponding to human specific 
mRNAs were expressed as a ratio of the respective GAPDH product. To show that 
there were no false-positive results, PCR reactions were performed using non-reverse- 
transcribed RNA, and on reaction mixtures in which no RNA was added. Positive 
controls, including a number of human sample and cell line-derived cDNAs, were used 
to confirm the specificity of each primer pair under the conditions used. Products were 
analysed by agarose gel electrophorsesis and visualised by ethidium bromide staining 
under UV light. The identity of PCR products was confin-ned by cloning into PGEM-T 
(Promega) and sequence analysis on an ABI DNA sequencer (Molecular Biology Unit, 
University of Newcastle). 
2.5 Cloning of PCR products 
2.5.1 Isolation of PCR fragment 
PCR products were purified using a QIAquick PCR Purification Kit (Qiagen, Crawley, 
UK) as recommended by the manufacturer and the elutcd products kept at -20"C. A 
small few aliquots !ý5 pl of recovered cDNA were run on 1% agarose gel to confirm 
the purification. 
2.5.2 Ligation into pGEM-T 
Purified PCR products were added to the ligation reaction containing T4 DNA ligase, as 
directed by the manufacturers with pGEM-T or pGEM-T Easy Vector (Promega). High 
efficiency competent cells (JM109) Promega UK (Southampton, UK) were used for the 
transformation as recommended, in order to obtain a reasonable number of colonies. 
Selection for transformants was on LB/ampicillin/Isopropyl-beta-D- 
thiogalactopyranoside (IPTG)/X-Gal plates. Two LB/ampicillin/IPTG/X-Gal plates 
were prepared (for each ligation reaction) and the plates were equilibrated to room 
temperature prior to plating. Ligation reaction 2 VI was added to a sterile 1.5 ml 
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microcentrifiage tube on ice. JM109 cells were removed from -70*C and placed in an 
ice bath until just thawed and then 50 gl of cells were transfered to each ligation. The 
tubes were gently flicked to mix and placed on ice for 20 min before heat-shock at 42*C 
for 45 to 50 seconds. The microcentrifage tubes were immediately returned to the ice 
for 2 min, room temperature SOC medium 950 gI was then added to the tubes and 
incubated for 1.5 hr at 37C with shaking (-=200 rpm). Transformed bacteria (100 ýtl) 
were spread onto the LB plates containing ampicillin. The plates were incubated 
upside-down overnight (16-18hr) at 370C. Single white colonies from the plate were 
picked, and resuspended in 50 gI of distilled water, mixed well and kept at -70'C until 
required. 
2.5.3 Harvest and lysis of bacteria 
The resuspended colony 10 gl was used to inoculate 6.5ml of LB broth with 6.5 ýtl of 
ampicillin (50 ýtg/ml) in a 20 ml universal and incubated overnight at 37"C in a 
shaking incubator (200 rpm). From the cultured bacteria, a stock was first made; 450 
pl of the culture was added to 50 pI of glycerol, mixed well and kept at -70*C until 
required. The rest of the culture was transferred to 1.5 ml microcentrifuge tubes and 
spun for I min at 13,000 xg. The supernatant was discarded and re-suspended in 200 
pl of re-suspension solution as recommended in the Genelute plasmid mini-prep kit 
(Sigma). Plasmid was isolated using the Genelute kit as directed by the manufacturer. 
Elution buffer 80 gl was added to the column and spun for I min. The last step was 
repeated twice to make sure that most of the plasmid DNA was eluted and then the 
DNA was kept at -70T until required. 
2.5.4 Quantitation and digestion of plasmid DNA 
The DNA was quantified by its absorbance at 260/280mn and then 5 pg/ml of plasmid 
DNA was digested. A typical digest was performed in a 10 pl volume. Thus, for 3 pl 
of plasmid DNA, I pl of buffer A was added, I pl of enzyme Sac 1 (10 U/ýtl) and 
enzyme Apa I (10 U/pl), followed by distilled water to a final volume of 10 pl. The 
plasmid DNA was incubated for 3 hr at 37*C and subsequently loaded onto a small 
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1.5% agarose gel and electrophoresed at 80 V for I hr. The relevant band was cut from 
the gel and placed in a microcentrifuge tube. The DNA was purified from the agarose 
gel using a QIAquick gel Extraction kit or kept at -70"C until purified. 
2.6 Northern blot analysis 
2.6.1 RNA electrophoresis 
Principles: electrophoresis of RNA through an agarose gel allows separation of RNA 
based on size and electrostatic charge. Agarose is a linear polysaccharide. An agarose 
gel consists of inter-and intra-molecular hydrogen bonds within and between the long 
agarose chains. RNA is denatured to prevent hydrogen bond formation within or 
between polynucleotides. Formaldehyde is used as the denaturing reagent, and is 
included in the agarose gel. Moreover, samples are heat denatured in the presence of 
formaldehyde prior to electrophoresis, to disrupt the formation of secondary mRNA 
structures. 
The gel tray, comb and electrophoresis tank were soaked in 0.5 M NaOH for 15 min to 
ensure they were free from RNase and then were washed with DEPC-treated H20. 
1% agarose gel with 0.4 M fbrmaldehýLde 
Agarose (0.6 g) was weighed; 54.75 ml DEPC distilled water and 7.5 ml of IOX 
MOPS were added and heated in a microwave until dissolved (approx. 45 see on full 
power). Then the solution was left to cool in a fume hood (approx. 60"C) and then 
12.75 ml 37% (v/v) of formaldehyde (Merck) was added, the solution swirled and 
poured immediately into the scaled gel tray. 
I Ox runniniz buffer 
200 mM MOPS, 50 mM sodium acetate and 10 mM EDTA (pH 7.0). 
5X RNA loadinR buffe 
0.25% (v/v) Bromophenol blue, 4 mM EDTA, 7.2% (v/v) formaldehyde (37% solution), 
20% (v/v) glycerol, 31% (v/v) formamide, 40% lOx running buffer and 0.1 mg/ml 
ethidium bromide. 
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Methods 
RNA was electrophoresed using 1% agarose /0.4 M formaldehyde gels. Equal amounts 
of RNA (typically: 10 - 20 pg for human osteosarcoma cells SaOS2, MG-63 and 8- 15 
[tg for human synovial fibroblast) were made up to a volume of 20 pl with DEPC 
d. H20. A RNA ladder (I kDa) was prepared in the same manner. To each sample, 10 til 
of 5x RNA loading buffer was added. Samples were then incubated at 551C for 15 min 
and placed on ice. The gel was run at 60 V for I-2 hr in Ix running buffer, viewed 
under UV light to check the integrity of the RNA and photographed. 
2.6.2 RNA transfer 
Principle: Through the process of capillary action, RNA can be transferred from the 
agarose gel onto a nylon membrane. The RNA can then be "cross-linked" permanently 
onto the membrane through baking or exposed to UV irradiation. 
Solutions 
20x saline-sodium citrate (SSC) 
This reagent is supplied as a 20x concentrate: 0.3 M sodium citrate, with 3M NaCl, pH 
7.0. 
Method 
RNA was transferred to Hybond-N (Amersham, Pharmacia Biotech) with 200 ml I 5x 
SSC overnight as follows. Formaldehyde was removed from the gel by washing in 
DEPC d. H20 (3 x5 min washes). The Hybond-N membrane and four pieces of filter 
paper were cut to the size of the gel. One piece of filter paper was cut longer than the 
size of the gel to act as a wick. The membrane, filter paper and wick were then pre- 
soaked in 15x SSC. The transfer stack was prepared on a sponge in the following 
order: one piece of filter paper, the wick, and the gel (upside down), Hybond-N 
membrane, three sheets of filter paper, approximately (5 - 10 cm) of paper towel, a 
glass plate and a weight. Cling filming to prevent evaporation and ensure there was no 
contact between the wick and the layers above the gel was used to surround the stack. 
The blot was removed the following day, checked under UV light to ensure transfer of 
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RNA and washed briefly in 2x SSC to remove traces of agarose. The membrane was 
blotted dry and then baked at 80"C for at least 2 hr, in order to cross-link the RNA onto 
the membrane. The blot was stored between two pieces of filter paper at room 
temperature until required. 
2.6.3 Labelling of cDNA probes and membrane 
hybridisation 
2.6.3.1 Labelling cDNA probes 
Principles: the random primed labelling method was used to label the cDNA probe. 
The cDNA was denatured and then renatured in the presence of a mixture of different 
random sequences of hexamers. The hexamers bind to the cDNA where they 
encounter the complementary sequence and the DNA therefore rapidly acquires an 
approximately random distribution of hexamers. The hexamers have an exposed 3'- 
hydroxyl group and act as primers for the synthesis of a fresh cDNA catalysed by the 
Klenow fragment of DNA polymerase with the incorporation of [oc 32p] -dCTP. Ready- 
to-Go DNA labelling beads are used. Each bead consists of dATP, dGTP, dTTP, 
klenow fragment and random oligodeoxyribonucleotides. 
Materials 
cDNA probe. 
Ready to Go tube containing DNA labelling beads (Amersham Phannacian Biotech). 
OC32 P-dCTP. 
Column chromatography (G50 micro columns). 
Methods 
The appropriate required volume of cDNA insert (25 ng cDNA) was adjusted to 45 gl 
with d. H20. The probe was boiled for 5 min (then immediately put on ice to prevent 
renaturation). This was then added to a Ready to Go tube containing 'DNA labelling 
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beads'. OC32p-dCTP (5 pl) (3000 Ci/mmol) was added and the mixture incubated at 
37C for 30 min. The labelled probe was purified from unmincorporated label by 
column chromatography (ProbeQuant G50 micro columns) according to the 
manfacturer's instructions. The probe was assessed for incorporation of label in B- 
counter. The probe was labelled to 5-7x 106 Bq/jig DNA. 
2.6.3.2 Hybridisation 
Principle: Salmon sperm DNA was used to block non-specific sites on the blot and 
labelled probe was added that allowed hybridising with its specific mRNA on the blot. 
After hypridisation, blot were washed to remove unbound label and labelled mRNA 
visualised by phosphorimaging. 
Materials 
QuikHyb@ Hybridization solution (Stratagene). 
Salmon sperm DNA. 
Methods 
The blot was pre-soaked in 100 ml of 2x SSC and placed into a hybridisation bottle. 
The membrane was then incubated with 10 ml of Hybridization solution following the 
manufacturer's protocol. The bottle was placed (with a balance) into the hybridisation 
oven and incubated at 68"C for at least 30 min. The labelled probe was added to 100 
gl of 10 mg/ml salmon sperm DNA and boiled for 5 min and immediately placed on 
ice for 5 min to prevent renaturation. The labelled probe was directly added to the 
hybridisation bottle and incubated at 68"C for 2 hr. The membrane was washed twice 
with 100-200 ml 2x SSC buffer contained 0.1% SDS for 15 min at room temperature. 
Then the membrane was washed once with 100-200 ml O-lx SSC buffer + 0.1% (w/v) 
SDS washing solution for 30 min at 60"C. The blot was blotted semi-dry on filter 
paper, wrapped in cling film and exposed to a Storage phosphor screen (Molecular 
Dynamics, Chesham, UK) overnight at room temperature. Radioactive bands were 
visualised by using a Phosphor Imager (Storm 860, Molecular Dynamics). 
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2.6.4 Stripping RNA blots 
solutions 
0.1% SSC buffer and 0.1% SDS 
Methods 
The probe then stripped from the blot by washing (3 times) for 5 min with 200 ml of 
boiling 0.1% SSC buffer with 0.1% SDS. Blots were then re-exposed to the phosphor 
screen to check if they were adequately stripped. If the blot was not stripped very well, 
the blot was washed again in boiling 0.1% SSC buffer and 0.1% SDS for 15 minutes. 
In order to prevent the blot drying out between each probing, the blot was wrapped in 
cling film, followed by aluminium. foil and stored at -20T. 
2.7 Protein electrophoresis and Western Blotting 
2.7.1 Protein assay 
Principle: Protein concentrations can be evaluated based upon the formation of a 
colorimetric complex. The bicinchoninic acid reagent supplied forms a complex with 
the copper I produced by the interaction of protein with alkaline copper IL This 
complex is water-soluble allowing spectrophotometric measurement in aqueous solution 
at 560 run. 
Methods: 
A standard curve was constructed using BSA (2 mg/mI stock) diluted in H20; a range of 
standards (0.625 -2 mg/mI BSA) were prepared in aI ml total volume. Sample or 
standard 10 pl. was added in triplicates to 96 well microtitre plates, and the reaction 
initiated by addition of 200 pL of assay reagent made up according to the 
manufacturer's instructions. The plates were incubated for 30 min at room temperature 
prior to the absorbance being read at 560 run. Protein concentrations were estimated 
from the standard curve. The dilution factor was taken into account to determine the 
protein concentration of the undiluted samples. 
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2.7.2 Western Blot 
2.7.2.1 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Principle: Proteins are separated based on size by SDS-PAGE performed under 
reducing conditions (Laemmli UK, 1970). The polymerisation of acrylamide is initiated 
by the addition of ammonium persulphate (APS) and the base TEMED. TEMED 
catalyses the decomposition of persulphate to give a free radical which initiates the 
polymerisation reaction. Samples are prepared by boiling in P-mercaptoethanol and 
SDS. P-mercaptoethanol reduces any disulphide bridges and the SDS, an anionic 
detergent denatures proteins by wrapping around the polypeptide backbone in a ratio of 
approximately 1.4 grams SDS per gram of protein. The bound SDS masks the charge of 
the proteins, forming anionic complexes with constant net negative charge per unit 
mass. The purpose of the stacking gel is to concentrate the protein sample into a sharp 
band before it enters the main separating gel. The protein-SDS complexes concentrate 
in a very tight band between glycinate and chloride boundaries. Once the glycinate ions 
reach the separating gel, it becomes more ionised due to the higher pH and its mobility 
increases. The interface between the chloride and glycinate ions leaves behind the 
protein-SDS complexes, which are left to electrophorese at their own rates. The 
protein-SDS complexes continue to move towards the anode. Proteins are separated by 
their size. Smaller proteins pass more easily through the pores of the gel. Larger 
proteins are retarded by frictional resistance due to the sieving effects of the gels. After 
the tracking dye (bromophenol blue) reaches the bottom of the gel, electrophoresis is 
stopped. 
Materials: 
N, N, N'N'-tetramethylenediamine (TEMED), Acrylamide/bis-acrylamide (37.5: 1) 
solution [40% (w/v)] was obtained from Anachem (Luton, UK). Pre-stained protein 
SDS-PAGE molecular weight standards (Broad Range) were obtained from BIO-RAD 
Laboratories UK. 
Solutions: 
10% Resolving gel buffer containing 0.5 1M Tris base, pH 8.8. 
Stacking gel buffer containing 142 mM Tris base, pH 6.8. 
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Sx running buffer consisted of 200 mM Tris base, 192 mM glycine and 0.1 % (w/v) 
SDS. 
For monitoring the progress of the gel run and the efficiency of the Western transfer 10 
pl of pre-stained standard were used. 
Methods: 
Electrophoresis was carried out in a Bio-Rad Mini-Protean 11 apparatus with 1.5 min 
spacers and combs. For a 10% gel, 3.75 ml of a 40% stock acrylamide-bis-acrylamide 
solution was mixed with 10% of gel buffer, pH 8.8 (11 ml). All solutions were allowed 
to reach room temperature before mixing. Gel mixture (14.2 ml) was polymerised by the 
addition of 20 pl, of TEMED and 75 pl of a 10% (w/v) solution of APS, and the 
solution poured into a gel cassette and left to polymerise. Following polymerisation, a 
4% stocking gel was formed by mixing I ml of the 40% stock acrylamide/bisacrylamide 
solution with 8.8 ml of stacking gel buffer, 50 gL of 20% SDS, 100 pl of 10% APS and 
20 pl of TEMED. 
Reduced samples were prepared for electrophoresis by addition of SDS loading buffer 
containing 142 mM Tris base pH 6.8,0.8g SDS, 50% of glycerol (v/v), 0.5% 
bromophenol blue (w/v) and 50 mM DTT (di-thio-threitol) and a nonreduced samples 
which were the same reagent but with out DTT. The samples were boiled for 5 min in a 
water bath. Following a brief centrifugation, samples were applied to the gel along with 
molecular weight markers and electrophoresed at 150V for approximately 1.5 hr, or 
until the dye front passed the end of the gel. Following electrophoresis gels were 
transferred to a nitrocellulose membrane. 
2.7.2.2 Protein Transfer 
Principle: Proteins are electro-transferred from a SDS-PAGE gel onto nitro-cellulose 
membrane. Proteins bind irreversibly by hydrophobic interactions to the membrane. 
The protein is transferred by applying a current. This is the actual blotting process and 
is necessary to expose the proteins. The membrane is "sticky" and binds proteins non- 
specifically (i. e., binds all proteins equally well). 
Materials 
1,10-phenanthroline and polyoxyethylenesorbitan monolaurate (Tween 20) were 
obtained from Sigma-Aldrich Company Ltd. Precision protein standards and 
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Streptavidin-horseradish peroxidase (HRP) were obtained from Bio-Rad Laboratories. 
Enhanced chemiluminescence (ECL) Western blotting detection reagents and Hyper 
Film were obtained from Amersharn Pharmacia Biotech Ltd. (Buckinghamshire, UK). 
Streptavidin-HRP and HRP-conjugated antibodies were obtained from DAKO Ltd. 
(Cambridgeshire, UK). 
Solutions 
Western Transfer Buffers: Transfer buffer for blotting contained 190 mM glycine, 25 
mM Tris base and 20% (v/v) methanol. 
Blocking Buffer: 5% (w/v) Marvel fat-free dried milk in PBS/I%Tween. 
Method 
Western transfer of proteins for immunoblotting was carried out using a Semi-dry 
blotter. All materials were soaked in the transfer buffer prior to use. A sandwich was 
formed on the anode of the blotter consisting of 9 sheets of filter paper, 1 sheet of 
nitrocellulose, the SDS gel and finally a further 9 sheets of filter paper. A current of 80 
mA for each gel was then passed through the sandwich for 1.5 hr. Following transfer 
the blot was reversibly stained with Ponceau Red solution to check whether the transfer 
was completed. Then the membrane was washed with PBS, 0.5%Tween and blocked 
over night in blocking solution (5% milk in PBS/0.5%Tween). The membrane was 
screened with the Anti h-OPG antibody (R&D) at 1: 1000 for one hour. The membrane 
was then washed once with PBS/Tween for 5 min and the secondary antibody (Rabbit 
anti-goat HRP; Dako po449) was added at 1: 10,000 for 30 min. The membrane was 
then washed with PBS/Tween three times, for 10 minutes. Using ECL reagents, 
antibody-protein complexes were detected as directed by the manufacturer. The light 
emitted is detected by exposing the blot to blue-light sensitive autoradiography film. 
2.8 Real-Time PCR 
Principles: Real-time quantitative PCR is a powerful tool that can be used for gene 
expression analysis. Two types of real time PCR were used (Taq-Man and 
LightCycler). Taq-Man is based on fluorescence labelled sequence-specific 
hybridization probes (resonance energy transfer). The LightCycler uses the DNA 
binding dye, SYBR green I. This dye binds in the minor groove of double-stranded 
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DNA in a sequence independent way. When it binds, its fluorescence increases over 
I 00-fold. 
With real-time PCR it is possible to detect a signal (threshold cycle) and use this to 
determine the starting level of a certain mRNA preparation. Fluorescent signal from 
each PCR reaction is collected as peak-normalized values plotted versus the cycle 
number. Reactions are characterized by comparing threshold cycle (CT) values. The CT 
is a unit-less value defined as the fractional cycle number at which the sample 
fluorescence signal passes a flxed threshold above baseline. Samples with high starting 
copy number show an increase in fluorescence early in the PCR process, resulting in a 
low CT number, whereas lower starting copy number results in a higher CT number. 
Quantitated transcript levels of the GAPDH gene are used as the endogenous control; 
with each unknown sample normalized to GAPDH content. The aim of real time PCR 
is to improve the sensitivity and accuracy of the quantification, especially in the case of 
low abundance mRNA (Dhar AK et al., 2001; Mackay A 2004). 
2.8.1 LightCycler 
Principles: The Quantitative PCR instrument detects accumulation of PCR products, 
allowing easy and accurate quantitation in the exponential phase of PCR reactions. For 
the monitoring of PCR with SYBR Green, conventional PCR primers are needed. The 
primers used for quantitative PCR can be used for LightCycler PCR experiments by 
using SYBR Green 1. 
A successful, highly specific and sensitive quantitative PCR experiment primers must 
fulfil some general properties, such as firstly the target sequence should contain only a 
single annealing site. Secondly the primers should not contain any intra-molecular 
sequence complementarities, which could form secondary structures. No inter- 
molecular complementarities should exist between the primers, which could potentially 
lead to the formation of primer-dimers. Finally target product size should ideally be SO- 
150 bp in length and should not exceed 500 bp. 
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2.8.2 Oligonucleotide Primers and TaqMan Probe Design 
RANKL and OPG complementary DNA (cDNA) sequences (GenBank Accession No. 
AF019047 and U94332, respectively) were evaluated using the Primer Express 
software (Perkin-Elmer). The forward and reverse primers were designed to lie in 
adjacent exons (separated by a long intron) to prevent an amplification of genomic 
DNA that may be contained in the samples. The primers for RANKL and OPG had a 
calculated annealing temperature of 65T. Primers were ordered from (Sigma-Genosys 
Ltd). For RANKL, forward and reverse primers were 
5'AGAGAAAGCGATGGTGGATG and 5'TATGGGAACCAGATGGGATG, 
respectively, creating an amplicon of 116 bp. For OPG, forward and reverse primers 
were 5'AAGAAGATCATCCAAGATATTGACC and 
5'CGGTAAGCTTTCCATCAAGC, respectively, creating an amplicon of 108 bp. The 
primers for GAPDH had a calculated annealing temperature of 60"C. The Taqman 
GAPDH primers and probe were used from R&D (part number 402869) (Rubin j. et al 
2002). 
2.8.3 Quantitation of RANKL and OPG mRNA levels by QT- 
PCR 
To quantify RANKL and OPG cDNA levels: the relative standard curve method and 
the comparative CT method were used. In the relative standard curve method, standard 
curves with known amounts of total cDNA (relative) are analysed for the gene of 
interest (RANKL and OPG). For each unknown sample, the relative amount is 
calculated using linear regression analysis from respective RANKL and OPG standards 
curves. Expression values are then obtained by division of the RANKL and OPG 
value by the GAPDH value. 
2.8.4 Total RNA quantification for Real Time PCR. 
Principles: RiboGreen RNA to quantitate as little as I ng/ml RNA with a fluorescence 
microplate reader, standard spectrofluorometer or filter fluorometer, using fluorescein 
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excitation and emission wavelengths. The excitation maximum for RiboGreen reagent 
is -500 run and the emission maximum is -525 mn using a fluorescence microplate 
reader. Total RNA (2-3 pg) was reverse transcription as reported in section (2.4.2). 
Then the cDNA was diluted 5 times for real time PCR and 2pl of template used for each 
reaction. 
2.8.5 Polymerase chain reaction 
PCR amplification was carried out in a 20 pl volume with 2 pl of LightCycler DNA 
Mastermix (Roche Molecular Biochemicals, Mannheim, Germany). Quantitative (QT) 
PCR amplification and analysis were achieved using a LightCycler instrument. For each 
primer combination optimal MgCI2 (2 mM) concentration and annealing temperature 
were experimentally determined for OPG and RANKL primer pairs (650C) and for 
GAPDH primer pairs were 60T. The reaction mixture consisted of cDNA (2 PI), 0.5 PI 
(which is 0.3 mM) of each primer, 2 pl LightCycler FastStart DNA Master SYBR Green 
I mix (Roche, 2239264), and MgC12 (2 mM), in a total volume of 20 111. cDNA 
conditions to be compared were made with the same PCR master mixes and within a 
single LightCycler run. All templates were amplified using the following LightCycler 
protocol. The FastStart polymerase was activated and cDNA denatured by a 
preincubation for 10 sec at 95T, the template was amplified for 45 cycles with 
denaturation for 20 sec at 95T, annealing of primers at 65T programmed for 5 sec, 
and extension at 72*C for 10 sec. Fluorescent data were acquired during each extension 
phase. After 45 cycles a melting curve was generated by heating the sample to 95"C 
programmed for 0 sec followed by cooling down to 60*C for 15 sec and slowly heating 
the samples at O. VC to 95T while the fluorescence was measured continuously. Fast 
loss of fluorescence is observed at the denaturing/melting temperature of a DNA 
fragment, which is a unique feature of that individual fragment. The melting peak can 
be obtained by plotting the negative first derivative of fluorescence against temperature. 
Finally, the samples were cooled down to 400C for 30 sec. 
The fluorescence emitted by the reporter dye was detected online in real-time, and the 
threshold cycle (CT) of each sample was recorded as a quantitative measure of the 
amount of PCR product in the sample (Zijlstra, A. et al. 2002). 
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The fluorescence emitted by the reporter dye was detected online in real-time, and the 
threshold cycle (CT) of each sample was recorded as a quantitative measure of the 
amount of PCR product in the sample (Zijistra, A. et al. 2002). 
2.8.6 Interpretation of QT-PCR data-Standard curve 
Standard curves were generated from cDNAs made from good quality total RNA. The 
cDNA was serially diluted 12 times starting vAth the equivalent of 250 ng/ml of total 
RNA down to 0.061 ng/ml as shown in (Fig 2-1a) and (Fig 2-1b). The CT values were 
subsequently used to calculate and plot a linear regression line by plotting the logarithm 
of template concentration (X-axis) against the corresponding threshold cycle (Y-axis) as 
shown in (Fig 2-2). 
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Fig 2.1a shows the CT value from each sample from standard 
curve. An example of the CT report observed from Taq-Man CT 
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Fig 2.1b The melt curve of the standard samples, showing only one 
peak at equivalent temperature for all samples as observed from Taq- 
Man. 
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Fig 2.2a An example of the calculated standard curve for the 
expression of OPG mRNA. 
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Fig 2.2b Established general standard for OPG, RANKL and/or 
GAPDH primers. Six dilutions for each individual experiment were 
used. 
2.9 Osteoclast-like cell formation in vitro 
2.9.1 Extracellular matrix (ECM) isolation 
Solutions: 
Hypotonic buffer: 5 mM Tris-Base, 0.5 mg/ml BSA, 0.1 mM CaC12. 
Hypotonic buffer with Igepal: hypotonic solution with 0.5% Igepal (Sigma). 
Method: 
MG-63 cells (2.8 x 104 cells/well) were seeded and grown for 7 days in each well of an 
8 well chamber slide. Cells were fed with DMEM/10% FCS, 100 U/ml penicillin and 
100 /. ig/ml streptomycin every 3 days. After 7 days, MG-63 cells had deposited an 
extracellular matrix. Medium was replenished 24 hr before cells were removed to 
leave the ECM in the culture wells. The cell layer was washed twice with DPBS and 
cells were removed by incubation at 370C with hypotonic buffer for 8 min followed by 
25 - 
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hypotonic buffer with Igepal for 3 min at 370C. The remaining ECM was washed once 
in DPBS containing 10% FCS followed by two washes in DPBS alone. The chamber 
slides were stored at -20'C until required. Before use, slides were washed twice in 
DPBS and once in DMEM medium. 
2.9.2 Isolation Peripheral Blood Mononuclear cells 
Preparation: 
Human peripheral blood was collected from healthy normal donors in syringes and 
immediately transfered to a universal tube containing 1,000 U/ml of heparin solution 
and inverted 34 times to mix. The Histopaqe gradient 1077 (Sigma) was removed from 
the fridge and allowed to warm to room temperature. Histopaque (15 ml) was pipetted 
on to a filter disc in a 50 ml leucosep tube. The leucosep tube (s) were centrifuged at 
1100 rpm (200xg) for 5 min to allow the histopaque to travel through the filter. 
Heparinised blood was then diluted (1: 1) with DPBS and gently pipetted in to the filter 
tube; only 30 ml of blood was used in each leucosep tube. Immediately, the gradient 
was then centrifuged at 1500 rpm (272xg) for 30 min. After centrifugation, the 
mononuclear cell layer is visible as a white fluffy layer sandwiched between a clear 
histopaque and yellow plasma layer interface. The cells were harvested from the 
leucosep tube using a3 ml plastic Pasteur pipette, using a gentle swirling motion to 
remove the cell layer. Then the cells were pipette into a 30 ml universal and centrifuged 
at (327g) 1800 rpm for 5 min. The cells were washed by resuspended the pellet in 20 ml 
of Dulbecco's PBS and centrifuged at (200g) 1100 rpm for 1-2 min, the cells were 
resuspended in 10 ml of media RPMI 1640 with 20% FCS. The numbers of cells in the 
resulting suspension of peripheral blood mononuclear cells (PBMCs) were counted 
using a haemocytometer. 
2.9.2.1 Cultured of peripheral Blood Mononuclear Cells 
(PBMCs) 
PBMCs were cultured in the prepared 8-well chamber slide. Cells were seeded at 5x 
105 cells/well for 24 hr in medium/FCS (20% vol/vol). Then fresh untreated medium 
was added as -ve control, and to the treated wells; medium. /FCS with IL-17 at different 
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concentrations and RANKL and M-CSF were added as a positive control. The cultures 
were maintained for 21 days; culture medium was replenished every three days with 
fresh medium supplemented with the agents as described above. 
2.9.2.2 Preparation of Peripheral Blood/Synovial Fibroblast 
Cell Cocultures 
PBMCs cells (5 x 105) were cultured in the prepared 8-well chambered slide for 24 hr in 
medium/FCS (20% vol/vol). Then 2x 104 SFB cells were added to each well and 
incubated overnight with untreated medium/FCS. Then the cultures were replenished 
with fresh untreated medium as -ve control, medium/FCS with a low and a high 
concentration of IL-17, RANKL, M-CSF, and OPG were added. The cultures were 
maintained for 21 days, during which time the culture medium and added factors 
(including cytokines/growth factors) were replenished every 3 days. 
2.9.2.3 Culture of PBMCs on ivory slices 
Elephant ivory (a kind gift of HM customs and Excise, Heathrow Airport, London, UK) 
was cut into small pieces, then into a thin slices (0.6 mm thick) of (0.8 cm) diameter is 
with an Isomet 2000 (BUEHLER DIAL Engineering UK) using a slow speed diamond- 
edged wafering blade. These slices were washed and sterilized with 70% ethanol then 
placed in 96 or 48 well tissue-culture plates. PBMCs (5 x 105 in 96 wells) plates and (I 
X 106 in 48 wells) plates were seeded in each well and cultured on ivory slices for (2 hr - 
4hr). The ivory slices were then washed in culture medium to remove the nonadherent 
cells and debris. Then the culture media/FCS 20% and medium containing OPG were 
used as a negative control, medium/FCS with RANKL + M-CSF as a positive control, a 
low and a high concentration of IL-17, IL-17 + M-CSF at different concentrations and 
M-CSF were added. The experiments were performed with five replicates. The 
cultures were maintained for 21 days, during which time the medium and added factors 
(including cytokines/growth factors) were replenished every 3 days. 
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2.9.2.4 PBMCs/Synovial Fibroblast co-cultures on ivory 
slices 
Ivory slices were placed in (96 or 48) well tissue-culture plates. Then PBMCs (5 x 105 - 
IX 106) were added to each well and cultured on ivory slices for (2 hr -4 hr). The 
wells were then washed in medium/FCS 20% to remove nonadherent cells and debris. 
SFB cells (2 x 104) were then added and incubated overnight, the fresh medium/FCS 
with OPG was added as a negative control, mediurn/FCS with RANKL + M-CSF as a 
positive control, IL-17, IL-17 + M-CSF and M-CSF were added in 5 wells to each 
treatment. The cultures were maintained for 21 days, during that time the medium and 
added factors (including cytokines/growth factors) were replaced every 3 days. 
2.9.3 Cytochemical and Functioni Assessment of 
osteoclast Formation 
Solutions: 
4% paraformaldehyde in DBPS. 
For TRAP, a commercially available kit (Sigma, UK) was used. 4'-6-Diamidino-2- 
phenylindole (DAPI) (10 pg/ml) stock solution in dH20 stored in dark at -20"C, and 
Triton X- 100 (T-ocytlphenoxypoly-ethoxyethanol) were obtained from Sigma. 
Methods: 
After culture for an indicated period, cells were fixed in 4% paraformaldehyde solution 
for 10 min then washed twice in DBPS. After staining for acid phosphatase, naphthol 
AS-BI phosphate is used as a substrate, in the presence of 1.0 mol/I tartrate. The 
product then reacts with Fast Garnet GBC salt. TRAP-positive cells containing more 
than three nuclei were counted as OCLs as shown in Fig 2.3. 
DAPI was used to visualize the DNA in our experiment and therefore to determine the 
number of nuclei in each OCL (Fig 2.3). For DAPI binding the slides were washed two 
times with PBS for 5 min each time then DAPI (10 pg/ml) with 0.1% Triton x-100 in 
PBS was added for 30 min. After incubation the slides were washed three times in PBS. 
The images were visualized with an incidence fluorescent microscope. 
69 
Chapter-') Materials and Methods 
Alb -0 
1 
1W4 --9 
N 
v- * el 6ý. 
-* 
,4 ,A 
#I 
OCL 
Fig 2.3 shows the multinucleated cells stained for TRAP with or without 
DAPI. A is the PBMC treated with RANKL and M-CSF ('30 + 25 ng/ml) as a 
positive control stained only for TRAP-activity. B The positive control is stained 
for TRAP and DAPI to make clear that the cells which were counted have three or 
more nuclei. The bar is 50 pm. Osteoclast-like (OCL) and Nuclei (N). 
Functional assessment of osteoclast formation was determined at the end of the co- 
culture period using a resorption assay. Cells were stained for TRAP activity. The cells 
were then removed from the ivory slices by immersing them in 10% (vol/vol) sodium 
hypochlorite in distilled water for 30 min at room temperature. Ivory slices were washed 
in distilled water, and briefly sonicated, to completely remove all cells. This permitted 
examination of the ivory surface for evidence of lacunar resorption (Louise, E. et al. 
1996). The slices were stained with 0.5% (w/v) toluidine blue for 3) min, air dried, and 
examined by reflected light microscopy. The surface of each slice was examined for 
evidence of lacunar resorption using a Metallurgical microscope (Axiovert I OOA ZEISS 
Germany). The extent of resorption was determined by measuring the area of discrete 
pits counted on each slice. Resorption pits were observed as either individual small pits 
or large multilocular areas. 
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2.10 Statistical analysis 
The difference between sample group means was tested for statistical significance by 
ANOVA (analysis of variance) with Tukey and Duncan post test, where *** P: 5 0.001; 
** P-. 5 0.01; * P: 5 0.05 
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3 The effect of IL-17 on the expression and production 
of OPG by synovial fibroblasts and osteoblast-like 
cells 
3.1 Introduction 
RA is a chronic inflammatory joint disease, and bone erosion is a major complication 
(Firestein GS. et al., 1990; Chen E. et al., 1993). In areas of pannus infiltration, erosion 
of cartilage and subchondral bone is common, leading to characteristic marginal 
erosions seen radiographically in this disease. The area of contact between pannus and 
cartilage/bone represents an erosive front, and the role of osteoclasts in the erosion of 
bone in arthritis has been recognized (Bromley M. and Wooley DE. 1984; Suzuki Y. et 
al., 1998). IL-1, IL-6 and TNF-cc are proinflammatory cytokines that mediate the 
continuation of synovitis and cartilage/bone destruction and are produced in increased 
quantities by RA synovium and detected in synovial fluid (Arend WP et al., 1998; 
Feldmann M. et al., 1997). The important role of these cytokines on osteoclastic 
recruitment, proliferation and differentiation has been described (Pfeilschiffer J. et al., 
1989; De la Mata J. et al. 1995). Furthermore, the potency of IL-17 as a stimulator of 
osteoclastogenesis has been shown in vitro (Kotake S. et al. 1999), and this T-cell- 
derived cytokine was found in the synovium, of patients with RA (Kotake S. et al. 1999; 
Chabaud M. et al. 1999). OPG inhibits osteoclast formation in a co-culture system of 
osteoblasts and bone marrow cells, pit formation by osteoclasts in vitro, and bone 
resorption in organ culture of fetal mouse long bones (Kwon BS. et al., 1998; Simonet, 
WS. et al., 1997; Okada T. et al., 2003). 
The importance of OPG in normal bone physiology has been shown in OPG deficient 
mice produced by targeted disruption of the gene (Mizuno A. et al., 1998, Bucay N. et 
al., 1998). OPG knockout (OPG -/-) mice were viable and fertile; they exhibited severe 
osteoporosis marked by excessive bone resorption caused by enhanced osteoclast 
formation and function. The strength and mineral density of their bones were decreased 
dramatically (Mizuno A. et al., 1998, Bucay N. et al., 1998). Bone histomorphometric 
analysis showed that the osteoblast surface as well as the osteoclast surface was 
increased in OPG-deficient mice (Bucay N. et al., 1998). OPG (-/-) mice also 
developed medial calcification of the aorta and renal arteries (Bucay N. et al., 1998). 
These results indicate that OPG is a physiological regulator of osteoclast-mediated bone 
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resorption during postnatal bone growth. In vivo administration of OPG results in an 
increase in bone mineral density and bone volume associated with a decrease of active 
osteoclast number in normal and ovariectomized rats. Serum Ca+2 concentrations were 
also decreased by injecting OPG into rats (Morony S et al., 1999; Tomoyasu A. et al., 
1998; Yamamoto M. et al., 1998). In addition OPG administration has been shown to 
be anti-resorptive in postmenopausal women and in patients with lytic bone metastases 
(Kong YY and J. M. Penninger. 2000). 
Surface plasma resonance experiments revealed that RANK, RANKL and OPG are able 
to form a tertiary complex; suggesting that OPG is not only a soluble decoy receptor for 
RANKL but also may have direct effects on osteoclast functions (Theoleyre S. et al., 
2004). In addition, RANK and RANKL expression are inhibited from the murine 
monocyte cells RAW-264.7 stimulated with OPG while MMP-9 and Cathepsin K 
mRNA expression were not modulated. This suggests that some of the OPG effects are 
RANKL-dependent (Wittrant Y. et al., 2004). 
For instance, a recent study reported that estrogen appears to inhibit the effects of 
RANKL by enhancement of the production of OPG (Aubin JE. and Bonnelye E. 2000). 
In addition, RANKL secreted by T cells can induce osteoclastogenesis and this 
mechanism is enhanced by cytokines such as TNFa, IL-I and IL-17. Conversely, this 
system is blocked by OPG, IL-4 and IL-10, which inhibit both inflammation and 
osteoclastogenesis (Saidenberg Kennanac'h N et al., 2002). This information may 
explain part of the abnormal phenomena in diseases such as RA characterized by both 
inflammation and destruction. Activated T cells within the rheumatoid synovium 
express RANKL. Cells within the synovium are capable of differentiating to osteoclast- 
like cells under some conditions, particularly when supported by M-CSF and RANKL. 
This suggests that bone erosion seen in RA might result from the RANKURANK 
system through activated T cells. This opens up the possibility that OPG may have 
therapeutic effects in RA (Saidenberg et al., 2002). The new understanding provided by 
the RANK/RANKL/OPG paradigm for both differentiation and activation of osteoclasts 
has had tremendous impact on the field of bone biology and has opened new avenues 
for development of possible treatments of diseases characterized by excessive bone 
resorption. 
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3.1.1 The aims of this chapter are to: 
Determine the effects of IL-17 and OSM on the expression of OPG by SFB 
derived from patients with RA. 
Establish the effects of IL-17 and OSM on the expression and production of 
OPG by SFB derived from patients with OA. 
Establish the effects of IL-17 and OSM on the expression and the production of 
OPG by osteoblast-like (human osteosarcoma) MG-63 cells. 
Demonstrate the effects of IL-17 and OSM on the expression and the production 
of OPG by osteoblast-like (human osteosarcoma) SaOS2 cells. 
3.2 Materials and Methods 
SaOS-2, MG-63 cells and human fibroblasts were cultured and stimulated as outlined in 
(2.2.1 and 2.2.2). After cytokine treatment, gene expression was assessed by analysis of 
mRNA levels as mentioned in section (2.3) and reverse transcribed into complementary 
DNA (cDNA) section (2.4.1 and 2.4.2). 
Complementary DNA was amplified by PCR using primer pairs to generate products 
corresponding to specific gene products as listed in Table 2-1 section (2.4.3). Primers 
were designed against human sequences for OPG, GAPDH. PCR was performed for 35 
cycles for OPG and GAPDH. Amplification products were identified by electrophresis 
on a 1% (w/v) agarose gel as mentioned defore in chapter-2 section (2.3.4) 
Furthermore gene expression was assessed by Northern blot analysis. Agarose gel were 
prepared as mentioned in (2.6.1). RNA was electrophoresed in equal amounts. OPG 
and GAPDH probes were labelled as reported in section (2.6.3). In addition OPG 
production was assessed by Western Blot analysis; equal amounts of proteins were used 
for Western blot and screened for OPG as in section (2.7.2.2). 
For real time PCR, the OPG cDNA sequence was used to design the forward and 
reverse primers, spanning intron/exon boundaries to prevent the amplification of 
genomic DNA that may be contained in the samples. The primers for OPG had a 
calculated annealing temperature of 65"C. For OPG, forward and reverse primers 
created an amplicon of 108bp. The primers for GAPDH had a calculated annealing 
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temperature of 60"C. The Taq-man GAPDH control reagents primers and the probe 
were used from R&D (part number 402869) as in section (2.8.2). In the elative standard 
curve method, standard curves with known amounts of total cDNA (relatively) are 
analysed for the gene of interest OPG. For each unknown experiment, the relative 
amount is calculated by division of the OPG value with GAPDH value as in section 
(2.8.3). The reverse transcription was performed in 20 pl reactions as mentioned in 
section (2.8.5). Then the cDNA was diluted 5 times for real time and 2 ýtl of template 
was used as for each reaction. 
PCR amplification was carried out in a 20 pl volume with 2 pl of LightCycler DNA 
Mastermix as in section (2.8.5). All templates were amplified following LightCycler 
protocol. The fluorescence emitted by the reporter dye was detected online in real-time, 
and the threshold cycles (CT) of each sample together with the standard curve samples, 
were recorded as a quantitative measure of the amount of mRNA product in the original 
sample. 
3.3 Results 
3.3.1 The effects of IL-17 and OSM on the expression of 
OPG by SFB derived from patients with RA. 
To study the effects of IL-17 and OSM on the expression of OPG by synovial cells in 
vitro. SFB cells were examined using tissue obtained at joint replacement surgery to 
assess the ability of SFB from RA to express and produce OPG mRNA- In this 
experiment no DNase treatment was used as a result the cDNA in some samples was 
contaminated with the genomic DNA. However, The results from this experiment 
showed that there was no increase in the expression of OPG in response to IL-17 (5 and 
50 ng/ml) at 6 hr but there was increase in OPG mRNA expression following OSM (10 
ng/ral) treatment as shown in (Fig 3.1). These results were later confirmed by Northern 
blot analysis using the same mRNA (Fig 3.2). 
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Fig 3.1 The expression of OPG' mRNA by human RA SFB. S113 (IýA) were 
cultured, serum reduced to 0.5% IVS overnight and stimulated for 6 hr with IL-17 
(5 and 50 ng/ml) and OSM (10 ng/ml). RNA was extracted using trizol reagent. 
Total RNA was analyzed by RT-PCR with specific primers using the conditions 
described in Materials and Methods. PCR was performed for 35 cycles. The PCR 
products were run on a 1% agarose gel, stained with ethidium bromide and 
visualized under UV light. (+) is cDNA and (-) is negative control containing 
untranscribted total RNA. 
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Kb 5N. 0 
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2.8 3.0 
GAPDH 2.0 
2.2 
IL-17 -- 50 5 50 5 
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Fig 3.2 The expression of OPG mRNA by human RA SFB. SFB (RA) cells 
were cultured, serum reduced to 0.5% FCS overnight and stimulated for 6 hr by 
IL-17 (5 and 50 ng/ml) and OSM (10 ng/ml). RNA was extracted using trizol 
reagent. Equal amounts of RNA were electrophoresed using 1% agarose/0.4M 
Formaldehyde and Northern analysis performed. GAPDII was used to normalise 
for RNA loading. 
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A second sample from another RA patient was assessed by quantitative PCR (real time 
PCR). OPG mRNA in these cells appears to be expressed in a biphasic way with the 
cells responding at 6 hr and 48 hr but not at 24 hr (Fig 3.3). However, there was no 
OPG mRNA expressed in response to IL-17 (5 ng/ml) but levels were enhanced by IL- 
17 (50 ng/ml) about 6-fold at 6 hr while the expression of OPG rnRNA was increased in 
response to OSM about 19-fold compared to the control. The control is very high at 24 
hr so it is difficult to interpret the results at this time point. In addition, there was no 
increased expression of OPG rnRNA by IL-17 (5 ng/ral) while the expression was 
increased by IL-17 (50 ng/ml) about 1.5-fold at 48 hr. There was a decrease in 
expression of OPG mRNA level in response to OSM at 24 hr and 48 hr compared to the 
controls. 
6.00 
= 5.00 
4.00 
3.00 
0 
2.00 
9 1.00 
0.00 
IL-17 5 50 -5 so -5 50 - 
osm = 10 - 10 -- 10 
6 hr 24 hr 48 hr 
Fig 3.3 The expression of OPG mRNA by human RA synovial fibroblast. SFB 
(RA) cells were cultured, serum-reduced to 0.5% FCS overnight and stimulated for 
6 hr, 24 hr and 48 hr by IL-17 (5 and 50 ng/ml) and OSM (10 ng/ml). Total RNA 
was analyzed by RT and Quantitative PCR analysis with OPG primers using the 
conditions described in Materials and Methods. 
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3.3.2 The effects of IL-17 and OSM on the expression and 
production of OPG mRNA from SFB cultured from 
patient with OA. 
3.3.2.1 OPG mRNA expression by SFB (OA). 
A sample from a patient with OA was assessed by conventional PCR. The results show 
that there was no expression of OPG mRNA from cells stimulated with IL- 17 (5 and 50 
ng/ml) but there was a very low level of OPG mRNA expressed by cells treated with 
OSM (10 ng/ml) at 6 hr compared with the control. OPG mRNA expression was dose 
dependently enhanced in the cells stimulated with IL-17 and the expression of OPG 
mRNA was increased in cells treated with OSM compared to untreated cells at 24 hr. 
At 48 hr OPG mRNA expression was still increased by IL-17 treatment, but apparent 
levels were higher in cells treated with IL-17 (5 ng/ml) than cells treated with IL-17 (50 
ng/ml). The expression of OPG mRNA from cells stimulated with OSM was enhanced 
at 48 hr but less than the cells treated with OSM at the 24 hr time point compared to the 
control as shown in Fig 3.4. 
However, another two samples from patients with OA were examined by Northern blot 
analysis and the pattern of both samples shows that OPG mRNA is expressed in 
response to IL-17 (5 and 50 ng/ml) at a very low level at 6 hr and the expression is 
slightly more elevated by IL-17 (5 ng/ml) than by IL-17 (50 ng/ml) at 6 hr. The 
expression of OPG mRNA was low but slightly elevated by IL-17, dose dependently at 
24 hr. In general, the expression of this gene was higher at 6 hr compared to 24 hr. 
There was expression of the gene following OSM treatment at 6 hr and 24 hr compared 
to the control. OPG mRNA was expressed in response to IL-17 dose dependently and 
also upon treatment with OSM at 48 hr (Fig 3.5). In addition, the second sample 
showed that the gene was expressed in response to IL-17 (5ng/ml) at 6 hr and to IL-17 
(50 ng/ml) at 24 hr at low levels while the gene was expressed at high levels in response 
to IL-17 dose dependently at 48 hr (Fig 3.6). However, the general pattern of these 
results from conventional PCR and Northern blot analysis showed that expression of 
this gene was elevated in response to IL- 17 at 48 hr. 
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Fig 3.4 The expression of OPG rnRNA by synovial fibroblasts cells. Sl`B 
from an osteoarthritis patient were cultured and stimulated for 6 l1r, 24 hr and 48 
hrby IL-17(5 and 50ng/ml) and OSM(10 ng/ml). RNA was extracted by using 
trizol reagent. Total RNA was analyzed by RT-PCR with 013G primers using 
the conditions described in Materials and Methods. PCR was performed for 35 
cycles. The PCR products were run on 1% agarose gel, stained with ethidium 
bromide and visualized under UV light. (+) is cDNA and (-) is negative control 
containing untranscribted total RNA. 
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Fig 3.5 The expression of OPG mRNA by human OA SFB. SFBs cclls were cultured, 
serum-reduced to 0.5% FCS overnight and stimulated for 6 hr, 24 hr and 48 hr by ll-- 17 (5 
and 50 ng/ml) and OSM (10 ng/ml). RNA was extracted using trizol reagent. Equal 
amounts of RNA were electrophoresed using 1% agarose/0.4M I-ormalehyde and 
Northern analysis performed. GAPDH was used to normalise for RNA loading. 
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Fig 3.6 The expression of OPG mRNA by synovial fibroblasts from an OA patient. 
SFBs cells were cultured, serum starved overnight and stimulated for 6 l1r, 24 lir and 48 lir 
by IL-17 (5 and 50 ng/ml) and OSM (10 ng/ml). Total RNA was harvested Equal 
amounts of RNA were electrophoresed using 1% agarose/0.4M Formalchyde and 
Northern analysis performed. GAPDH was used to normalise for RNA loading. 
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I have used four samples from OA patients undergoing joint replacement surgery and 
analysed OPG expression by real-time PCR. OPG mRNA was detectable in all samples 
but there were some variation in its expression and in the response of these cells. 
However, the expression of OPG mRNA by SFB cells is stimulated with IL-17 (5 and 
50 ng/ml) and OSM (10 ng/ml) compared to untreated cells for 6 hr, 24 hr and 48 hr as 
shown in (Fig 3.7A-C) OPG mRNA was strongly expressed in response to IL-17 (50 
ng/ml) at 6 hr in 4 of the 5 samples. In addition, in one sample the upregulation was 
maintained over a 48 hr time course. However, in 3 of the 5 patient samples 
upregulation only observed at 6 hr and was not apparent at 24 hr. Upregulation appears 
to be dose dependent with 50 ng/ml of IL-17 providing stronger upregulation than 5 
ng/ml. For OSM stimulation, no upregulation of OPG mRNA was apparent in any of 
the samples. 
In another experiment with OA synovial fibroblasts (Fig 3.71)) the results show that 
there was no OPG mRNA expressed in response to IL-17 at 6 hr compared to the 
control. The induction of this gene was dose dependent in response to IL-17 at 24 hr 
but there was no induction at 48 hr. There was expression of OPG mRNA in response 
to OSM at 6 hr and 24 hr. 
The general pattern of 8 samples from OA patients undergoing joint replacement 
surgery and analysed for OPG expression by Northern blot and real-time PCR analysis 
are shown in Table 3. L OPG mRNA was detectable in all samples but there were some 
variation in its expression and in the response of these cells. OPG expression in 
response to IL-17 from these samples shows that in some of them OPG mRNA 
expression was up-regulated at 6 hr and in the other samples the expression enhanced at 
48 hr. 
3.3.2.2 OPG production from SFB (OA) 
The production of OPG from (OA) synovial fibroblasts was studied by Western blot 
analysis. These experiments showed that the pattern of OPG production was increased 
by IL-17 (50ng/ml) and OSM in the conditioned medium of both samples at 6 hr. OPG 
production was increased in the first sample by IL-17 (5 ng/ml) and in the second 
sample by IL-17 (50 ng/ml) and OSM at 24 hr compared with the control. While OPG 
production was increased by IL-17 (5 and 50 ng/ml) in the first sample and by only IL- 
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17 (50 ng/ml) at 48 hr and the production of OPG was decreased in response to OSM 
with increase in time (Fig 3.8). 
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Fig 3.7 The expression of OPG mRNA by human synovial fibroblast from 
OA patient. SFB cells were cultured, serum-reduced to 0.5% FCS overnight 
and stimulated for 6 hr, 24 hr and 48 hr by IL-17 (5 and 50 ng/ml) and OSM (10 
ng/ml) and compared to untreated cells. Total RNA was analyzed by 
Quantitative PCR analysis with OPG primers using the conditions described in 
Materials and Methods for four independent samples (A, B, C and D). 
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Fig 3.8 The OPG production by hurna synovial fibroblasts (SFB). SFB cells 
were cultured, serum-reduced to 0.5% overnight and stimulated Ilor 6 hr, 24 hr and 
48 hr by IL- 17 (5 and 50 ng/ml) and OSM (10 ng/m 1). The conditioned media were 
collected for Western blot analysis. (A) Lanes 1-8 were run on a separate gel. (B) 
Lanes 1-6 were run on a separate gel and samples 5 and 7, and 6 and 8 are duplicate 
samples. These data were representative of two independent experiments. 
3.3.3 The effects of IL-17 on the expression and production 
of OPG by human osteosarcoma cell line, MG-63 
3.3.3.1 OPG mRNA expression by MG-63 
No increase in OPG mRNA expression was seen in MG-63 cells stimulated 'ývith IL-17 
(5 and 50 ng/ml) and with OSM (10 ng/ml) at 6 hr compared to the untreated cells. 
While the expression of OPG mRNA was increased by 11-- 17 and OSM at 24 hr and 48 
hr compared to the control, there was no clear difference between the different doses of 
IL-17 (Fig 3.9). Northern analysis was performed and representative results are shown 
in Fig 3.10. OPG mRNA levels are not significantly different between treatments at 6 
hr and 24 hr. There was some evidence of elevated OlIG rnRNA levels at 48 hr when 
treated with IL- 17 or OSM. 
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OPG 
400bp 
GAP 
4831 
Fig 3.9 The expression of oi% rnRNA by conventional PCR by MG-63. MG-63) 
cells were stimulated with 11,17 (5 and 50 ng/nil) and OSM (10 ng/ml). The cells 
were cultured for 6 hr, 24 hr and 48 hr. RNA was extracted by using trizol reagent. 
Total RNA was analyzed by RT-PCR with OPG primers using the conditions 
described in Materials and Methods. PCR was performed for 35 cycles. The PCR 
products were run on 1% agarose gel, stained with ethidium bromide and visualized 
under UV light. This result is representative of three independent experiments. 
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Fig 3.10 The expression of OPG mRNA by Northern blot analysis by MG-63- 
MG-63 cells were cultured, serum starved overnight and stimulated with IL-17 (5 and 
50 ng/m 1) and OSM (10 ng/ml), the cells were cultured for 6 hr, 24 hr and 48 hr. total 
RNA was harvested. Equal amounts of RNA were electrophorescd using 1% 
agarose/0.4M Formalehyde and Northem analysis performed. GAPD11 was used to 
normalise for RNA loading. This result is representative of three independent 
experiments. 
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3.3.3.2 OPG production by MG-63 cell line 
The production of OPG from MG-63 cells into the culture medium was studied by 
Western blot analysis. These experiments showed that OPG production was increased 
by IL-17 (50 ng/ml) and by OSM at 6 hr compared with the control. Also, OPG 
production was increased in the conditioned media from the cells stimulated by IL- 17 (5 
and 50 ng/ml) and OSM at 24 hr. The production of OPG was further detected at 48 hr 
by IL- 17 (5 and 50 ng/ml) and OSM (Fig 3.11). 
1 10 11 12 
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Fig 3.11 The OPG production by MGJP-63 cell line. MG-63 cells were cultured, 
serum starved overnight and stimulated for 6 lir, 24 lir and 49 hr by IL- 17 (5 and 50 
ng/ml) and OSM (10 ng/rnl). I'he conditioned media have collected for Western blot 
analysis. Lanes 1-8 were run on a separate gel. These data were representative of 
two independent experiments. 
3.3.4 The effects of IL-17 on the expression of OPG by 
SaOS-2 cells. 
3.3.4.1 OPG mRNA Expression by SaOS-2 
In this study I examined the effiects of IL-17 and OSM on the expression of OPG 
mRNA by human osteosarcoma cells, SaOS-2. The results showed that OPG 11IRNA 
was apparently expressed in all the treatments (Fig 3.12). There was no clear difference 
between the different treatments and the control at each of the different time points. 
Northern blot analysis was also performed for these experiments (Fig 3.13). I'liese 
studies show that there was no increase in OPG mRNA expression in cells stimulated 
with IL- 17 (5 and 50 ng/ml) at 6 hr and 24 lir compared to the untreated cells. There 
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was enhancement in the level of OPG mRNA in an apparent dose dependent response to 
IL-17 at 48 hr. OPG mRNA was elevated in response to OSM at 6 hr and there was no 
ftu-ther regulation of OPG mRNA levels by OSM at 24 hr and 48 hr. 
Quantitative RT-PCR was also performed on the same total RNA used in the Northern 
blot analysis. The results for 24 hr and 48 hr showed that there was no OPG mRNA 
expressed in response to IL-17 (5 and 50 ng/ml) at 24 hr compared to the control and 
OPG was enhanced in response to IL-17 (5 and 50 ng/ml) dose dependently at 48 hr 
compared to control. There was no expression of OPG mRNA in response to OSM at 
24 hr and 48 hr (Fig 3.14). SaOS-2 cells, after several passages old, responded 
differently to IL-17 and OSM treatment. However, the results from these cells by 
conventional PCR show that there was no difference between different treatments at 6 
hr and 48 hr but there was expression of OPG mRNA in response to OSM at 24 hr (Fig 
3.15). Furthermore, quantitative PCR analysis for this experiment shows that the 
expression of OPG mRNA after several passages changed (Fig 3.16). The expression of 
the gene was enhanced by IL-17 (5 ng/ml) at 6 hr but there was no OPG mRNA 
expression in response to IL-17 (5 and 50 ng/ml) at 24 hr and 48 hr. There was 
expression of OPG in response to OSM at 6 hr and 24 hr, and this was increased at 48 
hr. In general, the expression of OPG mRNA was at a very low level compared to the 
previous experiments. 
3.3.4.2 OPG production by the SaOS-2 cell line 
The production of OPG from the human osteosarcoma SaOS-2 cell line was studied by 
Western blot analysis. The pattern of results showed that OPG production was 
increased by IL-17 compared with the control. The production of OPG was increased 
dose dependently by treatment with IL-17 (5 and 50 ng/ml) and increased by OSM at 24 
hr compared to the control. The production of OPG was induced by IL-17, but not dose 
dependently, and the production of OPG by OSM was decreased at 48 hr (Fig 3-17). 
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Fig 3.12 The expression of OPG mRNA by conventional PCR. SaOS-2 cells \vere 
stimulated with IL-17 (5 and 50 ng/ml) and OSM (10 rig/nil) t'()r 61irs, 24 hr and 48 l1r. 
RNA was extracted by using trizol reagent. Total RNA was analyzed by RT-PCR with 
OPG primers using the conditions described in Materials and Methods. PCR was 
performed for 35 cycles. The PCR products were run on 1% agarose gel, stained with 
ethidium bromide and visualized under UV light. This result is representative of three 
independent experiments. 
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Fig 3.13 The expression of OPG rnRNA by SaOS-2 cells. SaOS-2 cells 
were stimulated with IL-17 (5 and 50 ng/ml) and OSM (10 ng/ml). The cells 
were cultured for 6 hr, 24 hr and 48 hr. Total RNA harvested and analysed 
with Northern blot. GAPD11 was used to nori-nalise for RNA loading. This 
result is representative ofthree independent experiments 
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Fig 3.14 Ratio of OPG/CAPDH mRNA expression by SaOS-2 cells. 
SaOS2 cells were stimulated with ll, 17 (5 and 50 ng/rnl) and OSM (10 
ng/mI) for 24 hr and 48 hr. Total RNA was analyzed by QuantitatiVe 
PCR analysis with OPG primers using the conditions described in 
Materials and Methods. 
6 hr 24 hr 48 lir 
Fig 3.15 The expression of OPG mRNA by conventional PCR. SaOS-2 cells 
stimulated with IL-17 (5 and 50 ng/ml) and OSM (10 ng/rnl). The cells were 
cultured for the time points (6 hr, 24 hr and 48 hr). RNA was extracted by USIng 
trizol reagent. Total RNA was analyzed by RT-PCR with OPG primers using the 
conditions described in Materials and Methods. IICR was performed for 38 cycles. 
The PCR products were run on 1% agarose gel, stained with ethidium bromide and 
visualized under UV light. 
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Fig 3.16 Ratio of OPG/(, API)li rnRNA expression by SaOS-2 cells. SaOS-2 
cells stimulated with IL-1 7 (5 and 50 ng/ml) and OSM (10 ng/ml) for 6 hr, 24 hr 
and 48 hr. Total RNA was analyzed by Quantitative PCR analysis with OPG 
primers using the conditions described in Materials and Methods. 
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Fig 3.17 OPG production by SaOS-2. SaOS-2 cclls werc culturcd, serum 
reduced overnight and stimulated for 6 hr, 24 hr and 48 hr with I L- 17 (5 and 50 
ng/ml) and OSM (10 ng/ml). The conditioned media collected for Western 
blot analysis. Lanes 1-4 Nvere run on a separate gel. This result is 
representative of the pattern ofthree independent experiments. 
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3.4 Discussion 
OPG production is important for understanding the interaction between synovial 
fibroblasts, osteoblasts and osteoclasts and it is possible that a major step in the 
regulation of bone resorption lies in variations of OPG levels in the bone 
microenvironment. Based on animal studies it is postulated that OPG plays a crucial 
role in the regulation of bone mass. Not only transgenic animals have shown this but 
also treatment with recombinant OPG causes rapid effects on bone resorption in a 
model of malignant hypercalcemia in mice (Capparelli, C. et al. 2000). However, the 
precise role of secreted OPG in humans is not as well established. Measuring OPG in 
serum has shown somewhat contradictory data with regard to bone mass (Bornefalk, E 
et al., 1998), and it is not known to what extent serum levels reflect the actual 
concentration of OPG in the bone marrow microenvironment. Therefore, the effects of 
inflammatory cytokines such as IL-17 and OSM were assessed on the expression of 
OPG by synovial fibroblasts from RA and OA patients. These studies were contrasted 
with experiments on human osteosarcoma MG-63 and SaOS-2 cell lines. 
For SFBs from patients with RA, OPG mRNA levels appear to increase in response to 
IL-17 in a biphasic way. The cells responded at 6 hr and 48 hr but did not respond at 24 
hr while OPG mRNA was expressed in response to OSM at only 6 hr compared to the 
control. Furthermore, two samples from OA responded to IL-17 in the same way. In 
addition, in this study I found that there was no increase in the expression of OPG at 24 
hr. The biphasic data suggest that the initial response to IL- 17 at 6 hr is followed by a 
second wave of OPG expression at 48 hr. The exact mechanism underlying this 
observation is unknown but previous studies have demonstrated that IL-17 affects the 
production of PGE2 from synovial tissue cells. PGE2 increases the expression of 
RANKL whilst decreasing the expression of OPG. So, production of PGE2 may be 
responsible for the effects on OPG expression at 24 hr (Kotake S et al., 1999). 
Although another study reported that in primary cultures of human bone marrow stroma 
cells (hBMSC) PGE2 dose- and time-dependently down-regulated the mRNA levels of 
OPG after 4 hr of stimulation with PGE2 (I mM), OPG mRNA levels were significantly 
decreased and the inhibitory effect was seen at and above I nM PGE2 (Brandstrom H. 
et al., 1998a). Furthermore the reduction in mRNA levels also results in a reduction of 
protein secretion. Brandstroin H et al., (2001) subjected hBMSC to stimulation with 
PGE2, and measured OPG in culture media. Inhibition of OPG secretion after treatment 
with PGE2 (I pM) was detected after 16 hr of incubation and the inhibition was 
95 
Chapter-3 Results 
sustained for 72 hr. In addition, expression of OPG in ST2 stromal cell line and human 
bone marrow stromal cells is downregulated by bone-resorbing factors such as PGE2 
and glucocorticoids and upregulated by vit D3, Ca2 ions, or TGFP (Hofbauer LC, 2000; 
Kong YY. and Penninger JM 2000; Brandstrom et al., 1998a, b; Huang L. at al., 2001). 
Alternatively, the expression of this gene in a biphasic way may be due to the secretion 
of insulin-like growth factor I (IGF-I) from the synovial tissue as a previous study 
reported that IGF-I has an inhibitory effect on OPG mRNA that is maximal by 24 hr. 
IGF-I in a dose- and time-dependent manner regulates OPG and RANKL in vitro and in 
vivo. These studies suggest that IGF-I may act as a coupling factor in bone remodelling 
by activating both bone formation and bone resorption; the latter effect appears to be 
mediated through the OPG/RANKL system in bone (Rubin J. 2002). However, in 
contrast to my findings Nagasawa T, et al., (2002) reported that the production of OPG 
was evident already after 6 hr and increased consistently to 24 hr while OPG decreased 
at 48 hr in human gingival fibroblasts in response to lipopolysaccharides (LPS). 
In my study OPG mRNA expression was detectable in all samples from OA, but the 
general pattern of OPG expression in response to IL-17 between samples showed some 
variation. In some of them the expression occurred at 6 hr, 24 hr, and 48 hr, in others 
the expression was biphasic. While in a third group expression occurred at 24 hr. 
However, the expression of OPG from OA tissue was evident in response to IL-17 (50 
ng/ml) from 4 samples at 6 hr out of 8 samples. Furthermore, the expression of the 
OPG mRNA level at 48 hr was in general slightly increased compared to the control. 
The variation in response of synovial fibroblasts from OA patients as shown in table 3-1 
suggests that there may well be considerable heterogeneity between patients, and that 
several different disease states were evident despite the general OA diagnosis. A 
previous study reported that OPG was highly expressed in RA synovial fibroblasts 
compared to OA and non-inflammatory synovial fibroblasts, and different levels of 
OPG expression were found among patients with RA (Kubota A. et al., 2004). 
However, the variety in the expression of OPG in response to IL-17 and OSM may be 
due to the number and the affinity of the IL-17 receptor. The variations in some 
samples may be caused by differences in the number of IL-17R on the synovial 
fibroblasts from one patient to another. IL-17R is present on the surface of the cells and 
if IL-17R numbers decreased with increasing in time, the response to IL-17 by the cells 
may vary in different samples which may reflect the response of OPG expression to IL- 
96 
Chapter-3 Results 
17. These different modes of regulation may reveal an unexpected complexity of the 
dynamics of IL-17R-mediated transcription. 
In general, the production of OPG in response to IL-17 was decreased at 48 hr 
compared to the production of OPG at 24 hr. The decreases in OPG production if 
reproduced in vivo combined with RANKL levels that remained the same or where 
higher could lead to bone and cartilage degradation. However, inflammatory joint 
diseases such as RA tend to destroy joint cartilage and bone matrices. Since bone 
resorption is a common characteristic of osteoclasts, osteoclastogenic factors such as 
inflammatory cytokines and RANKL present within inflamed joints are thought to play 
a vital role in the destruction of these matrices (Kaplan C and Finnegan A. 2003). 
Furthermore, inflammation of knee joints in patients with RA was confirmed by 
significantly higher proinflammatory cytokine levels in the synovial fluid and the 
synovium than those seen in patients with OA (Sugiyama T. T. 2001). 
Consistent with previous reports I have shown that both SaOS-2 and MG-63 cells 
express OPG (Kinpam K. et al., 2000; Dovio A et. al., 2003). Results from MG-63 and 
SaOS-2 suggested that there was some evidence of elevated OPG mRNA levels in 
response to IL-17 (50 ng/ml) and to OSM at 48 hr by MG-63 cells. There was 
enhancement in the level of OPG mRNA dose dependently in response to IL-17 at 48 hr 
by SaOS-2 cells while OPG mRNA was elevated in response to OSM at 6 hr by SaOS-2 
cells. In contrast, Vidal ON et al., (1998a) reported that IL-la induced OPG mRNA 
levels in MG-63 cells peaked at 4 hr and thereafter declined. 
In addition, this study suggests that SaOS-2 cells after several passages responded 
differently to IL-17 and OSM treatments. This may be due to marked and consistent 
proliferation of the cells for several passages that leads to cellular stress and a lack of 
responsiveness to some cytokines and growth factors. 
The production of OPG from MG-63 and SaOS-2 cells was detected in the conditioned 
media in response to IL-17 and OSM. Therefore enhancement of OPG at the mRNA 
and protein levels in MG-63 and SaOS-2 cells could be related to its stimulatory effects 
on osteoblastic differentiation. However, recent studies reported that OPG bound to 
TRAIL and inhibited TRAIL-induced apoptosis of Jurkat cells. They also showed that 
TRAIL blocked OPG in co-culture experiments. These results indicate a potential 
cross-regulatory mechanism involving OPG and TRAIL, which may also participate in 
the regulation of osteoclastic bone resorption (Emery JG. et al., 1998; Bucay N. et al., 
1998). 
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In summary, this data indicate that IL-17 and OSM induces the secretion of OPG, a 
potent inhibitor of bone resorption. Thus, regulation of these cytokines in the bone 
microenvironment may be an important paracrine mechanism whereby OPG reduces 
bone resorption. 
3.4.1 In this chapter I have demonstrated that: 
9 IL-17 regulates the expression of OPG mRNA in a biphasic manner in synovial, 
cells isolated from RA. 
* IL-17 regulates the expression of OPG mRNA in a variable manner in synovial 
cells isolated from OA patients. 
IL-17 affects the production of OPG in a dose-dependent manner in OA SFBs at 
24 hr. 
* IL-17 affects the expression of OPG mRNA in a time dependent manner in the 
human osteosarcoma cells SaOS-2 and MG-63. 
e IL-17 and OSM affects on the production of OPG in the human osteosarcoma 
cells SaOS-2 at 24 hr 
9 IL-17 affects on the production of OPG in the human osteosarcoma cells MG- 
63. OPG production indicates in MG-63 cells in response to OSM. 
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4 The effect of IL-17 and OSM on the expression and 
production of RANKL 
4.1 Introduction 
Bone loss represents a major clinicaly unsolved problem in RA. The skeletal 
complications of RA consist of focal bone erosions and periarticular osteoporosis at 
sites of active inflammation, and generalized bone loss with reduced bone mass 
(Miossec P. 2001). Patients with RA frequently present not only with juxtaarticular 
osteopenia and bone erosions but also with generalized axial and appendicular 
osteoporosis at sites distant from inflamed joints. The pathogenesis of bone loss in RA 
is multifactorial; disease activity certainly is a major determinant of bone mass. Further 
pathogenic factors include effects of anti-inflammatory therapies (in particular 
glucocorticoids (Brosch S. et al., 2003). New evidence indicates that osteoclasts are key 
mediators of all fonns of bone loss in RA. TNF-a is a pivotal in the pathogenesis of 
RA. In addition, to other proinflammatory cytokines in RA are largely produced by 
CD4 T-cells and include IFN-f, IL-17, RANKL, IL-I, IL-6, IL-11, PTHrP. Other 
cytokines produced by monocytes and macrophages such as IL-I, IL-12, IL-18 and 
OSM are also involved in RA (Funk JL et al., 1998; Horwood NJ. et al., 1998; Kotake 
S. et al., 1999; Quinn JM. et al., 2000; Ross FP. et al., 2000; Thomson BM. et al., 1987; 
Miossec P. 2001; Romas, E. 2002). 
Osteoclast formation and function is regulated by cells of the osteoblastic linage. 
Recently, the molecular basis for the regulation was identified; osteoblastic cells induce 
osteoclastic differentiation and resorptive activity through expression of RANKL 
(Chamber TJ. 2000). Stromal cells supporting osteoclastogenesis are known to express 
RANKL (Yasuda H. et al., 1998). However, the stage at which stromal cell express 
RANKL can be regulated remains to be investigated. Therefore RANK, RANKL, and 
OPG have well-established regulatory effects on bone metabolism (Udagawa N. et al., 
2002). 
T cells infiltrating the synovium may play a pivotal role in the pathogenesis of 
rheumatoid synovium since both fibroblasts and activated T cells express RANKL and 
thereby promote osteoclast recruitment and activation. Thus, osteoprotegerin and 
RANKL appear to represent important molecular links between the immune system and 
bone metabolism in rheumatoid arthritis (Romas, E. 2002; Brosch S. et al., 2003). 
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A recent study in healthy human volunteers found that activated T cells expressing 
RANKL induced the formation of osteoclast-like cells from peripheral blood 
mononuclear cells (Kotake S, et al., 2001). Thus, the evidence indicates that T-cell 
activation in vivo results in bone loss via an effect that involves RANKL. This is 
consistent with a RANKL-mediated effect of T cells on bone resorption. 
IL-17 is aT cell-derived proinflammatory cytokine almost certainly involved in 
physiological responses to infection, but also in immunopathology of autoimmune 
disorders. But their direct involvement in disease and joint destruction has been harder 
to demonstrate. Locally, they interact with other blood-derived and resident cells. IL- 
17 enhances the production of proinflammatory cytokines by monocytes and further 
increases their effects on matrix destruction (Miossec P. 2000). However, the increase 
of this cytokines in the synovial tissues of RA patients is suspected to be involved in the 
development of the disease. IL-17 increases RANKL expression by mouse stromal- 
osteoblasts (Kotake S. et al., 1999). The pathogenic roles of IL-17 in the development 
of RA, however, still remain to be elucidated. Previous studies have shown that, in 
vivo, IL- 17 over-expression in the knee joints of type Il collagen-immunized mice leads 
to bone erosion and synovial RANKL/RANK/OPG expression. Local IL-17 promoted 
osteoclastic bone destruction and also RANKL/RANK/OPG expression was found in 
the synovial infiltrate and at sites of focal bone erosion (Lubberts E. et al., 2003). 
Previous studies, have hypothesized that, RANKL has a fundamental role in inducing 
osteoclastogenesis in RA, suggest the possibility that this (RANKL-OPG-RANK) 
system plays an important role in pathological bone destruction (Udagawa N. et al., 
2002; Romas E. et al., 2002; Zheng MH. et al., 2001). In addition, abnormally high 
levels of RANKL are expressed in peri-implant tissues of patients with prosthetic 
loosening suggesting that RANKL may contribute significantly to aseptic implant 
loosening (Crotti TN. Et al., 2004). 
In turn, RANKL has been shown to be expressed on T cells and fibroblast-like cells in 
synovium. This suggests that RANKL provides an important link between the action of 
hormones and physiological cytokines and bone resorption (Wong B. et al., 1997), 
where it induces dendritic cell survival, thereby enhancing T cell priming (Wong B. et 
al., 1997, Anderson, DM. et al., 1997). Therefore, RANKL may also regulate antigen 
presentation during an immune response. 
Additional studies have confirmed that T lymphocytes produce cytokines other than 
RANKL, such as IL-17, GM-CSF and IFNy, which have powerful regulatory effects on 
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osteoclastogenesis (Udagawa N. 2002). Experimental blockade of RANKL has been 
shown to be highly effective in preventing local bone erosion, but not synovial 
inflammation, in animal models of arthritis (Kong YY. et al., 1999; Pettit AR. et al., 
2001). However, articular changes caused by chronic and excess of expression of TNFa 
are not totally blocked by monotherapies that target TNF, IL-I, or RANKL. Combined 
approaches, especially the combined blockade of TNF and IL-1 and, to a lesser extent, 
TNF and RANKL, lead to essentially a complete reduction of disease. Differences in 
abilities to block synovial inflammation, bone erosion, and cartilage destruction further 
support the rationale for using combined blockade of more than one proinflammatory 
pathway (Zwerina J. et al., 2004). 
In summary, IL-17 acts on osteoblasts, resulting in PGE2 synthesis and RANKL 
expression, the latter directly inducing differentiation of osteoclast progenitors into 
mature osteoclasts by binding to RANKL receptors present on osteoclast progenitors 
(Kotake S. et al., 1999). However, IL-17 appears to be involved in not only immune 
responses but also osteoclastogenesis in RA patients. Excess production of IL-17 by 
memory T cells and excess expression and production of RANKL by synovial 
fibroblasts and osteoblasts may contribute to osteoclastic bone resorption in RA 
patients. The control of expression of IL-17, RANKL, or OPG in RA patients will 
provide direction to the development of new treatment strategies for bone destruction in 
RA patients. 
4.1.1 The alms of this chapter are to: 
Determine the effects of IL-17 and OSM on the expression of RANKL by SFB 
derived from patients with RA. 
Establish the effects of IL-17 and OSM on the expression and production of 
RANKL by SFB derived from patients with OA. 
Establish the effects of IL-17 and OSM on the expression and the production of 
RANKL by osteoblast-like cells (human osteosarcoma) MG-63 cell line. 
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41 Demonstrate the effects of IL-17 on the expression and the production of 
RANKL by osteoblast-like cells (human osteosarcoma) SaOS2 cell line. 
4.2 Materials and Methods 
Human synovial fibroblasts were derived from patientS with RA and OA. Human 
osteosarcoma cell line SaOS-2, was cultured in ocMEM, and MG-63 cells were 
cultured in DMEM as mentioned in chapter 2. The cells were grown until they 
reached confluence at 37"C, 5% C02. Then the cells were serum-reduced in medium 
containing 0.5% (v/v) FCS overnight and stimulated as in chapter 2 (2.2.1). 
After cytokine treatment, gene expression was assessed by analysis of mRNA levels as 
mentioned in chapter 2 section (2.3). RNA samples were treated with DNase I to 
remove genomic DNA contamination, see chapter-2 (2.4). RNA was reverse 
transcribed into complementary DNA (cDNA). Between 3-5 ýtg of the total RNA was 
used as template from each sample for cDNA synthesis in a final volume of 20 ýtl. The 
cDNA was diluted to 50 Itl and stored at -20"C, in details are in section (2.4.1 and 2.4. 
2). cDNA was amplified by PCR using primer pairs to generate products corresponding 
to specific gene products as listed in Table 2-1 section (2.4.3). The amplification of 
cDNA and a negative control reaction was run with each experiment and contained all 
the reagents except cDNA template. PCR was performed for 35 cycles for GAPDH, 
RANKL, and 38 cycles for IL-17R. Amplification products were identified by 
electrophoresis on a 1% (w/v) agarose gel, stained with ethidium bromide and 
visualized under UV light 
Agarose gel electrophoresis was used as outlined in chapter 2 section (2.6.1) for 
Northern blot analysis. Equal amounts of RNA (typically 15 - 20 pg for human 
osteosarcoma cells SaOS2, MG-63 and human dermal fibroblast; 8- 15 Pg for human 
synovial fibroblast). The gel was run at 60 V for I-2 hr in Ix running buffer, viewed 
under UV light to check the integrity of the RNA and photographed. RNA was 
transferred to Hybond-N with 200 ml 15x SSC overnight (section 2.6.2). The probe 
was typically labeled to 5-7x 106 Bq/ptg DNA. The blot was pre-soaked in 2x SSC 
and placed into a hybridization bottle. The blot was blotted semi-dry on filter paper, 
wrapped in cling film and exposed to a Storage phosphor screen (Molecular Dynamics, 
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Chesham, UK) overnight at room temperature. Radioactive bands were visualized by 
using a Phosphor Imager (Storm 860, Molecular Dynamics). 
In addition, Real-Time PCR analysis was used in this chapter. Forward and reverse 
primers for the RANKL cDNA sequence were designed. The primers for RANKL had a 
calculated annealing temperature of 65*C and amplicon size of 116 bp for more details 
see section (2.8.2). Taqman GAPDH control reagents, primers and probe were used 
from R&D (part number 402869). The reverse transcription was performed in 20 P1 
reactions as outlined in section (2.8.5). The cDNA was then diluted 5 times in DEPC 
dH20 for real-time PCR and 2 pl used as template for each reaction. PCR amplification 
was carried out in a 20 pl volume with 2 pI of the LightCycler DNA Mastermix, as 
outlined in section (2.8.5). 
In the relative standard curve method, standard curves with known amounts of total 
cDNA (relatively) are analysed for the gene of interest, RANKL. For each unknown 
experiment, the relative amount is calculated by division of the RANKL value with 
GAPDH value. Fold induction is calculated by dividing the treatment with the control. 
4.3 ReS'ults 
4.3.1 The effect of IL-17 and OSM on the expression of 
RANKL mRNA by SFB derived from patients with RA 
The ability of synovial fibroblasts (SFB) from patients with RA to express RANKL 
mRNA was examined. In the first experiment, cells isolated from a RA sample were 
treated for 6 hr. In this experiment DNase treatment was not performed so the cDNA in 
some samples was contaminated with genomic DNA and the results from this 
experiment show that RANKL mRNA was expressed at 6 hr in response to IL-17 (5 
ng/ml) but not in response to 0 SM (10 ng/ml) (Fig 4.1). 
The results from a second RA SFB samples show that RANKL mRNA was expressed 
in a biphasic way; the expression of the gene was initially 2.8-fold over control at 6 hr 
in response to IL-17 (5 ng/ml). There was no expression of RANKL at 24 hr in the cells 
stimulated with IL-17 (5 and 50 ng/ml) compared to untreated cells. RANKL 
expression was increased at 48 hr when treated with IL-17 (50 ng/ml), about 10-fold 
compared to the expression of RANKL mRNA in the untreated cells. There was no 
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expression of RANKL mRNA in the cells stimulated with OSM (10 ng/ml) in this 
experiment (Fig 4.2). 
RANKL 
386bp 
GAPDH 
483bp 
IL-17 5 50 
OSM -- 10 
Fig 4.1 The effect of IL-17 on the expression of RANKL mRNA by 
conventional PCR in human SFB from rheumatoid arthritis. The cells was 
serum-reduced overnight and treated with 11,17 (5 and 50 ng/ml) or OSM (10 
ng/ml) for 6 hr. Total RNA was analyzed by RT-PCR with specific primers using 
the conditions described in Materials and Methods. lICR was performed for 35 
cycles. The PCR products were run on 1% agarose gel, stained with ethidiurn 
bromide and visualized under UV light. (+) is cDNA and (-) is negative control 
untranscribed total RNA. 
0.25 
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0.15 
, %" 0.05 
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IL-17 5 50 5 50 
Osm -- 10 -- 10 
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1- 
-, 50 
- 10 
6 hr 24 hr 48 hr 
Fig 4.2 The effect of IL-17 on the expression ofRANKL mRNA by SFB from 
RA. SFB cells were cultured, serurn reduced to 0.5% FCS overnight and stimulated 
for 6 hr, 24 hr and 48 hr by IL-17 (5 and 50 ng/nil) and OSM (10 ng/ml). 
Quantitative PCR analysis was as described in Materials and Methods section. 
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4.3.2 RANKL mRNA expression by SFB cultured from 
osteoarthritic tissue 
The first sample from a patient with CIA was assessed by conventional PCR. III this 
experiment, contamination with genomic DNA was avoided by DNase treatment. The 
results show that RANKL mRNA was not expressed by these cells when treated with 
IL-17 (5 and 50 ng/ml) at all time points. However, RANKI, mRNA was expressed 
from the cells in response to OSM (10 ng/ml) at 6 lir and this increased at 24 hr but 
decreased at 48 hr (Fig 4.3). 
RANKL 
386bp 
IL, 17 5 50 5 50 
osm -- 10 -- 10 
GAPDI 
483bp 
I,, t 
5 50 
- 10 
IIA7 5 50 5 50 5 50 
osm -- 10 -- 10 -- 10 
6 hr 24 hr 48 hr 
Fig 4.3 The effect of IL-17 on the expression of RANKIL mRNA by, conventional 
PCR by SFB OA. SFB cells were stimulated with IL-17 (5 and 50 ng/ml) or OSNI 
(10 ng/rnl) for 6 hr, 24 hr and 49 hr. Total RNA was analyszed by RT-PCR with 
RANKL primers for 35 cycles using the conditions described in Material and 
Methods. PCR products were run on 1% agarose gel, stained math ethidium bromide 
and visualized under UV light. 
106 
6 hr 24 hr 48 lir 
Chapter-4 Results 
In total, five different patient samples were used for Quantitative PCR to detect 
RANKL mRNA expression in OA SFB. The results from these experiments show that 
RANKL mRNA expression was detectable in all five samples. In the first OA sample, 
quantitative PCR showed that RANKL mRNA was expressed in response to IL-17 (50 
ng/ml) compared to control at 24 hr and this expression was increased about 30-fold 
after IL-17 (5 ng/ml) treatment compared to untreated cells at 48 hr. The expression of 
RANKL mRNA in response to OSM at 6 hr was a very low, and there was no 
expression of RANKL mRNA compared to control at 24 hr but the expression of 
RANKL mRNA was increased by 54-fold at 48 hr (Fig 4.4 A). In a second sample of 
OA SFB Quantitative PCR showed that there was a gradual increase of RANKL mRNA 
expression in response to IL-17 (5 ng/ml) at 48 hr compared to control. RANKL 
mRNA in respons to OSM in this experiment at 24 hr, but there was no expression at 48 
hr (Fig 4.4 B). 
In another three samples of synovial fibroblasts from patient with OA the ratio of 
RANKL/GAPDH mRNA expression was assessed by Quantitative PCR. The results 
from these experiments show that RANKL mRNA is expressed in a biphasic way in 
response to IL-17. The expression is induced at 6 hr, no expresion at 24 hr and 
enhanced again at 48 hr. The expression of RANKL mRNA in response to IL-17 in the 
first two samples was concentration-dependent at 6 hr. There was no expression of 
RANKL mRNA following IL-17 treatment (5 and 50 ng/ml) at 24 hr compared to 
untreated cells. While the expression of RANKL was increased at 48 hr by IL-17 (5 
ng/ml) compared to control cells, there was no increase in the expression of RANKL in 
response to IL-17 (50 ng/ml) at 48 hr. Also, there was no expression of RANKL 
mRNA from the cells stimulated with OSM (10 ng/ml) as shown in (Fig 4.4 C and D) 
The last sample of SFB cells from an OA patient shows that RANKL mRNA was 
expressed at a low level in a biphasic way. RANKL started to be expressed in response 
to IL- 17 (5 ng/ml) at a higher level than IL- 17 (5 0 ng/ml) treatment at 6 hr. There was 
no expression of RANKL mRNA in response to IL-17 at 24 hr compared to control. 
The expression of RANKL mRNA was increased again following IL-17 treatment in a 
dose dependent manner at 48 hr compared to the untreated cells. There was no 
expression of RANKL from the cells stimulated with OSM (10 ng/ml) at 6 hr and the 
expression was increased about 1.5 fold at 24 hr while no expression was observed at 48 
hr (Fig 4.4 E). 
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Fig 4.4 The effect of IL-17 and OSM on the expression of RANKL mRNA in 
OA assessed by Quantitative PCR. SFB cells were cultured, serum-reduced to 
0.5% FCS overnight and stimulated for 6 hr, 24 hr and 48 hr by IL-17 (5 and 50 
ng/ml) and OSM (10 ng/ml). Total RNA was analyzed by Quantitative PCR analysis 
with RANKL primers using the conditions described in Materials and Methods. 
Five separate OA samples were analyzed (A-E). 108 
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4.3.3 The effects of IL-17 on the expression of RANKL 
mRNA by human osteosarcoma cell lines MG-63 
The effect of IL-17 and OSM on the expression of RANKL mRNA in MG-63 human 
osteosarcoma cells was assessed by conventional and quantitative RT-PCR. The results 
(Fig 4.5) from these experiments show that RANKL mRNA is expressed at low levels 
in cells treated with IL-17 or OSM. The results shown are representative of three 
separate experiments. Northern blot experiments confirmed the low level of this 
transcript (data not shown). 
To more accurately assess RANKL expression, quantitative PCR was performed. The 
ratio of RANKL/GAPDH mRNA expression was then plotted. The data show that 
RANKL mRNA is expressed in a biphasic way in response to IL-17 and OSM (Fig 4.6). 
RANKL mRNA was expressed in response to IL- 17 (5 ng/ml) about 2.5-fold at 6 hr but 
there was no expression of RANKL in response to IL-17 (50 ng/ml) at 6 hr compared to 
control. Expression of RANKL was increased about 1.5-fold by IL-17 (5 ng/ml) at 24 
hr but there was no increased expression in response to IL-17 (50 ng/ml). At 48 hr the 
expression of RANKL mRNA increased by 1.5-fold in response to IL-17 (5 ng/ml) and 
4.3-fold by IL-17 (50 ng/ml). The expression of RANKL mRNA was increased by 3.2- 
fold in response to OSM at 6 hr compared to untreated cells, decreased at 24 hr and 
increased by 3.2-fold at 48 hr. 
4.3.4 The effects IL-17 on levels of RANKL rnRNA in SaOS-2 
cells. 
The effects of IL-17 on the expression of RANKL mRNA by the SaOS-2 human 
osteosarcoma cell line were assessed by conventional and quantitative PCR. These 
experiments show that RANKL mRNA is detected by conventional PCR at low levels 
in SaOS-2 cells. RANKL is expressed but there were no differences between different 
treatments and time points (Fig 4.7). In addition, Northern blot analysis failed to detect 
RANKL expression (data not shown). Examination of IL-17 receptor expression 
showed that IL-17 R was expressed on SaOS-2 cells (Fig 4.8). Quantitative PCR results 
(Fig 4.9) show that the ratio of RANKL/GAPDH mRNA expression in SaOS-2 cells 
stimulated with IL-17 (50 ng/ml) is 11.5-fold higher than control at 24 hr but the level 
of expression was decreased at 48 hr. The expression of RANKL mRNA was increased 
by about 2-fold by IL-17 (50 ng/ml) compared to control at 48 hr. The expression level 
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of RANKL mRNA in response to OSM appears to be only enhanced at 48 hr (3-fold) 
compared to untreated cells. In addition, a subsequent experiment t, rom these cells was 
performed after the cells had had several passages. The results show that there was no 
RANKL mRNA expressed by these cells compared to untreated cells. Also there was 
no expression for RANKL mRNA following OSM treatment compared to untreated 
cells (Fig 4.10). Both IL-17R and alkaline phosphatase mRNA levels were examined 
by conventional PCR for these cells-, ll. -17R and alkaline phosphatase mRNA were still 
expressed (Fig 4.11 ) and (Fig 4.12), respectively, suggesting that these cells have 
maintained their osteoblastic phenotype. 
RANKL 
386bp 
GAPDH 
483bp 
lig, 1111 
osm - 10 10 10 
6 hr 24 hr 48 hr 
Fig 4.5 The effect of IL-17 on the expression of RANKL rnRNA by human 
osteosarcoma cell line. MG-63 cells were cultured, serum reduced overnight and 
stimulated for 6hrs, 24hrs and 48hrs by IL-] 7 (5 and 50 ng/rnl) and OSM (10 ng/nil). 
Total RNA was analyzed by RT-PCR with RANKL primers for 35 cycles and PCR 
products were run on 1% agarose gel, stained with ethidiurn bromide and visualized 
under UV light. These data are representative ofthree separate experiments. 
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Fig 4.6 The effect of IL-17 on the expression of RANKL rnlINA by hurnan 
osteosarcorna cell line. MG-63 cells were cultured, serum reduced overnight and 
stimulated for 6 hr, 24 hr and 48 hr following IL-17 (5 and 50 ng/nil) or OSM (10 
ng/ml) treatments. Total RNA was analyzed by Quantitative PCR analysis with 
RANKL primers using the conditions described in Materials and Methods. 
RANKI. 
386bp 
GAPDI I 
483bp * F6 
IL-17 
osm 
ng/ml 
6 hr 24 hr 48 hr 
Fig 4.7 The effect of IL-17 on the expression of RANKL rnlINA as determined 
by conventional PCR in SaOS-2. SaOS-21 cells were cultured, serurn-reduccd to 
0.5% FCS overnight and treated with IL-17 (5 and 50 ng/ml) or OSM (10 119/1111) 
and control for 6hrs, 24hrs and 481irs. Total RNA was analyzed by RT-PCR Nvith 
specific primers using the conditions described in Materials and Methods. PCR 
was performed for 35 cycles and run on 1% agarose gel, stained with ethidium 
bromide and visualized under UV light, stained with ethidiuni bromide and 
visualized under UV light. Data are representative of three independent 
experiments. 
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Fig 4.8 The expression of IL-17-receptor on SaOS-2 cells as 
determined by conventional PCR. The same cDNA in the previous 
figure was examined by using IL-17R primers using the conditions 
described in Materials and Methods. PCR was performed for 35 
cycles and run on 1% agarose gel, stained with ethidiurn bromide and 
visualized under UV light. 
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Fig 4.9 The effect of IL-17 on the expression of RANKL mRNA assessed by 
Quantitative PCR in SaOS-2. SaOS-2 cells were cultured, scrurn -reduced to 
0.5% FCS overnight and treated with IL-17 (5 and 50 righril) or OSM (10 rig/ml) 
and control for 6 hr, 24 hr and 48 hr. Total RNA was analyzed by RT-PCR with 
RANKL primers using the conditions described in Materials and Methods. This 
result is representative of the results from two experiments. 
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Fig 4.10 The effect of IL-17 on the expression of RANKI, mRNA assessed by 
Quantitative PCR in human osteosarcoma cell line SaOS-2. Cells were eulturcd 
after several passage, serurn reduced to 0.5% FCS over night and treated with IL-17 
(5 and 50 ng/ml) or OSM (10 ng/ml) and control for 6 hr, 24 hr and 48 l1r. 
Quantitative PCR analysis as described in Materials and Methods section. 
IL, 17 ý 
500bp -,, 
331 bp, " 
GAPDH 
483bp 
IL-17 5 50 -5 50 -5 50 - 
OSM -- 10 -- 10 -- 10 
6 hr 24 hr 48 hr 
Fig 4.11 The expression of IL-17-receptor on SaOS-2 cells after several 
passages old. The expression of IL-17R as determined by conventional PCR 
SaOS-2 cells were cultured, serum-reduced to 0.5% FCS overnight and treated 
with IL- 17 (5 and 50 ng/mi) or OSM (10 ng/rnl) and control for 6 hr, 24 hr and 
48 hr. Total RNA was analyzed by RI'-PCR with 11,17R primers using tile 
conditions described in Materials and Methods. IICR was pcrlormed for 35 
cycles and run on 1% agarose gel, stained with ethidiurn bromide and 
visualized under UV light. 
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Alkaline 
phosphatase 
281 bp 
osm 10 
Fig 4.12 The expression of Alkaline phosphatsae in the SaOS-2 cells 
after several passage. cDNA prepared as described in figure 4.11 was 
examined using Alkaline phosphatsae primers using the conditions 
described in Materials and Methods. PCR was pcri'ori-ned for 35 cycles 
and run on 1% agarose gel, stained with ethidiurn bromide and 
visualized under UV light. 
4.4 Discussion 
Arthritis is a chronic inflammatory disease characterized by articular cartilage and bone 
destruction. The pathogenesis of inflammation and tissue destruction in RA results 
from complex cell-cell interactions between, among others, T lymphocytes, nionocytes 
and synoviocytes. It was reported previously that numbers ofactivated T cells varied 
during RA. Activated T cells release a number of' factors that may cause osteoclast 
differentiation, maturation and activation. Moreover, it was found that interleLikiii-17 
(IL-17) is a pro-inflammatory cytokine secreted exclusively by activated T-cells and 
accumulates in RA (Chabaud M. et al 2001). However, recent studies and the discovery 
of RANKL, RANK and OPG, and the role of these molecules in promoting osteoclast 
differentiation suggest that these molecules may be the target of factors such as IL-17 
and OSM. Furthermore, the molecular mechanisms that underlie this phenomenon have 
not been well understood. 
A direct demonstration of the role oflocal RANKL and OPG in IL-17 action has been 
restricted to in vitro studies (Nakashima T et al., 2000 and Atkins GJ. et al., 2000). To 
confirm the role of these molecules and to characterize molecular mediators in the 
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physiology of abnormal bone resorption triggered by IL-17, studies that further examine 
the expression and regulation of these molecules are needed. 
In the present chapter, I demonstrate that the expression of RANKL by synovial 
fibroblasts and osteoblast-like cells is rapidly and robustly enhanced within 48hrs in 
response to IL-17. This result indicates that IL-17 causes an increase in the pathogenic 
condition of bone. The changes in RANKL and OPG levels that may be lead to 
increase in bone resorption. These results provide further evidence that the disturbance 
of these molecules by cytokines such as IL-17 and OSM may interrupt the mechanism 
linking osteoblasts and osteoclasts. The quantitative -PCR and conventional PCR 
studies presented here and elsewhere clearly establish that osteoblasts and synovial 
fibroblasts express RANKL and that it is regulated in vitro upon IL-17 and OSM 
treatment. The increase in RANKL confirmed that the balance of RANKL and OPG 
could be altered to favour bone resorption. This is consistent with an important 
regulatory role for these molecules in the initiation and maintenance of bone catabolism 
in normal physiology and of osteoclast differentiation. It has been demonstrated 
previously that an elevation of RANKL and a reduction of OPG occursadjacent to 
alveolar bone loss. This identifies the OPG/RANKL/RANK pathway of osteoclast 
differentiation as a possible target for regulating the bone destruction in patients with 
periodontitis (Crotti T et al., 2003). Also, it has been reported previously that RANKL 
mRNA is expressed in cells within RA tissues, and the ratio of RANKL: OPG mRNA 
expressed in RA tissues significantly correlates with the formation of functional 
osteoclasts (Haynes DR. et al., 2001). 
However, its remains to be clarified whether RANKL is produced in joint cells, how its 
expression is regulated by systemic calciotropic hormones and local inflammatory 
mediators, and whether RANKL produced in the joint microenvironment plays any 
significant role in normal bone remodeling or pathological conditions such as 
osteoporosis. To address these issues, I examined expression of RANKL in SFB (RA 
and OA) and contrasted them with osteoblastic cells (human osteosarcoma cell lines 
MG-63 and SaOS-2). In the present study, I found that RANKL mRNA is expressed in 
these cells stimulated by IL-17 in vitro. These results indicate that IL-17 has effects in 
synovial fibroblasts and osteoblastic cells. In addition, the time course and dose 
response of RANKL mRNA expression in response to IL-17 show that IL-17 caused 
marked and transient induction of RANKL mRNA in SFB RA and OA cells and MG-63 
and SaOS-2 cell lines. The increase in RANKL mRNA level was apparent in some 
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samples as early as 6 hr after the addition of IL-17, and RANKL mRNA level returned 
to baseline at 24 hr after addition of IL-17 while the expression was increased at 48 hr 
as shown in one sample from RA and in three samples from OA out samples. These 
results from RA and OA were similar to the results from MG-63. However, the earliest 
production of RANKL mRNA at 6 hr and decreased at 24 hr agreed with a previous 
study that demonstrated that the expression of RANKL mRNA in Porphyromonas 
gingivalis (P. gingivalis) infected mouse osteoblasts was enhanced at 6 hr after which 
mRNA levels decreased by 24 hr (Okahashi N et al., 2004). Also, increases in RANKL 
mRNA levels appeared as early as 6 hrs after the addition of IL-17. A similar finding 
has been reported for histamine in that it modulates RANKL expression and/or 
production of cytokines in stromal cells (Tasaka K. et al., 1993; Zheng T. et al., 1994). 
Histamine markedly increased the steady-state level of RANKL mRNA in a dose- 
dependent manner. The effect of histamine on the expression of RANKL mRNA by 
osteoblastic MC3T3-E I cells was transient; with a peak at 6 hr while the increase in the 
production of RANKL protein by El cells was at 12 hr (Deyama Y. et al., 2002). In 
addition, another study showed that hPTH also induces RANKL mRNA expression 
from osteoblast cells in the early hours and hPTH cause a significant increase in bone 
resorption at 6 hr (Buxton EC et al., 2004). 
In another two samples from OA the expression of RANKL mRNA was enhanced by 
IL-17 at only 48 hr. Furthermore the expression of RANKL mRNA by SaOS-2 was 
enhanced by IL-17 at 24 hr and at 48 hr. The expression of RANKL at 24hr and 48 hr 
in this study is agree with Frick KK and Bushinsky DA (2003) reported that cultured 
neonatal mouse calvariae in acidic and neutral medium for 24 hr and 48 hr. The results 
from this model of metabolic acidosis show significantly increased expression of 
RANKL mRNA at both 24 hr (2-fold) and 48 hr (5-fold) compared with the respective 
controls. Furthermore, the effect of IL-17 on RANKL mRNA was dose-dependent in 
MG-63 and SaOS-2 cell lines and in three samples (one RA and two OA) at 48hr. In 
general, RANKL mRNA was expressed by RA, OA, MG-63 and SaOS-2 cells treated 
with IL- 17 at 48hr. 
Overall, there was some variation between the results from different patients samples in 
the expression of RANKL mRNA by IL-17 and OSM. These variations may be due to 
the differences in the genetic and environmental conditions of the individual or the 
differences in the age, stage of disease or treatment regime. Therefore, mRNA levels 
may not mirror protein expression. More recently, it has been shown that OPG and 
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sRANKL levels did not show sex-related modifications but sRANKL/OPG plasma 
levels were age-dependent (Pulsatelli L et al., 2004). Furthermore, variations in the 
expression of RANKL mRNA in response to IL-17 may be due to difference in IL-17 
receptor numbers. 
However, as mentioned before very low concentrations of RANKL induced OCL 
formation in RA and OA as well as in Paget's disease, whereas much higher 
concentrations of RANKL mRNA were required for OCL formation in normal marrow 
cultures (Menaa C. et al., 2000). 
In this study, IL-17 stimulated RANKL mRNA expression in both synovial fibroblast 
cells and osteoblasts. These results suggest that IL-17 may be directly involved in 
osteoclastogenesis through RANKL production by synovial fibroblast cells and 
osteoblasts. Moreover, IL-17R mRNA was expressed by theses cells so these finding 
suggests that the effect of IL-17 on RANKL mRNA expression in osteoblasts is 
mediated by stimulation of IL-17 receptors. However, this study provides further 
evidence that IL-17 may induce osteoclastogenesis by the stimulation of RANKL, 
which binds to RANK in osteoclast precursors. In conclusion, the results of the present 
study indicate that IL-17 induces expression of the RANKL gene in osteoblastic cells 
and synovial fibroblasts which leads to the production of sRANKL and non-soluble 
RANKL. These responses may influence osteoclastogenesis. 
However, the cell-cell contacts in these phenomena are very important as shown in a 
recent study by real-time PCR in the breast cancer cell line, MDA-MB-23 I AL. Alone, 
these cells did not express RANKL while, co-culture of these cells with stromal or 
osteoblastic cells induced RANKL mRNA expression and decreased OPG mRNA 
expression (Park HR. et al., 2003). During bone resorption, T cells release IL-17, which 
induces production of RANKL by stromal cells, osteoblasts and SFB. Further studies 
are needed to elucidate the molecular mechanisms by which IL-17 regulates the 
expression of RANKL. In addition, study of the signal transduction pathways of IL-17, 
TNF, and RANKL and the cross-talk between them may enable us to limit their affects 
in disease. 
4.4.1 In this chapter I have demonstrated that: 
IL-17 affects the expression of RANKL mRNA in a variable way in synovial cells 
from patients with RA and OA. 
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* There are no effects on the expression of RANKL mRNA by OSM in synovial cells 
from patients with RA. 
OSM affects the expression of RANKL mRNA in a variable way in synovial cells 
from patients with OA. 
IL-17 affects the expression of RANKL mRNA by increasing expression, time 
dependently in the human osteosarcoma cells SaOS-2 and in a biphasic way in MG- 
63 cells. 
9 OSM affects the expression of RANKL mRNA by increasing expression with time 
in the human osteosarcoma cells SaOS-2 and in a biphasic way in MG-63 cells. 
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6. The effect of IL-17 in combination with OSM on the 
expression and production of RANKL and OPG by 
synovial fibroblast and osteoblasts cells 
5.1. Introduction 
RA is a polyarticular disease characterised by chronic inflammation of the synovium with 
hyperplasia of synovial lining cells and pannus formation. The invasiveness and 
perpetuation of this pannus is maintained by new blood vessels that allow numerous 
immuno-modulatory cells such as T cells, B cells, monocytes and macrophages to infiltrate 
which may perpetuate elevated proliferation and activation of synovial fibroblasts 
(Chabaud. M., et al 2001; Firestein 1997). Cytokines are regulatory proteins secreted by 
white blood cells and a variety of other cells in the body. The pleiotropic action of 
cytokines includes numerous effects on cells of the immune system and modulation of 
inflammatory responses. Cytokine's are tools in modulating pathogenic responses; in RA 
inflammation the interaction between various cell types alters the joint cytokine population, 
leading to the initiation and propagation of an inflammatory response. Many pro- 
inflammatory cytokines are present in thejoint, including TNF-a, IL-1, IL-17, IL-6 and LIF 
and these are thought to play a pivotal role in bone and cartilage degradation. 
Other cytokines are secreted that can be considered anti-inflammatory; they promote matrix 
synthesis and decrease cartilage and bone degradation. These include IL-4, IL-10, IL-13, 
IL-IR antagonist, transforming growth factor TGF-P and insulin-like growth factor. In 
some cases, the cellular response is vastly altered after combinations of cytokines interact 
with the cells. This is regarded as synergism; meaning the response observed is greater 
than the sum of the cytokines individual effects. IL-17 has previously been shown to 
synergise with IL-I in RA synoviocytes, enhancing the production of IL-6 (Chabaud., et al 
1998). IL-17 mediated synergy with IL-I and TNFa has also been observed in 
chondrocytes, osteoblasts and myoblasts (reviewed by Miossec, 2003). 
Many pro-inflammatory cytokines have been show to be present in the synovial fluids of 
RA patients, including IL-I and TNF-a, which represent key pro-inflammatory cytokines in 
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RA. Both cytokines elicit a broad spectrum of cellular responses including cell cell 
proliferation, migration, and apoptosis. 
Studies from our laboratory have established that OSM acts synergistically with IL-la to 
induce cartilage collagen breakdown and collagenase expression. IL-6 can mimic OSM in 
synergizing with IL-1a to induce chondrocyte-mediated cartilage collagen breakdown and 
collagenase production. Since OSM, IL-6, and sIL-6R levels have all been shown to be 
elevated in the rheumatoid joint, these studies suggest that these cytokines may be key 
mediators of cartilage collagen catabolism in inflammatory arthritides (Rowan AD., et al., 
2001). In addition, another study demonstrated that IL-6/sIL-6R and OSM play an 
important role in the regulation of IL-6 expression within the central nervous system (CNS), 
particularly in conjunction with the proinflammatory cytokines TNF-a and IL-lP (Van 
Wagoner NJ., et al. 1999). 
IL-17 induces the release of cytokines and prostaglandins from stromal cells and 
macrophages (Yao, ZS. et al., 1995; Jovanovic, DV. et al., 1998). Both TNF-a and IFN-y 
have an additive effect on IL-17-induced secretion of IL-6, and the combination of IL-17 
plus TNF-a was effective in promoting GM-CSF release from synovial fibroblasts (Fossiez, 
F. et al., 1996). Furthermore, IL-17 was shown to enhance cell surface expression of 
ICAM-1 on human fibroblasts (Yao, ZS. et al., 1995). Thus, a broad set of effects are 
induced by IL- 17, and its action can be potentiated by other cytokines. Also IL- 17 has been 
shown to induce NF-kB, consensus sequence binding in mouse fibroblasts (Yao, Z., et al., 
1995) and human macrophages (Jovanovic, DV., et al., 1998). Subsequently, the 
expression of several cytokines known to contain NF-kB recognition sites in their 
promoters were demonstrated to be regulated by IL-17. These cytokines include IL-8, IL-6, 
and GM-CSF (Starnes T. et al., 2002). Furthermore, TNF-a and IFN-y have an additive 
effect on the stimulation of IL-6 expression by IL-17 (Fossiez, F. et al., 1996), and the 
combination of IL-17 and TNF-a can stimulate the expression of granulocyte-macrophage 
CSF by fibroblasts (Fossiez, F. et al., 1996). However, the IL-17-induced signal 
transduction events leading to the activation of NF-kB are not entirely known. 
The understanding of different cytokines effects on cartilage and bone are confounded by 
their overlapping biological functions, resulting in redundancy, and moreover by their 
altered potency in the presence of other cytokines, which can be additive or synergistic 
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(Furst DE et al., 1999). In the present study, we investigated the combination of IL-17 and 
OSM on the expression and the production of RANKL and OPG, by synovial fibroblasts 
from patients with OA and RA and the human osteoblast-like cell lines MG-63 and SaOS2. 
5.1.1 Therefore the alms of this chapter are to: 
* Determine the effect of the combination of IL-17 and OSM on the expression of 
RANKL and OPG mRNA by synovial fibroblast cells from patients with RA. 
* Investigate the effect of the combination of IL-17 and OSM on the expression of 
RANKL and OPG mRNA by synovial fibroblast cells from the patients with OA. 
* Establish the effect of the combination of IL-17 and OSM on the expression of 
RANKL and OPG mRNA in human osteosarcoma, MG-63 and SaOS2 cell lines. 
Determine the effect of the combination of IL-17 and OSM on the production of 
OPG in synovial fibroblast cells from patients with OA and from the human 
osteosarcorna MG-63 and SaOS2 cell lines. 
5.2 Materials and Methods 
Human synovial fibroblasts were obtained from patients with RA and OA. The 
osteosarcoma cell lines used in this chapter were SaOS-2 and MG-63. Cells were cultured 
and serum-reduced as in section (2.2.1 and 2.2.2). After the old media was discarded then 
new media with the cytokines at different concentration IL-17 (5 or 50 ng/ml), OSM (10 
ng/ml) and a combination of IL-17 (5 and 50 ng/mI with OSM 10 ng/ml respectively) 
were added for 6 hr, 24 hr and 48 hr. RNA was extracted after cytokine treatment; gene 
expression was assessed by Northern blot and quantitative PCR analysis as mentioned in 
section (2.7.2 and 2.8.5) respectively. Conditioned media was retained at -20'C for 
Western blot analysis as outlined chapter 2. 
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5.3 Results 
5.3.1 Effect of IL-17 combined with OSM on the expression of 
RANKL and OPG by SFB cells from patients with RA. 
The results from one patient only show that there was a down-regulation in the expression 
of RANKL and OPG in synovial fibroblasts at 6 hr and 48 hr respectively when OSM is 
combined with IL-17, in comparison to OSM alone or IL-17 alone (Fig 5.1). 
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Fig 5.1 The effect of IL-17 combined with OSM on the expression of RANKL 
and OPG by RA SFB. SFB cells were cultured, serum-reduced to 0.5% FCS 
overnight and stimulated for 6 hr, 24 hr and 48 hr by IL-17 (5 and 50 ng/ml) and 
OSM (10 ng/ml) and IL-17 (5 or 50 ng/ml) and OSM (10 ng/ml) respectively. Total 
RNA was analyzed by Quantitative PCR analysis with (A) RANKL and (B) OPG 
primers using the conditions described in Materials and Methods. The data are 
presented relative to GAPDH. 
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5.3.2 Effects of IL-17 combined with OSM on the expression of 
RANKL and OPG mRNA and production of OPG by SFB 
cells from patients with OA 
5.3.2.1 The effect of the combination of IL-17 with OSM on the 
expression RANKL In SFB (OA) 
The effect of combining IL-17 with OSM on the expression of RANKL in synovial 
fibroblast cells cultured from four patients with OA was studied. The ratio of 
RANKUGAPDH was quantified by quantitative PCR in first two samples the results show 
that RANKL mRNA expressed in response to IL-17 at 48 hr (Fig 5.2 A and B). The 
expression of RANKL in response to OSM in (Fig 5.2 A) was at 48 hr but in (Fig 5.2 B) at 
24 hr. However, there was a down-regulation in RANKL transcription levels in response to 
the combination of both cytokines. In another two samples the results show that there was 
no induction of RANKL mRNA in cells treated with IL-17 combined with OSM (5 and 50 
ng/ml IL-17 with OSM 10 ng/ml, respectively). While RANKL mRNA was expressed in 
response to IL-17 (50 ng/ml) at 6 hr and by IL-17 (5 ng/ml) at 48 hr (as previously 
described) but there was no RANKL mRNA induction in response to OSM alone or in 
combination with IL-17 (Fig 5.3 A). In one sample there was a very low level of RANKL 
mRNA expression in response to the combination of IL-17 with OSM at 24 hr (Fig 5.3 B). 
However the general pattern of the results shows that there is a down-regulation in the 
expression of RANKL mRNA by the combination of IL-17 and OSM. 
5.3.2.2 Effect of the combination of IL-17 with OSM on the 
expression of OPG In SFB (OA) 
The effects of IL-17 and OSM on the expression of OPG mRNA by synovial fibroblasts 
isolated from patients with OA were investigated by Northern blot and Quantitative-PCR 
analysis. The pattern of results shows that OPG mRNA is expressed in cells treated with 
IL-17 (5 and 50 ng/ml) and OSM (10 ng/ml) at 6 hr, but there was no increase in expression 
of OPG by the combination of IL-17 with OSM. The expression of OPG mRNA was 
increased dose dependently by IL-17 and OSM alone at 48 hr but there was no increase in 
the expression of OPG by the combination of IL-17 and OSM. In another sample OPG 
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mRNA was expressed in cells treated for 24 hr and there was down-regulation of OPG 
mRNA by the combination of IL-17 and OSM (Fig 5.4). Furthermore I have analysed by 
quantitative PCR another five samples from patients with OA. The cells were treated as 
previously and in general the results show that OPG mRNA is expressed in response to IL- 
17 alone but there was down-regulation when IL-17 and OSM are added together at 6 hr 
(Fig 5.5). 
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Fig 5.2 Effect of IL-17 combined with OSM on the expression of RANKL by 
OA SFB. SFB cells were cultured, serum-reduced to 0.5% FCS overnight and 
stimulated for 6 hr, 24 hr and 48 hr by IL-17 (5 and 50 ng/ml) and OSM (10 
ng/ml) and IL-17 (5 or 50 ng/ml) combined with OSM (10 ng/ml). Total RNA was 
analyzed by Quantitative PCR analysis with RANKL primers using the conditions 
described in Materials and Methods. The data are presented relative to GAPDH. 
Two independent OA samples (A) and (B) were used. 
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Fig 5.3 A and B Effect of IL-17 combined with OSM on the expression of 
RANKL by SFB cells from OA patient. SFB cells were cultured, serum- 
reduced to 0.5% FCS overnight and stimulated for 6 hr, 24 hr and 48 hr by IL-17 
(5 and 50 ng/ml) and OSM (10 ng/ml) and by the combination of IL-17 (5 or 50 
ng/ml) and OSM (10 ng/ml). Total RNA was analyzed by Quantitative PCR 
analysis with RANKL primers using the conditions described in Materials and 
Methods. The data are presented relative to GAPDH. 
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Fig 5.4 Effect of IL-17 and the combination of IL-17 and OSM on the expression of 
OPG by SFB from OA patients. Sl-B cells ýýcrc cultured, serurn reduced to 0.5Mo I-'CS 
overnight and stimulated for 6 hr, 24 hr and 48 lir by 11,17 (5 and 50 ng/rnl) and OSM (10 
ng/ml) and by the combination of' IL- 17 (5 or 50 ng/rnl) and OSM (10 ng/rnl. RNA was 
extracted using trizol reagent. Equal amounts of' RNA were electrophorescd Using 1% 
agarose/0.4M Forrnalehyde and Northern analysis performed. GAIIDI I was used to 
normalise for RNA loading. A and 11 from the same patient, and C frorn a second patient. 
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Fig 5.5 Effect of IL-17 and OSM on the expression of OPG by SFB from five 
different OA patients. SFB cells were cultured, serum-reduced to 0.5% FCS 
overnight and stimulated for 6 hr, 24 hr and 48 hr by IL-17 (5 and 50 ng/ml) and 
OSM (10 ng/ml) and by IL-17 (5 or 50 ng/ml) and OSM (10 ng/ml). Total RNA 
was analyzed by Quantitative PCR analysis with OPG primers using the conditions 
described in Materials and Methods for five independent samples (A-E). 
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5.3.2.3 The effect of the combination of IL-17 and OSM on the 
production of OPG by SFB (OA) 
The effects off L- 17 and OSM on the production ofOPG by synovial fibroblasts (OA) were 
determined by Western analysis. The conditioned media frorn two independent experiments 
were compared. The pattern of results show that OPG production was increased in the 
conditioned media from cells treated with ll, 17 (50 ng/ml) and OSM alone in both samples 
at 6 hr. OPG production was increased by IL-17 (5 ng/ml) but not by OSM in the first 
sample and by 17 (50 ng/ml) and OSM in the second sample at 24 hr. There was an 
increase in OPG production by IL-17 (5 and 50 ng/ml) by the First sample and by 11,17 (50 
ng/ml) in the second sample but not by OSM at 48hr. I lowever, there were no synergistic 
effects of IL- 17 and OSM on the production of'OPG by synovial I ibroblast (Fig 5.6). 
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Fig 5.6 The effect of the combination of IL-17 and OSM on the production 
of OPG by SFB OA. SFBs were cultured, serum reduced overnight and 
stimulated for 6 hr, 24 hr and 48 fir by IL-17 (5 and 50 ng/ml) and OSM (10 
ng/ml) and by the combination of IL-17 (5 or 50 ng/ml) and OSM (10 ng/rnl). 
The conditioned media collected for Western blot analysis. (A) lirst sample 
lanes 1-12 run on a separate gel. (B) Second sample lanes 1-8 were run oil a 
separate gel and samples 7 and 9, and 8 and 10 are duplicate samples. These 
data were representative of the pattern of two independent experiments. 
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5.3.3 Effects of the combination of IL-17 with OSM on the 
expression of RANKL and OPG mRNA and production of 
OPG by MG-63 
The effects of IL-17 combined with OSM on the expression of OPG mRNA by the human 
osteosarcoma cell line MG-63 was assessed by Northern blot analysis. The pattern of 
results show that OPG mRNA was expressed by the cells treated with IL- 17 (50 ng/ml) and 
cells treated with OSM (10 ng/ml) at 48 hr but there was no increase in the expression by 
the combination of IL-17 with OSM (Fig 5.7). Furthermore I have analysed by quantitative 
PCR another experiment using MG-63 cells after several passages. The cells were treated 
as previously described and the patterns of results show that OPG mRNA is expressed in 
response to IL-17 alone at 48 hr but there were no synergistic effects by the combination of 
IL- 17 with OSM (Fig 5.8 A). 
The effects of IL-17 combined with OSM on the expression of RANK mRNA by MG-63 
cells. Results by quantitative PCR analysis show that RANKL mRNA was expressed at a 
very low level at 48 hr in response to IL-17 (5 ng/ml) and there was no RANKL mRNA 
expression in response to OSM. In addition, RANKL mRNA expressed in response to IL- 
17 is down-regulated by the combination of IL- 17 with OSM in Fig 5.8 B. 
The effects of IL-17 and OSM on the production of OPG by human osteosarcoma MG-63 
cells were determined by Western analysis. The pattern of results shows that the OPG was 
produced from the cells treated with IL-17 (50 ng/ml) alone at 6 hr, 24 hr and 48 hr and by 
OSM (10 ng/ml) alone at 6 hr, 24 hr and 48 hr. However there were little synergistic effects 
on the production of OPG from the cells stimulated by IL-17 and OSM (50ng/ml with 
I Ong/ml) at 24 hr and in response to IL- 17 and OSM (5ng/ml with I Ong/ml) at 48 hr in (Fig 
5.9). 
5.3.4 Effects of the combination of IL-17 with OSM on the 
expression of RANKL and OPG mRNA and production of 
OPG by the human osteosarcoma cell line, SaOS-2 
The effects of IL-17 and OSM on the expression of OPG mRNA by human osteosarcoma 
SaOS-2 cell line, was investigated by Northern blot analysis. The pattern of results show 
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that OPG mRNA was expressed from the cells treated with OSM (10 ng/ml) at 6 hr but 
there was no increased in the expression of OPG mRNA by the combination of IL-17 with 
OSM. The expression of OPG mRNA remains steady at 24 hr. OPG mRNA is expressed 
following treatment with IL-17 dose dependently and there was a little synergistic increase 
in its expression when both cytokines IL-17 (50 ng/ml) and OSM (10 ng/ml) are added at 
48 hr (Fig 6.10). Further analysis was done by quantitative PCR, using SaOS-2 cells after 
several passages, treated as previously described. OPG mRNA is expressed following 
treatment with IL-17 (5 ng/ml) alone and in response to OSM alone at 6 hr while there was 
no increase in expression of OPG mRNA following treatment with IL-17 combined with 
OSM at 6 hr. OPG mRNA is expressed following treatment with OSM at 24 hr and there 
was a little synergistic effect in response to the combination of IL-17 (50 ng/ml) and OSM 
together at 24hrs. There was no increase in expression of OPG mRNA responses to IL-17 
(5 and 50 ng/ml) but OPG mRNA is expressed following treatment with OSM at 48 hr and 
there was some synergism in response to the combination of IL-17 (5 ng/ml) and OSM at 
48hr (Fig 6.11 A). 
The effect of IL-17 and OSM on the expression of RANKL mRNA by human 
osteosarcoma SaOS-2 cell line was also studied. The results show that these cells did not 
respond to the treatment with changes in the abundance of RANKL mRNA (Fig 6.11 B). 
The effects of IL-17 combined with OSM on the production of OPG by human 
osteosarcoma SaOS-2 cells were also studied by Western blot analysis. The pattern of 
results shows that OPG is produced following IL-17 (5 and 50 ng/ml) treatment and also in 
response to OSM (10 ng/ml) at 6 hr. The production of OPG was increased in response to 
IL-17 (5-50 ng/ml) at 24 hr and also at 48 hr. However, there were no synergistic effects of 
combining IL-17 and OSM on the production of OPG from these cells (Fig 5.12). 
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Fig 5.7 The effect of IL-17 and the combination of IL-17 with OSM on the 
expression of OPG by human osteosarcorna MG-63 cell line. MG-63 cells 
were cultured, serurn reduced to 0.5% FCS overnight and StIMUlated Im 6 lit-, 24 
hr and 48 lir by IL-17 (5 and 50 ng/ml) and OSM (10 m-Yrril) and the 
combination of IL-17 (5 or 50 ng/ml) and OSM ( 10 ng/ml. RNA was extracted 
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used to normalise for RNA loading. 
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Fig 5.8 A and B The effect of IL-17 combined with OSM on the expression of OPC 
in MG-63 cells. MG-63 cells were Cultured, scrum-reduced to 0.5% I'CS overnight and 
stimulated for 6 hr, 24 hr and 48 hr by 11,17 (5 and 50 ng/rnl) and OSM (10 ng/rnl) and 
by IL-17 (5 or 50 ng/ml) and OSM (10 ng/ml). Total RNA was analyzed by 
Quantitative PCR analysis with (A) OPG and (B) RANKL primers using the conditions 
described in Materials and Methods. 
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Fig 5.9 The effect of the combination of IL-17 combined with OSM on 
the production of OPC' by MG-63. MG-63 cells were Cultured, serum- 
reduced to 0.5% FCS overnight and stimulated for 6 hr, 24 hr and 48 hr by 
IL- 17 (5 and 50 ng/rnl) and OSM ( 10 ng/ml) and by the combination of I I, 
17 (5 or 50 ng/ml) and OSM (10 ng/rnl). The conditioned rnedia were 
collected for Western blot analysis. Lanes 1-12 were run on a separate gel. 
These data were representative of the pattern of' three independent 
experiments. 
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RNA was analyzed by Quantitative PCR analysis with (A) OPG and (B) RANKL 
primers using the conditions described in Materials and Methods. The results are 
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Fig 5.12 The effect of the combination of IL-17 combined with OSM on 
the production of OPG by SaOS-2 cells. SaOS2 cells were cultured, 
serum-reduced to 0.5% FCS overnight and stimulated for 6 lir, 24 fir and 48 
hr by IL-17 (5 and 50 ng/ml) and OSM (10 ng/nil) and by the combination of' 
IL-17 (5 or 50 ng/ml) and OSM (10 ng/ml). The conditioned rnedia were 
collected for Western blot analysis. Lanes 1-6 were run on a separate gel. 
5.4 Discussion 
The activated T cell cytokinc, IL-17 has been shomi to promote bone and cartilage 
destruction, through PGE2, RANKL, IL-6, GM-CSF, IL-8 and M-CSF release in vivo and 
in vitro (Lubberts E et al., 2004; Yamamura Y et al., 200 1; Chabaud M et al., 200 1; Yao, 
et al., 1995). However, IL- 17 is not a solitary cytokine in thejoints ofarthritic patients, and 
a possible immuno-modulatory role has been suggested for IL-17 (Katz et al., 2001). 
Previous studies have shown that the destructive potential of IL-17 is possibly amplified in 
the presence of other pro-inflammatory cytokines, leading to a synergistic release of' 
cartilage and bone degradation factors (Chabaud M et al., 2001 ). In addition, the response 
of chondrocytes is amplified after stimulation with two pro-inflarnmatory cytokines, 
including combinations of IL-1, OSM, lL-6/slL-6R and TNFu (Cawston et al., 1995,1998; 
Rowan et al., 2001; Hui et al., 2003). 
As such, the present study has investigated the hypothesis; "IL-17 potentiates increased 
bone catabolism through interaction with other pro-inflarnniatory cytokines". The main 
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focus of this chapter is the effect of IL-17 combined with OSM on the expression of 
RANKL and expression and production of OPG in vitro. 
In this study the effect of IL-17 combined with OSM on the expression of OPG mRNA by 
synovial fibroblast cells from a patient with RA and OA, showed that there was down- 
regulation in the expression of OPG mRNA in synovial fibroblasts. Furthermore the 
effects of IL-17 and OSM on the production of OPG by OA synovial fibroblasts show that 
there were no synergistic effects of the combination of IL-17 and OSM on the production 
of OPG by synovial fibroblast. 
The effect of IL-17 combined with OSM on the expression of RANKL mRNA by RA and 
OA synovial fibroblast cells showed that there was down-regulation in the expression of 
RANKL mRNA. 
From these results from RA and OA synovial fibroblasts, I suggest that the presence of 
both of these cytokines in the same area together may modulate effects of each other on the 
expression of RANKL and OPG and also on the production of OPG. The important finding 
in this study that the effect of the combination of IL-17 and OSM is that leads to the 
decreased expression of RANKL mRNA in arthritis (which may lead to an decrease in bone 
and cartilage degradation). In contrast, Koshy PJ. et al., (2002) reported that IL-17 can, 
alone and synergistically in combination with other proinflammatory cytokines such as 
TNF-alpha, IL-I, OSM and IL-6 promote chondrocyte mediated MMP dependent type Il 
collagen release from cartilage and this effect is significantly reduced by IL-4, IL-13, TGF- 
betal, and IGF-l. Koshy PJ. et al., (2002) suggested that IL-17 may act as a potent 
upstream mediator of cartilage collagen breakdown in inflammatory joint diseases. 
However, IL-17 may in combination with other proinflammatory cytokines have effects on 
cartilage and bone degradation through the release of factors that cause osteoclastogenesis 
(Kotake S. et al. 1999). In addition, Langdon C. et al., (1997) and Hui W et al., (1997) both 
demonstrated that OSM was detectable in variable levels in synovial fluids of RA patients 
but not in OA patients and Langdon C. et al., (1997) suggested that OSM has a potentially 
important function in the modulation of chemokine and MMPS production by synovial 
cells of the joint. In addition, adenoviral over expression of OSM induces increased 
inflammation and destruction in murine joints in vivo (Langdon et al., 2000; de Hooge AS 
et al., 2002). However, these observations suggest that OSM may have another role in 
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combination with IL-17 modulating the expression of RANKL and OPG. Because OSM 
favours bone apposition at periosteal sites instead of resorption in vivo. In spite of the 
expression of RANKL and its receptor RANK, in the periosteum, osteoclasts were not 
detected at sites of bone apposition. (de Hooge AS. et al., 2002) 
In this study human osteoblast-like MG-63 and SaOS2 cell lines showed some synergestic 
effects on the expression of OPG mRNA in response to the combination of IL-17 and 
OSM. While the effect of the combination of IL-17 and OSM on the expression of 
RANKL mRNA by MG-63 and SaOS2 showed that RANKL mRNA is down-regulated. In 
addition, the effects of IL-17 and OSM on the production of OPG by MG-63 cells, showed 
a little synergistic effect but there were no synergistic effects of combining of IL-17 and 
OSM on the production of OPG by SaOS2 cells. From this study I concluded that synovial 
fibroblasts from patients with RA and OA and human osteosarcoma cell lines (MG-63 and 
SaOS2 cells) show that the combination of IL-17 and OSM down-regulated expression of 
RANKL mRNA and OPG mRNA in most of our samples from arthritis but there is some 
synergistic effect on the production of OPG by SFB (OA) at 48 hr and MG-63 at 24 hr and 
48 hr. 
However, previous studies demonstrated that IL- 17 enhanced RANKL and OPG expression 
in mice fibroblasts and osteoblasts (Kotake S. et al. 1999). Also induction of IL-17 is 
considered as an early stage in the arthritis (Buch KA et al., 2001). Thus, a broad set of 
effects are induced by IL-17, and its action can be potentiated by other cytokines. 
In this chapter, synergistic effects could be expected because both of the cytokines have 
different receptors belonging to different families. IL-17 activates NF-k13 and/or API 
while OSM transduces its signal via heterodimeric receptor complexes consisting of two 
subunits. The first is the glycoprotein gpl30 which is universal for all of the IL-6 family 
members, and the second receptor complex subunit can be either the LIF receptor-P or 
OSM receptor-P (Mosley et al., 1996). In mice, OSM only utilizes the gpl30/OSM 
receptor-P complex. Stimulation with OSM leads to activation of the mitogen activated 
protein kinase (MAPK) cascades and the Janus kinase signal transducer and activator of 
transcription (JAK/STAT) pathway, and modulation of AP-I (Taga and Kishimoto 1997). 
In the cytoplasm, the receptor molecules transmit the signal to the ras-raf extracellular- 
response kinase 2 (ERK2) and MAPK pathway or Jak to STAT (Heinrich PC. et al., 2003; 
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Lin SK. et al., 2004; Palmqvist N. et al., 2002). After receptor activation and 
oligomerization, signal transduction pathways become activated. Subsequently, STAT 
factors translocate to the nucleus and initiate transcription of acute phase response genes 
(Mori S. et al., 1999). In my studies there was no synergism but there was decreased 
expression of RANKL and a little or no increased expression and production of OPG in 
MG-63 and SaOS-2 respectively. These finding could be due to the production of some 
other regulatory cytokines such as IL-4, IL-13 or IL-10 from these cells. Alternatively, the 
downstream signaling pathway of IL-17 cross through ras as reported in IEC-6 cells that 
IL-17-mediated activation of extracellular signal regulated kinase mitogen-activated protein 
kinases was mediated through ras, c-Jun N-terminal kinase activation was dependent on 
functional TRAF6. These data suggest that NF-kappa B-inducing kinase serves as the 
common mediator in the NF-kappa B signaling cascades triggered by IL-17, TNF-alpha, 
and IL-1 beta in intestinal epithelial cells (Awane M, et al., 1999). Furthermore, previous 
studies have highlighted the activation of MAPK cascades, STAT protein, NF-kB, and AP-1 
binding complexes in IL-17 signaling, although their exact roles can differ between cell 
types and gene production of interest (Reviewed by Miossec P. et al., 2003; Shalom-Barak 
T et al., 1998) 
In addition, an initial study reported that OSM regulates the expression of Tissue Factor 
(TF) by vascular smooth muscle cells (SMCs) in a biphasic manner leading to sustained 
pattern of TF mRNA. The effect of OSM on TF mRNA expression is regulated at the 
transcriptional level. These authors suggest that the induced expression of TF by OSM is 
primarily through the activation of NF-kappaB and that activation of NF-kappaB is 
regulated in part by the MEK/Erk- 1/2 signal transduction pathway (Nishibe T. et al., 200 1). 
In addition OSM induces chemokine (C-C motif) ligand 2 (CCL-2) expression in 
osteoblasts. Activation of the MEK/ERK and STAT pathways, which leads to c-Fos 
expression and AP-l-DNA binding, is involved in this process (Lin SK et al., 2004). 
Both of cytokines, used in this study, signal through the same pathway which may lead to 
hyper-phosphorylation of the same signal pathway proteins leading to down-regulation of 
other downstream signal pathways (Fig 5.13). The exact proportion and function of IL-17 
and OSM remain to be determined. Conversely, control of such an effect may lead to an 
anti-inflammatory therapeutic. 
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5.4.1 In this chapter I have demonstrated that: 
* IL-17 combined with OSM down-regulates the expression of OPG mRNA in 
synovial cells isolated from RA and OA. 
9 IL-17 combined with OSM down-regulates the expression of RANKL mRNA in 
synovial cells isolated from RA and OA. 
IL-17 combined with OSM has no synergestic affect on the production of OPG 
synovial cells isolated from OA patients 
IL-17 combined with OSM down-regulates the expression of OPG mRNA by the 
human osteosarcoma cells SaOS2 and MG-63. 
9 IL-17 combined with OSM down-regulates the expression of RANKL mRNA by 
the human osteosarcoma cells SaOS2 and MG-63 
9 IL-17 combined with OSM has no synergestic affect the production of OPG in the 
human osteosarcoma cells SaOS2 and MG-63. 
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6 Osteoclastogenesis 
6.1 Introduction 
Bone loss is a major unsolved problem in RA, a common autoimmune disease 
characterized by chronic synovial inflammation and hyperplasia culminating in joint 
destruction (Feldmann, M., 1996; Mulherin, D., 1996). The skeletal complications of RA 
consist mainly of erosions of marginal and subchondral bone, juxtaarticular osteoporosis, 
and universal bone loss with reduced bone mass. The consequences of this profound bone 
loss are pain, joint deformity, progressive functional disability, an increased risk of bone 
fractures, and increased mortality rates. The skeleton is constantly remodelled and 
regenerated by a dynamic process of resorption and replacement. Osteoclastic activation is 
the initial step in the remodelling sequence. Osteoclasts are large, multinucleated cells that 
arise by fusion of committed precursors that originate from haernatopoietic progenitors of 
the monocyte-macrophage lineage. Osteoclasts form a ruffled membrane rim against the 
bone surface and secrete a multiplicity of specialized factors, including proteases, 
collagenases, phosphatases, and protons that break down the bone matrix, releasing mineral 
ions into the extracellular fluid (Suda, T. et al. 1992, Roodman, G 1996, Itonaga, 1. et al. 
2000; Weilbaecher 2000). 
Numerous other adult skeletal diseases are due to inappropriate osteoclastic activity, 
leading to an imbalance of bone remodelling, which favours resorption. Such diseases 
include osteoporosis, periodontal disease, multiple myeloma and metastatic cancers. For 
individuals with osteoporosis, bone fractures represent life-threatening events, and today 
there are large numbers of people worldwide at danger. Recently, our understanding of 
osteoclast differentiation and activation has advanced rapidly with the discovery of a family 
of biologically related TNFR/TNF-like proteins: OPG, RANK and RANKL, which 
together profoundly control osteoclast function (Matsuzaki K. et al. 1998; Itonaga, 1. et al. 
2000; Wong BR. et al., 1997; Anderson DM. et al., 1997). The study of this pathway is 
providing a deeper understanding of how diverse physiological and pathophysiological 
signals exert their effects and induce osteoclastogenesis, bone resorption and skeletal 
remodeling, and so manage bone mass. RANKL can also stimulate mature osteoclasts to 
resorb bone and increase the fusion of mononuclear precursor osteoclasts and the survival 
of multinucleated osteoclasts (Burgess, TL. et al., 1999; Jimi, E. et al., 1999). 
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Much of our understanding of osteoclastogenesis has come from in vitro studies in which 
cells are grown in the presence of osteoblasts, stroma, growth factors, and/or hormones. 
These studies demonstrated that close contact between stromal and bone marrow cell types 
was essential for osteoclastogenesis, and suggested that stromal-derived factors stimulate 
this process. It is now known that this organization allows production of two 
haematopoietic factors that are both required and sufficient for osteoclastogenesis, the 
TNF-related cytokine, RANKL and the polypeptide growth factor, M-CSF. Together, M- 
CSF and RANKL are necessary to stimulate expression of genes that characterize the 
osteoclast lineage, including those encoding tartrate-resistant acid phosphatase (TRAP), 
cathepsin K (CATK) and the calcitonin receptor leading to the development of mature 
osteoclasts (Matsuzaki K. et al. 1998). RA is characterized as both an autoimmune reaction 
initiated by lymphocytes and proliferation of inflamed synovial membrane accompanied by 
inflammatory cell infiltration and bone damage. Bone erosion at the site of RA lesions is 
caused by osteoclasts, and this site is the so-called bare area (Goldring SR., 2002; Bromley 
M.; Wooley DE. 1984). 
TNF-a is a pro-inflammatory cytokine believed to play a key role in the inflammatory 
response in RA. Sabokbar A. et al. (2003); Kudo 0. et al., (2002) established that TNF- a 
in the presence of M-CSF is sufficient to induce human osteoclast differentiation from 
arthroplasty cells derived from tissue isolated at joint replacement surgery and that TNF-a 
acts synergistically with IL-l-a to stimulate lacunar resorption in mouse cultures. This 
process is distinct from the RANK/RANKL signaling pathway and is likely to operate in 
periprosthetic tissues when there is heavy wear particle deposition and cytokine production. 
Interleukin-17 is a recently identified proinflammatory cytokine that displays a number of 
pleiotropic features. IL-17 is produced by activated human memory T lymphocytes 
(CD45+RO), as well as by apTCR+; CD4/CD8' (double negative) murine thymocytes 
activated with CD3mAb, and IL-17 is found excessively in the pannus of inflamed 
synovium of rheumatoid suffers (Fossies et al., 1996; Shin et al., 1999; Kennedy et al., 
1996 and Chabaud et al., 1998). A number of cytokines and inflammatory mediators 
present in the rheurnatoidjoint could be induced by IL-17. These include the expression of 
IL-1p, IL-6, G-CSF, PGE2, TNF-a, LIF and RANKL in fibroblast, osteoblasts, endothelial 
and epithelial cells (Chabaud et al., 1998; Kotake et al., 1999; Kotake et al., 2001). In 
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addition, IL- 17 in combination with TNF-a, but not IL- I P, augments osteoclastic formation 
in vitro (Van Bezooijen RL et al., 1999). Therefore, IL-17 may play a role in regulating 
bone degradation characterized by the existence of activated T cells and TNF-a production 
in pathologies such as RA and loosening of bone implants (Van Bezooijen RL et al., 1999). 
6.1.1 The alms of this chapter were: 
9 To establish the effects of IL-17 on the formation of TRAP positive cells in cultures 
of mononuclear cells (PBMCs). 
9 To establish the effects of IL-17 on the formation of TRAP positive cells in cultures 
of mononuclear cells (PBMCs) on extracellular matrix. 
9 To establish the effects of IL-17 on the resorption of mineralized matrix by long 
term cultures of mononuclear cells (PBMCs). 
* To establish the role of RANKL in IL-17-induced osteoclastogenesis. 
To study the role of IL-17 in the regulation of the interaction between synovial cells 
(both RA and OA) and PBMCs leading to osteoclastogenesis in vitro. 
6.2 Materials and Methods 
6.2.1 Multinucleated cell formation 
PBMCs were isolated and cultured in eight-well multi-chambered slides. Cells were 
seeded at (5 x 105) cells/well for 24 hr in RPMI 1640 (chapter 2, sections 2.8.9 and 2.8.9.1). 
Two sets of experiments were used, one with ECM (sections 2.8.8.1 and 2.9.1) and the 
other without ECM. Then fresh untreated medium was added as -ve control, and to the 
treated wells; medium/FCS with different growth factor combinations, IL-17 (5 and 50 
ng/ml) with or without M-CSF (25 ng/ml), RANKL and M-CSF (30 + 25 ng/ml, 
respectively), were added to duplicate wells. The cultures were maintained for 21 days; 
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culture medium was replenished every three days with fresh medium supplemented with 
the agents described above. The entire experiment was repeated three times. 
6.2.2 Cytochemical and Functional Assessment of osteoclast 
Formation 
Cells were fixed in 4% paraformaldehyde solution for 10 min then washed twice in DBPS. 
After staining for TRAP activity, using a commercial kit (Sigma) according to the 
manufacturer's instructions, TRAP-positive cells containing more than three nuclei were 
counted as multinucleated cells by light microscopy. DAPI stain was also used to further 
confirm the presence of multinucleated cells as described in the materials and methods 
section (2.9.3). An example for TRAP activity and DAPI stain is shown in Fig 6.1. 
Functional assessment of osteoclast formation was determined at the end of the co-culture 
period using a resorption assay. Cells were stained for TRAP activity to identify 
osteoclast-like cells, grown on the ivory wafers. Then the cells were removed from the 
ivory slices by immersing them in sodium hypochlorite as described in materials and 
methods (2.9.3). Then the ivory slice and/or commercial dentine slice surfaces were 
examined for evidence of lacunae resorption. The slices were then stained with or without 
0.5% (w/v) toluidine blue for 3 min, air dried, and examined by light microscopy. The 
extent of resorption was determined by measuring the percentage of the eroded area on 
each slice by image analysis. 
6.2.3 Mineralised matrix resorption assay. 
The ivory slices were placed in (96 or 48) well tissue-culture plates. 5x 104 or IX 106 
PBMCs were seeded in each well and allowed to settle on the ivory slices for 2-4 hr. 
Nonadherent cells and debris were removed by pipetting after 2 hr; RPMl 1640 
medium/FCS was used to wash debris, or the ivory slice was moved to a new tissue culture 
plate with a fresh medium. Then culture medium/FCS containing OPG (100 ng/ml) were 
used as a negative control, medium/FCS with RANKL + M-CSF (100 + 30 ng/ml, 
respectively) as a positive control and treatments with IL-17 (5 and 50 ng/ml) with or 
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without (30 ng/ml) of M-CSF were added. Each experimental condition was repeated 
in five replicates. 
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Fig 6.1 TRAP-postive and DAPI staining identification of multinucleated cells (NI) 
in the PB'vlC culture. (A) -ve-control PBMC cells were treated with RANKL and M- 
CSF (30 - 25 ng/ml, respectively). (B) IL-17 (5 ng/ml) with M-CSF (25 ng/ml). (C) - 
ve control cells were cultured in RPMI-1640 with 10%FCS. Cells were cultured for 21 
days before fixing with 4% Paraformaldehyde and stained for TRAP-positive and 
DAPI stain as described in Materials and Methods. The nuclei of multinuclear cells 
appeared clear with the DAPI stain to count more than three nuclei in TRAP-positive 
cells - Magnification bar is 100ýLrn for all image. The intense blue staining clearly 
identifies multinucleated cells (marked by the arrows). 
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The cultures were maintained for 21 days, during which time the medium and added factors 
(including cytokines/growth factors) were replenished every 3 days. The whole experiment 
was repeated three times. 
Ivory slices (0.4 cm x. 0.4 cm squares, 0.6 mm thick) were placed in 48 wells tissue-culture 
plates. Then (I X 106) PBMCs were added to each well and cultured on slices for (2 -4 hr) 
as previously mentioned, then SFB cells (2 x. 104) from OA or from RA patients were 
added and incubated overnight. Then the ivory slices were washed and treated as 
mentioned before. 
Commercial dentine slices were placed in 96-well tissue-culture plates. PBMCs (5 x 105) 
were added to each well and cultured on slices for 2 hr. Then SFB cells (I x 104) from RA 
were added and incubated for overnight. Then the ivory slices were washed with fresh 
medium and treated medium/FCS with OPG (100 ng/ml) was added as negative control, 
medium/FCS with RANKL + M-CSF (100 + 30 ng/ml, respectively) was added as a 
positive control, IL-17 (5 and 50 ng/ml) with M-CSF (30 ng/ml) and IL-17 (50 ng/ml) 
without M-CSF were added in duplicate wells for each treatment. The cultures were 
maintained for 21 days as stated before. 
6.3 Results 
6.3.1 The effect of IL-17 on the formation of TRAP+ve 
multinucleated cells from PBMC 
The results show that a number of TRAP-positive multinucleated cells were formed in the 
eight-well multi-chambered slides under the culture conditions used. The cultures of 
PBMCs from healthy volunteers treated with IL-17 (5 and 50 ng/ml) with or without M- 
CSF (25 ng/ml) were compared to negative control (untreated cells) and also compared to 
the positive control wells which were treated with RANKL and M-CSF (30 and 25 ng/ml, 
respectively). The number of TRAP-positive multinucleated cells were increased in the 
chambers treated with IL-17, with and without M-CSF, and in the positive control RANKL 
with M-CSF compared to negative control (compare Fig 6.2 C-F with A). 
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Fig 6.2 Formation of TRAP-postive multinucleated cells in PBMC culture. Cells were 
cultured in 8 well multi-chambered slides. (A) -ve control which is treated with R_PMI- 
1640 with 10% FCS. (B) +ve-control that is RANKL and M-CSF (30 + 25 ng/ml, 
respectively ). (C) IL-17 (5 ng/ml ). (D) IL-17 (50 ng/ml). (E) IL-17 and M-CSF (5 + 25 
ng/ml, respectively). (F) IL-17 and M-CSF (50 + 25 ng/ml, respectively ). Cells were 
cultured for 21 days before fixing with 4% Parafon-naldehyde and stained for TRAP- 
activity as described in Materials and Methods. Magnification bar is I 00ýim for all images. 
Multinucleated cells are marked by the arrows. Each image is equivalent to I field. 
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The total numbers of multinucleated cells that were TRAP-positive were counted. To 
confirm cells were multinucleated with more than three nuclei DAPI stain was used to 
clearly identify the nuclei in multinucleated cells. The results from counting cells show 
that there was a highly significant difference in the cultures treated with RANKL (30 
ng/ml) and M-CSF (25 ng/ml), IL-17 (50 ng/ml) with and without M-CSF (25 ng/ml) and 
IL-17 (5 ng/ml) with M-CSF (25 ng/ml) compared to cultures incubated with M-CSF alone 
and -ve control with RPMl 1640 medium with 10% FCS (Fig 6.3). There is also a highly 
significant difference between IL-17 (5 ng/ml) with and without M-CSF (25 ng/ml). 
6.3.2 The effects of IL-17 on TRAP+ve multinucleated cell 
formation from PBMC cultured on ECM. 
Recognition of ECM components is an important step in initiating osteoclast function. 
PBMCs from healthy volunteers were cultured on tissue culture plastic coated with ECM 
and showed an increase in TRAP-positive staining but there was no enhancement in the 
numbers of multinucleated cells compared with cultures of PBMCs without ECM. TRAP- 
positive staining was observed in cells treated with IL-17. Moreover, overall the visualized 
TRAP+ve cells were enhanced and a proportion of these cells became large and the 
phenotypes of the cells were changed in the untreated cells on ECM (Fig 6.4) (B) compared 
to untreated cells without ECM (Fig 6.4) (A). Also, TRAP+ve cells were enhanced in the 
chambers treated with IL-17 (5 ng/ml) and M-CSF (25 ng/ml) on ECM (Fig 6.4) (D) 
compared to those without ECM as visualized by the light microscopy (Fig 6.4) (C). 
6.3.3 The effects of IL-17 on bone resorption activity of 
PBMC cultured on ivory. 
Bone resorption by PBMCs cultured with IL-17 was also examined. The percentage- 
eroded area on the surface of ivory slices was determined by reflected light microscopy and 
image analysis. The results from these experiments show a highly significant increase in 
the percentage of resorption areas in cultures treated with IL-17 (5 and 50 ng/ml) with M- 
CSF and in the +ve control (RANKL with M-CSF) compared to OPG -ve control. Also, 
there is a significant increase in bone resorption in cultures treated with IL-17 (50 ng/ml) 
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with M-CSF compared with IL- 17 (50 ng/ml) alone. Furthermore, the resorption observed 
with IL-17 (50 ng/ml) alone is significantly increased in comparison to OPG alone and ll-- 
17 with OPG (Fig 6.5). 
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Fig 6.3 TRAP+ve multinucleated cells (MNCs) formed in vitro from PBMC. 
PBMC cells were cultures in the presence ofIL- 17 (5 or 50 ng/nil) with or without M- 
CSF (25 ng/ml). The positive control was RANKI, and M-CSF (30 and 25 ng/ml 
respectively) and negative control was fresh RPMI with 10% FCS. RANKI, and M- 
CSF alone were also assessed. TRAP-positive MNCs containing more than three nuclei 
were counted, ten fields for each treatment per chamber slides. The results shown are 
the means of 10 fields from each duplicate cultures of P13MC. The clit'llerence between 
mean was assessed using one way analysis of variance (ANOVA), Tukey and Duncan 
post test. Where * indicates comparisons with -ve control and ip with IL- 17 (5 ng/ml). 
* (P< 0.05), *** (P: 5 0.001). 
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Fig 6.4 Formation of TRAP-postive multinucleated cells in the PBMC 
culture on ECM. PBMC cells were cultured in (A) -ve control which is treated 
with RPMI-1640 with 10%FCS. (B) -ve control which is treated with RPMl- 
1640 with 10%FCS and the cells were cultured on the ECNI from MG-63 as 
described in materials and methods. (C) PBMCs were treated with IL-17 with 
M-CSF (5 + 25 ng/ml, respectively) and cultured without ECM. (D) Cells were 
treated with IL-17 and M-CSF (5 + 25 ng/ml, respectively) and cultured on 
ECM. Cells were cultured for 21 days before fixing with 4% Paraformaldehyde 
and stained for TRAP activity as described in Materials and Methods. 
Magnification bar is 50gm. 
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Fig 6.5 Formation of resorption areas on ivory slices cultured with 111INICs. 
PBMCs ( 1.5 x 10") were plated oil ivory slices for 2 hr. The ivory slices were then 
transferred to 48-well plates and incubated for 24 hr in fresh medILIIII With M-CSF 
then washed and tile cultures were treated with IL-17, RANKL (100 lIgIIIII), M-CSF 
(30 ng/ml) and OPG (100 righ-ril). The cultures were grown for 21 days and tile 
media replenished every 3 days. Resorption pits formed on ivory slices were 
visualised under reflected light microscopy. The percentage of resorbed area was 
determined per wafer. Each bar represents the mean (n=5) ±SF. Statistical 
significant was determined by one way analysis of variance, Tukey and Durican 
post test. 
Where * indicates comparisons with tile OPG -ve control, tP with IL-17 (50 
ng/ml)+ M-CSF, §§§ with RANKL + M-CSF + OPG. 
* (P: ý0.05), *** (P<0.001). 
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6.3.4 The effects of IL-17 on bone resorption by PBMC co- 
cultured with SFB (RA) on Ivory. 
Unstimulated PBMCs (1.5 x 106) derived from a volunteer and SFB from a RA patient (I x 
104) were co-cultured for 21 days on ivory slices. The results show that the eroded area 
was increased on wafers treated with IL-17 and RANKL with M-CSF compared to OPG 
treatment alone as visualized by reflected light microscopy. The eroded area caused by 
these treatments is inhibited by adding OPG (100 ng/ml). Examples of eroded areas from 
RANKL with M-CSF and IL-17 compared to OPG are shown in Fig 6.6 (B and C 
compared to A). The resorption lacunae were further investigated and characterized by 
SEM (Fig 6.7). These selected images show focal de-mineralized zones (Fig 6.7A) and 
interconnected resorption pits (Fig 6.713). 
The mean of the percentage-eroded area on the surface of ivory wafer was significantly 
increased in the cultures treated with RANKL and M-CSF (100 with 30 ng/ml, 
respectively), IL-17 (50 ng/ml) with and without M-CSF (30 ng/ml) and IL-17 (5 ng/ml) 
with M-CSF compared with OPG (100 ng/ml) alone. Also there was a highly significant 
difference between IL-17 (5 ng/ml) without M-CSF compared with OPG treatment. The 
eroded area on ivory slices treated with RANKL, M-CSF and OPG is highly significantly 
inhibited compared to RANKL and M-CSF. In addition, the eroded area is highly 
significantly inhibited in response to OPG and IL-17 (50 ng/ml) compared to IL-17 alone 
(Fig 6.8). 
Additionally, to contrast between ivory and the commercial dentine slices, PBMCs were 
co-cultured with RA synovial fibroblasts on dentine slices. Examples of resorption areas 
visualized by reflected light microscope are shown in Fig 6.9. The results from this 
experiment show that the percentage-eroded area on the surface of dentine slices was 
highly significantly increased in the cultures treated with RANKL and M-CSF (100 with 30 
ng/ml), IL-17 (5 or 50 ng/ml) with M-CSF (30 ng/ml), and IL-17 (50 ng/ml) compared to 
the cultures treated with OPG (100 ng/ml) alone. Also, there was a significant difference 
between IL-17 (50 ng/ml) without M-CSF and IL-17 (50 ng/ml) with M-CSF as shown in 
(Fig 6-10). The experiment was in duplicate and only one experiment was performed. 
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Fig 6.6 Formation of resorption area on ivory slices in the cultures of PBNIC 
with s-*, iio-*-ial fibroblasts from a rheumatoid arthritis patient. A Cells wcrc 
treated with OPG (100 ng/ml). B Cells were treated by RANKI, and M-('Sl, '(30 f 25 
ng/ml, respectively) as +ve-control. C Cells were treated with 11,17 with M-('SI` 0 
+ 25 ng/ml, respectively). Cells were cultured for 21 days. before I`ixing with 41ý1() 
Para formaldehyde and staining for TRAP activity as described in Materials and 
Methods. After the cells were removed, images were taken by rellected light 
microscopy. Magnification bar is 50 gm for all images Resorption pits are marked 
by the arrows. 
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Figure 6.7 Formation of resorption pits on ivory slices by SEM. l'BN'lC 
co-cultured with RA synovial fibroblasts. A Cells were treated with 
RANKL and M-CSF (100 + 25 ng/ml, respectively). B cells were treated 
with IL-17 and M-CSF (50 + 25 ng/ml, respectively). Cells were c(IhUI-cd for 
21 days and medium and and added cytokines were replenished every three 
before fixing with 4% Para formaldehyde and staining for TRAP activity as 
described in Materials and Methods. After the cells were removed, the slices 
were visualized by SEMR pits cells are marked by the arrows 
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Fig 6.8 Formation of resorption area on ivory slices in the co-cultures of 
PBMC and Synovial fibroblasts from RA. PBMCs (1.5 x 10") were plated 
on ivory slices for 2 hr and then transferred to 48-well plates and incubated tor 
24 hr in in fresh medium with M-CSF as indicated in materials and methods. 
After one day RA synovial fibroblasts (2 x 104) cells were co-cultured with the 
PBMCs in the presence of IL-17 (5 and 50 ng/ml), RANKI, (100 ng/ml), M- 
CSF (30 ng/ml) and OPG (100 ng/ml). Then the cultures were fLIFther 
incubated for 21 days. Resorption pits formed on ivory slices were visuallsed 
under reflected light microscope, The percentage of resorbcd area was 
determined. Each bar present the mean (n=5) of independent ivory slices. 
Statistical significance was determined by one way analysis of variance and 
Tukey and Duncan post test . Where 
** indicates comparisons with OPG -ve 
control, §§§ with RANKL + M-CSF + OPG. with IL-17 + OPG- 
** (P!! ý0.01)' *** (P.! 5; 0.001). 
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Fig 6.9 Formation of resorption pits on commercial dentine slices in the cultures 
of PBMCs co-cultured Nvith synovial fibroblasts from RA patient by reflected 
light microscope. A OPG (100 ng/rnl). B IL- 17 (50 ng/nil). C Il, - 17 (50 lig"llil) 
with M-CSF (30 ng/ml). Cells were further cultured for 21 davs. before fixing with 
4()/'o Para formaldehyde and staining for TRAP activity as described in Materials and 
Methods. After the cells removed as described in material and methods and the 
pictures was taken by reflected light microscope. Magnification bar is 50ýtlll for all 
images. Resorption pits cells are marked by the arrows 
158 
Chapter-6 Results 
cc 
E 
7 
6 
5 
4 
3 
-dl-l 
OPG + 
IL-17 50 
RANKL 
M-CSF 
5 50 
Fig 6.10 Formation of resorption area on commercial dentine slices in the co- 
cultures of PBMC and Synovial fibroblasts from RA. PBM('s (I x 10") were 
plated on dentine slices for 2 hr. The dentine slices Were then transferred to 48- 
well plates and incubated for 24 hr in the presence of fresh medium with M-('Sl, ' 
(30 ng/mi). After one day RA synovial fibroblasts (1.5 x 104) cells were co- 
cultured with PBMCs on the dentine slices. The cultures were treated with 11,17 
(50 ng/ml), RANKL (100 ng/m), M-CSF (30 ng/ml) and OPG (100 ng/ml). Then 
the cultures were further incubated for 21 days. Resorption pits formed on 
dentine slices were visualised under reflected light microscope, The percentage of 
resorbed area was determined per wafer. Each bar present the mean (n=2) ± Sl` 
statistically significant was determined by one way analysis of variance and 
Tukey and Duncan post test . Where 
* indicates comparisons with tile OPG -ve 
control. 
* (P!! ý0.05), *** (P!: -ý0.001). 
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6.3.5 The effects of IL-17 on bone resorption activity of 
PBMC co-cultured with SFB from OA patients. 
To examine the potential role of IL-17 in OA, PBMCs were co-cultured with SFB (OA) 
treated with IL-17 with and without M-CSF, RANKL with M-CSF as a positive control and 
compared these treatments with OPG as a negative control. The results show that there was 
a highly significant difference in the percentage of resorption area between the cultures 
treated with IL-17 (50 ng/ml), IL-17 (5 and 50 ng/ml) with M-CSF (30 ng/ml) and RANKL 
with M-CSF (100 with 30 ng/ml, respectively) compared to the cultures treated with OPG 
alone (100 ng/ml) (Fig 6.11). There were no significant differences between IL-17 (5 and 
50 ng/ml) and IL-17 (5 and 50 ng/ml) with M-CSF, furthermore there were no significant 
differences between IL-17 (5 ng/ml) without M-CSF compared to the cultures treated with 
the OPG. However, there was significant inhibition in the cultures treated with RANKL 
and M-CSF (100 with 30 ng/ml, respectively) when OPG (100 ng/ml) was added and in the 
culture treated with IL-17 (50 ng/ml) when OPG (100 ng/ml) was added. IL-17 or RANKL 
with M-CSF have the ability to induce resorption of a mineralized substrate by PBMCs co- 
cultured with SFB from OA patients as demonstrated by the appearance of numerous 
resorption lacunae during co-cultures conducted on ivory slices. 
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Fig 6.11 Formation of resorption area on ivory slices in the co-cultures of PBN1C 
and OA synovial fibroblasts. PBMC's (1.5 x 10) were plated on ivory slices for 2 hr. 
The ivory slices wci-c then transferred to 48-well plates and incubated flor 24 hr in the 
presence of fresh medium with M-CSF (30 ng/ml). After one day the OA synovial 
fibroblasts (2 x 104) cells were co-cultured with the PBM(-'s. The cultures were treated 
with IL-17 (5 and 50 ng/ml), RANKL (100 ng/m), M-CSF (30 ng/ml) and OPG (100 
ng/ml). Then the cultures were grown for 21 days and the medium were replenished 
every three days. Resorption pits formed on ivory slices were examined under the 
reflected light microscopy. The percentage of resorbed area was determined per-1vory 
slice. Each bar represents the mean (n=5) ± SE. Statistical significance was 
determined by one way analysis of variance, Tukey and Duncan post test. Where *** 
indicates comparisons with the OPG -ve control, qj yj yj with IL-17 + OPG, §§§ 
with RANKL +M-CSF + OPG. 
*** (P<0.001). 
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6.4 Discussion 
To study the effect of IL-17 on osteoclast formation in vitro, I performed assays using 
PBMCs as osteoclast precursors. As a positive control, RANKL, a membrane expressed 
ligand that is a member of the TNF superfamily, was used (Wong BR. et al., 1997; 
Anderson DM. et al., 1997). In some experiment I used OPG, a novel member of the TNF 
receptor superfamily, which, in contrast with other family members lacks a trans-membrane 
domain (Morinaga T. et al., 1998; Yasuda H. et al 1998). This indicates that OPG is 
secreted as a soluble factor that may act to modulate osteoclast formation. I showed that 
IL-17 significantly increased the numbers of multinucleated TRAP-positive cells in 
PBMCs cultured in chambered slides. These results suggest that IL-17 stimulation induces 
the process that leads to the fusion of preosteoclasts. TRAP-positive stain was detected in 
the multinucleated cells induced by IL-17 (at 5 and 50 ng/ml) with and without M-CSF 
further inducing osteoclast formation. 
The role of IL-17 was further investigated by measuring the resorption areas on ivory 
wafers used as substrate for the culture of PBMCs. Treatment with RANKL and M-CSF, 
and IL-17 with or without M-CSF induced osteoclast formation. This study suggests that 
may IL- 17 have a role in the most aggressive forms of inflammatory bone and cartilage loss 
by directly stimulating osteoclast precursors to fuse and differentiate to become mature and 
active osteoclasts. 
However, results show that there was a dramatic decrease in the percentage of resorption 
area when OPG was added to IL-17 treated cultures. These results therefore suggest that 
IL-17 stimulated bone resorption is RANKL-dependent. sRANKL is released from 
activated T cells and the membrane form of RANKL is also expressed on the infiltrating T 
cells in rheumatoid synovial fluid. Kanamaru F et al., (2004) demonstrated that the 
expression of mRANKL on T cells is strictly limited, and the majority of RANKL protein 
produced by T cells may be active in the soluble form after shedding. In addition, in vitro 
studies suggested a role for IL-17 in bone erosion by induction of RANKL expression 
(Kotake S. et al., 1999). RANKL is expressed by stromal cells and osteoblasts and induces 
differentiation and maturation of osteoclast progenitors (which are monocyt-macrophage 
lineage cells), and modulates the survival and function of the resultant giant multinucleated 
osteoclasts (Suda et al, 1999; Takahashi et al, 1999). IL-17 may promote joint 
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inflammation as well as tissue destruction during the initial phase of arthritis. After words, 
RANKL and some other factors such M-CSF continue the osteoclastogenesis process. 
Bone marrow cells are able to differentiate in vitro into osteoclast-like cells in the presence 
of RANKL and M-CSF (Blin-Wakkach C. et al., 2004). However, the role of T cell IL-17 
during the effector phase of arthritis has still not been identified. M-CSF is shown to be a 
crucial factor in mouse osteoclast development (Kodama H. et al., 1991). Matsuzaki K. et 
al., (1998) demonstrated that M-CSF was also essential for inducing OCLs from human 
PBMCs. Without M-CSF, most of the PBMCs disappeared even in the presence of 
sRANKL during the 7 day-culture period, suggesting that M-CSF is involved in the 
proliferation and survival of osteoclast progenitors. IL-17 may be required with M-CSF to 
prolong the life span of osteoclasts. Therefore, IL-17 may increase the production of 
RANKL and M-CSF from PBMC in the culture medium which affects differentiation, 
maturation and activation of multinucleated cells, or perhaps IL-17 has some effect as M- 
CSF that leads PBMCs to prolong the life span of osteoclasts. In the co-cultures of P13MC 
with SFB from RA and OA, IL-17 may increase the production of RANKL in the culture 
medium which increases the differentiation of osteoclasts. In addition, synovial 
macrophage cells are capable of differentiating to osteoclast-like cells under some 
conditions, including culturing with M-CSF and RANKL (Itonaga I et al., 2000). 
The number of TRAP+ve cells formed and lacunae resorption surface area in the PBMCs 
co-cultured with SFB from RA and OA are more than the PBMCs alone. However, the 
number of the osteoclasts and lacunae resorption surface area formed by the PBMC co- 
cultured with SFB from OA is more than one and half times PBMC alone. The co-culture 
of PBMCs and SF13 from RA produced more resorption than the co-culture of PBMCs with 
SFB from OA. This resorption is RANKL-dependent and suggests that SFB from RA in 
response to IL-17 may produce increased levels of RANKL than from OA SFB. This result 
support the previous suggestion by Kotake, et al, 1999 in mouse as shown in Fig 6.12. 
RANKL is an essential factor in osteobiology (Simonet et al, 1997; Lacey et al, 1998), 
linking osteoblast/stromal cell functions to osteoclast formation and activation. Osteoclast 
activity is regulated by the differential expression of membrane-RANKL, as well as 
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sRANKL, its receptor RANK and decoy receptor OPG (Suda et al, 1999, Takahashi et al, 
1999). The previous studies may explain the finding of an increase in resorption area in the 
co-cultures of SFB cells with PBMC which may be mediated by cell-to-cell contact. 
Synovial Tissue Bone 
T-cells 
Osteoclast progenitors 
*, r 
OPG 
Fig 6.12 osteociastogenesis mechanism by activated T ceUs and osteoblasts cytokines. 
(taken from Kotake, et al, 1999). 
In addition, this phenomenon may be mediated by other cytokines, as, suggested by Atkins 
GJ (2000) who found that ST-2 cells in vitro express mRNA encoding a repertoire of many 
of the reported osteoclastogenic factors (IL-I/IL-1 Rl, IL-I 1, IL-6/IL-6R, IL-I 7 and TGF-P, 
as well as RANKL). The stromal cells also expressed mRNA encoding two molecules 
shown to be inhibitory to osteoclastogenesis, OPG and I L- 18. OPG, IL- 1,1 L- IR1, IL-6,1 L- 
6R, IL-I IR, IL-17, IL-18, IL-18R, TGF-O and M-CSF were expressed by both the stromal 
cells and the PBMC. This study showed that the resorption area formed by IL-I 7 with or 
without M-CSF and by RANKL with M-CSF was inhibited with OPG suggesting the 
eroded area was RANKL-dependent. 
Osteoclast adhesion to the bone surface induces cytoskeletal reorganization and cell 
activation. The recognition of ECM components is an important step in initiating 
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osteoclast function (Reinholt, F. P., et al., 1990; Lakkakorpi, P. T., et al., 1991). My results 
showed that ECM affects TRAP activity through the observation that TRAP activity was 
increased in general cell populations and the phenotype of cells became more fibroblastic 
but did not affect the number of multinucleated cells. This result suggests that period of 
time used in this experiment to extract ECM may be not long enough to produce mature 
ECM, while it affect on TRAP activity that is an indicators perhaps it will affect on 
multinucleated cells in long time period ECM. However, more investigations are needed to 
discover the importance of ECM. In general, ECM proteins are involved in the formation, 
migration, attachment, and resorptive activity of osteoclasts. In vitro, integrin-mediated 
adhesion to vitronectin, fibronectin, or collagen induces osteoclast spreading and actin 
rearrangement (Nakamura, I., et al., 1996). In addition, signaling pathways, which involve 
c-Src, c-CbI or P13-kinase are known to be important for osteoclastic bone resorption 
(Soriano, P., et al., 1991; Tanaka, S., et al., 1996). Furthermore, previous studies have 
mentioned the requirement of ECM proteins at targeted sites of bone resorption to attract 
osteoclast precursors and to promote their proliferation/differcritiation, and/or migration 
(Lakkakorpi PT and Vaananen HK 1991; Paolo M. et al., 2002; Mareel M. and Leroy A. 
2003). 
Moreover, Romas E (2002) provided further evidence that OPG protects bone integrity by 
downregulating osteoclastogenesis and promoting osteoclast apoptosis. Modulation of the 
RANKUOPG equilibrium in arthritis may provide additional skeletal benefits, such as 
chondroprotection. The nexus between T-cell activation, TNF-a overproduction, and the 
RANKL/OPG/RANK ligand-receptor system points to a unifying paradigm for the entire 
spectrum of skeletal pathology in RA. Strategies that address osteoclastic bone resorption 
will represent an important new facet of therapy for RA. 
6.4.1 The major findings of this chapter are 
e IL-17 enhances the number of multinucleated cells formed from PBMCs in vitro. 
9 IL-17 stimulates bone resorption activity by PBMCs in vitro. 
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e IL-17 stimulates bone resorption by PBMCs co-cultured with SFB (RA) in vitro. 
o IL-17 stimulates bone resorption activity of PBMCs co-cultured with SFB (OA) on 
ivory. 
o The effects of IL-17 on bone resorption in vitro is mostly RANKL-dependent. 
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7 General discussion 
Arthritis is a chronic inflammatory disease characterized by bone and articular cartilage 
degradation. The pathogenesis of inflammation and tissue destruction in arthritis results 
from cell-cell interactions between, among others, T lymphocytes, monocytes and 
synoviocytes. A number of factors are released that cause osteoclast differentiation, 
maturation and activation. Recent studies of the pathogenesis of RA have revealed that 
both synovial fibroblasts and T cells participate in the perpetuation of joint 
inflammation as dynamic partners in a mutual activation, via secretion of cytokines and 
chemokines that stimulate each other (Hwang SY et al., 2004). 
The main aim of this thesis was to investigate the role of IL- 17 (produced by activated 
T cells) in the activation of RA synovial fibroblasts, and the role of OSM, (a 
macrophage and activated T cell cytokine). In addition, this thesis examined the 
synergistic interaction of both cytokincs on factors such as RANKL and OPG that affect 
joint destruction. The early stage of the project involved the examination of cytokine 
activity in synovial fibroblasts and in osteoblast-like cells. The latter stages of the 
project involved the examination of the effects of IL-17 on osteoclast formation in vitro 
by using PBMC as osteoclast precursors. Furthermore, osteoclastogenesis was studied 
in co-cultures with the SFB from RA and OA patients. 
RANKL and OPG may be the target of some factors such as IL-17 and OSM. The 
molecular mechanisms that underlie this phenomenon have not been well understood. 
RANKL is a differentiation factor for osteoclasts but not an exclusive osteoclast 
commitment factor, as RANK is expressed not only in osteoclasts but also in T cells and 
dendritic cells (Anderson DM. et al., 1997). However, the role of local RANKL and 
OPG in IL-17 action has been restricted to in vitro studies. To confirm the role of these 
molecules and to characterize molecular mediators in the physiology of abnormal bone 
resorption triggered by IL- 17, studies that further examine the expression and regulation 
of these molecules are needed. 
The present study demonstrated that the expression of RANKL is rapidly enhanced in 
response to IL-17. This result indicates that IL-17 may affect the expression of RANKL 
and lead to an increase in bone resorption. The increase in RANKL expression may 
provide further evidence that the disturbance of the balance of RANKL and OPG by 
cytokines such as IL- 17 and OSM may be interrupting the mechanism linking osteoblast 
and osteoclast. The increase in RANKL confirmed that the balance of RANKL and 
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OPG is altered to assist bone resorption. However, the soluble or membrane bound 
cytokines, interacting with specific receptors expressed on a variety of cell types, 
modulate their synthesis, secretion, and expression, thus creating a complex cytokine 
network that influences immunity and inflammation. Although the balance between the 
production of pro- and anti-inflammatory cytokines and/or their functional receptors 
changes during the course of these processes, usually it is self-controlled and eventually 
reaches equilibrium. However, in certain situations e. g. RA, this balance may be shifted 
toward the production of proinflammatory cytokines for too long, resulting in catabolic 
effects. For example, in RA patients the overproduction of TNF-a and IL-lP that 
contributes to the induction of other proinflammatory mediators (IL-6, IL-8, GM-CSF, 
and many others), seems to be critical for chronic inflammation, ultimately resulting in 
joint destruction (Feldmann, M et al., 1996). In addition, Saidenberg Kermanac'h N 
(2002) explained his data as part of an abnormal phenomena in diseases such as RA 
characterized by both inflammation and bone destruction. RANKL is expressed in a 
variety of cell types including ostcoblasts; and activated T cells. In addition, under some 
conditions, synovial macrophage cells are believed capable of differentiating into 
osteoclast-like cells under stimulus from M-CSF and RANKL (Itonaga I et al., 2000). 
It has been demonstrated previously that in bone loss there is an elevation of RANKL 
and a reduction of OPG. In addition, RANKL mRNA is expressed in cells within the 
RA tissues, and the increases in the ratio of RANKL/OPG in RA tissues significantly 
correlated with the formation of functional octeoclasts. This identifies the 
OPG/RANKL/RANK pathway of osteoclast differentiation as a possible target for 
regulating the bone destruction (Haynes DR. et al., 2001; Crotti T et al., 2003). 
However, it remains to be clarified whether RANKL is produced in joint cells, how its 
expression is regulated by local inflammatory mediators, and whether RANKL 
produced in the joint microenvironment plays any significant role in pathological 
conditions such as osteoporosis. Firstly RANKL expression was examined in SFB (RA 
and OA) and contrasted with osteoblastic like cells MG-63 and SaOS2 cell lines. The 
results indicate that IL-17 transiently induces RANKL expression in synovial 
fibroblasts and osteoblastic-like cells. In addition, the early induction of RANKL 
mRNA at 6 hr and no expression at 24 hr agrees with a previous study in mouse 
osteoblasts (Okahashi N et al., 2004). A similar finding has shown that histamine 
modulates RANKL expression in stromal cells in a similar manner (Tasaka K. et al., 
1993 and Zheng T. et al., 1994). Histamine markedly increased the expression of 
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RANKL mRNA in a dose-dependent manner by osteoblastic cells, at the earliest time 
point, while the production of RANKL protein followed this pattern (Deyama Y. et al., 
2002). In my work I found in some OA samples and MG-63 and SaOS-2 cells that 
RANKL mRNA was enhanced by IL-17 and OSM at 6 hr and 48 hr or at 48 hr only. In 
addition, Frick KK and Bushinsky DA (2003) reported that cultured mouse osteoblasts 
in acidosis conditions showed significantly increased expression of RANKL mRNA at 
both 24 hr and 48 hr, supporting my observation of increased RANKL expression at 48 
hr in response to IL- 17. 
Arai F. et al., (1999) suggested that RANKL- RANK signaling plays several roles in 
organogenesis. M-CSF stimulates c-Kit+ Mac- I dull c-Fms' cells to induce RANK 
mRNA and protein in 24 hr. These cells can differentiate into osteoclasts in the 
presence of both M-CSF and sRANKL, whilst with M-CSF only they differentiate into 
macrophages but not osteoclasts. Pre-cultures of c-Kif+ Mac- Idull c-Fms+ cells with M- 
CSF for 24 hr or 72 hr result in different fates for osteoclast precursors. RANK+ cells 
after 24 hr pre-culture differentiate into osteoclasts more capably than after 72 hr pre- 
culture. RANK4* cells may separately differentiate into the macrophage lineage in the 
absence of sRANKL for 72 hr. By contrast, in the presence of both sRANKL and M- 
CSF after 24 hr pre-culture with M-CSF, RANK+ cells efficiently differentiate into 
osteoclasts. RANK7 cells, after pre-culture with M-CSF, may differentiate into RANK+ 
cells if they are continuously exposed to M-CSF. Once the cells express RANK, 
existing RANKL binds to the receptors. This is the most productive system for 
osteoclast differentiation, which may take place in vivo on bone surfaces. 
Previous report by Arai F (1999) may explain the results presented here that show 
RANKL mRNA expression at 6 hr which was followed by RANKL production 
subsequently at 24 hr. RANKL produced at 24 hr may induce the differentiation of 
osteoclasts instead of macrophage differentiation. Further expression of RANKL 
mRNA at 48 hr may also follow with the production of RANKL protein at 72 hr. These 
results suggest that IL-17 may be directly involved in osteoclastogenesis through 
RANKL production by synovial fibroblast cells and osteoblasts. 
It is therefore possible that the bone erosion seen in arthritis may result from 
RANKURANK activation by activated T cells. RANKL secretion by activated T cells 
can induce osteoclastogenesis. Consequently these mechanisms are enhanced by IL-17, 
which promote both inflammation and bone resorption Lubberts E et al., (2001). 
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Furthermore, the effect of IL-17 and OSM on the expression of OPG was examined by 
synovial fibroblasts from RA and OA and cell lines MG-63 and SaOS2. OPG mRNA 
levels in RA and OA samples appear to be enhanced in response to IL- 17 and OSM in a 
variable way at 6 hr and 24 hr or 48 hr compared to the control, and at 48 hr by MG-63 
and SaOS2. The mechanism underlying this observation is unknown but previous 
studies have reported that IL-17 affects the production of PGE2 from synovial tissue 
cells and osteoblasts. PGE2 decreases OPG levels in SFB and human bone marrow 
stroma cells (hBMSC) (Kotake S et al., 1999; Brandstrorn H. et al., 1998a). In addition, 
PGE2 inhibited OPG production after 16 hr of incubation and the inhibition was 
sustained for 72 hr in human bone marrow stromal cells (Brandstrom H et al., (2001). 
Furthermore, over expression of OPG in ST2 stromal cell line and human bone marrow 
stromal cells is down-regulated by bone-resorbing factors such as glucocorticoids and 
upregulated by vitamin D3 [1,25(OH)2D3], Ca2 ions, or TGF-P (Hofbauer LC, 2000; 
Kong YY. and Penninger JM 2000; Brandstrom et al., 1998a, b; Huang L. at al., 2001). 
In contrast to my findings Nagasawa T, et al., (2002) reported that the production of 
OPG was evident already after 6 hr and increased consistently during the 24 hr while 
OPG decreased at 48 hr in human gingival fibroblasts in response to LPS. 
Generally in this study OPG mRNA expression was detectable in all samples from RA, 
OA and osteoblast-like cells, but the general pattern of OPG expression in response to 
IL-17 and OSM between these samples showed some variation in SFB OA. This 
suggests that there may be considerable heterogeneity between patients. Pulsatelli L et 
al., (2004) demonstrated that there was an age variation in the expression of OPG in 
arthritis patients. In addition, a previous study reported that OPG was highly expressed 
in SFB RA compared to OA and non-inflammatory synovial fibroblasts, and different 
levels of OPG expression were found among patients with RA (Kubota A. et al., 2004). 
Alternatively, the induction of OPG at 6 hr and 48 hr may be due to the secretion of 
IGF-I from the synovial tissue as an initial study reported that IGF-I has an inhibitory 
effect on OPG mRNA at 24 hr. IGF-I, in a dose- and time-dependent manner, regulates 
OPG and RANKL in vitro and in vivo (Rubin J. 2002). However, these different modes 
of regulation may represent an unexpected complexity of the dynamics of IL-1711- 
mediated transcription. The signaling pathway(s) utilized by IL-17 in various cells still 
remain unknown. Several studies have provided further details about the physiological 
and pharmacological relevance of the multiple couplings and their dynamic regulation. 
In the near future we will know more about the signal transduction of IL-17. The 
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increase in the production of OPG opens up the possibility that OPG may have 
therapeutic effects mediated by blockade of the RANKURANK system. 
IL-17 has been shown to promote bone and cartilage destruction, through PGE2, 
RANKL, IL-6, GM-CSF, IL-8 and M-CSF release in vivo and in vitro (Lubberts E et 
al., 2004; Yamamura Y et al., 2001; Chabaud M et al., 2001; Yao, Z. et al., 1995). 
Previous studies have shown that IL-17 probably has a role in the presence of other pro- 
inflammatory cytokines, leading to a synergistic release of cartilage and bone 
degradation factors (Chabaud M et al., 2001). The present study has investigated the 
effect of IL-17 combined with OSM on the expression of RANKL and production of 
OPG in vitro. IL-17 combined with OSM affects on the expression of OPG and 
RANKL mRNA by RA and OA synovial fibroblast cells. In contrast, Koshy PJ. et al., 
(2002) reported that IL- 17 in combination with other proinflammatory cytokines such as 
TNF-a, IL-1, OSM and IL-6 promote chondrocyte mediated MMP dependent type 11 
collagen release from cartilage. However, IL-17 may in combinatidn with other 
proinflammatory cytokines have effects on bone degradation through the release of 
factors that cause osteoclastogenesis (Kotake S. et al. 1999). In addition, Langdon C. et 
al., (1997) and Hui W et al., (1997) both demonstrated that OSM was detectable in 
variable levels in synovial fluids of RA patients but not in OA patients. However, the 
results lead to the suggestion that OSM may have another role in combination with IL- 
17. OSM may function in equilibrium with IL-17 to affect the expression of RANKL 
and OPG. It is also possible that these cytokines are produced in different positions or 
at different point in time in unhealthy joints. However, a previous study shows that 
OSM effects the up-regulation of RANKL and its receptor RANK in the periosteum, 
while osteoclasts were not detected at sites of bone apposition (de Hooge AS. et al., 
2002). 
Also in this thesis MG-63 and SaOS-2 cells showed some synergistic effects on the 
expression and production of OPG mRNA in response to the combination of IL-17 and 
OSM. This combination had no effect on the expression of RANKL mRNA. However, 
IL-17 activates NF-kB and/or AP-1 while OSM transduces its signal via gpl30 and LIF 
receptor-P or OSM receptor-P (Mosley et al., 1996). In mice, OSM leads to activation 
of the mitogen activated protein kinase (MAPK) cascades and the Janus kinase-signal 
transducers and activator of transcription (JAK/STAT) pathway, and modulation of AP- 
I (Kasza A et al., 2001; Taga and Kishimoto 1997; Korzus E et al., 1997). 
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From results from RA and OA synovial fibroblasts, I suggest that the presence of both 
of these cytokines in the same area together may modulate the effects of each other on 
the expression of RANKL and OPG and on the production of OPG. OSM may decrease 
the effect of IL-17 alone. Therefore the combination of IL-17 and OSM together in 
vivo may decrease expression of RANKL mRNA in arthritis which may lead to a 
decrease in osteoclast differentiation, formation and activation decreasing 
osteoclastogenesis and lowering bone and cartilage degradation. OSM has a potentially 
important function in the modulation of chemokine and MMP production by synovial 
cells of the joint (Langdon C. et al., (1997). However, the exact proportion of IL-17- 
producing T cells and OSM and its function remain to be determined. The relative 
balance of 11-17 and OSM in arthritis might therefore be important in controlling the 
level of joint destruction. Control of such an effect may lead to a therapeutic anti- 
inflammatory property. 
Osteoclasts are highly specialized multinucleated cells which are uniquely capable of 
lacunar bone resorption; these cells are formed by fusion of marrow-derived 
mononuclear phagocytic osteoclast precursors which circulate in the monocyte fraction 
of peripheral blood (Fujikawa Y., et al., 1996; Massey HM, et al., 1999). Osteoclast 
differentiation from haematopoietic and circulating osteoclast precursors occurs in the 
presence of M-CSF and RANKL, which is expressed by bone stromal cells (Lacey DL. 
et al., 1998; Yasuda H, et al., 1998). RANKL interacts with RANK, which is present on 
osteoclast precursors (Nakagawa N. et al., 1998). In this study IL-17 induced a 
significant increase in the numbers of multinucleated TRAP-positive cells in PBMC 
cultures. These results suggest that IL-17 stimulation leads to the fusion of 
preosteoclasts. IL-17 induces the expression of TRAP-positive activity in 
multinucleated cells with and without M-CSF. 
Studies further examined the role of IL-17 on osteoclastogenesis by measuring 
resorption of ivory wafers in culture. IL-17 with and without M-CSF significantly 
induced osteoclast formation and excavation of resorption lacunae. Co-culture of 
PBMC and synovial fibroblasts from RA and OA on ivory slices showed increased 
resorption compared to the cultures of PBMC alone. Therefore, IL-17 may increase the 
production of RANKL and M-CSF from PBMC and SFB cells. Moreover, the cell to 
cell contact in the co-culture may increase the response of the cells to each other and the 
presence of membrane bounded RANKL by synovial fibroblasts may more effectively 
stimulate PBMC. A previous study demonstrated that membrane-bound RANKL works 
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more efficiently than sRANKL in osteoclastogenesis in murine bone marrow cell 
cultures (Nakashisma T. et al., 2000). 
TNFa and IL-la directly induce osteoclastogenesis in mouse marrow cultures, and 
evidence suggests that in the presence of M-CSF, TNFa is sufficient for inducing 
human osteoclast differentiation from circulating precursors by a process which is 
distinct from the RANK/RANKL signaling pathway (Kudo 0 et al., 2002). However, 
findings presented here is show that there is a dramatic decrease in the resorption area 
when OPG is added to IL-17-treated cultures. These finding suggest that IL-17- 
stimulated bone resorption is RANKL-dependent. The number of TRAP+ve cells and 
the lacunae resorption surface area in PBMC co-cultured with SFB (RA) and in the 
PBMC co-cultured with SFB (OA) are higher than the PBMC cultured alone. These 
results agree with the previous hypothesis by Kotake, et al., (1999) which suggest that 
IL-17 first acts on osteoblasts or other cell type, which stimulates both COX-2- 
dependent PGE2 synthesis and RANKL gene expression, which in turn induces 
differentiation of osteoclast progenitors into mature osteoclasts. IL-17 is therefore a 
crucial cytokine for osteoclastic bone resorption in RA patients. 
In humans, IL-17 generated by T cell activation may play a major role in bone 
resorption via RANKL-mediated mechanisms whether or not M-CSF is present. 
Researchers have suggested that there are two distinct pathways of osteoclast formation, 
one RANKL-independent and the other RANKL-induced (Fig 7.1). These pathways 
may operate under different tissue conditions: physiological (e. g. normal bone turnover) 
and pathological (e. g. RA) with IL-17 enhancing osteoclast formation and bone 
resorption through RANKL. 
Osteoclast adhesion to the bone surface induces cytoskeletal reorganization and cell 
activation. ECM interaction is an important step in initiating osteoclast function 
(Reinholt, F. P., et al., 1990; Lakkakorpi, P. T., et al., 1991). Data presented here shows 
that IL-17 regulates RANKL/OPG production by synovial cells and is capable of 
mediating increased osteoclastogenesis and bone resorption. Therefore understanding 
the role of ECM affects on TRAP activity but not multinucleated cell formation 
although more investigations are need. ECM proteins are involved in the regulation of 
osteoclast activity. In vitro adhesion molecules are needed to induce osteoclast 
spreading and rearrangement (Nakamura, I., et al., 1996). In addition, signaling 
pathways, such as c-Src, c-Cbl, or P13-kinase, are known to be important for 
osteoclastic bone resorption (Soriano, P., et al., 1991 and Tanaka, S., et al., 1996). 
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Pathological Physiological/Pathological 
(inflammatory) (non-inf lammatory) 
TNF-a and IL-1-a IL-17 
ML RANKL 
In-dependent dependen 
Bone resorption] 
Fig 7.1. Possible role of RANKL-dependent and RANKL-independent (cytokine- 
induced) osteoclast formation on pathological resorption associated, respectively, with 
non-inflammatory and inflammatory disorders of bone (Kudo 0 et al, 2002). 
In summary, these finding, support previous data that showed the abnormal phenomena 
in diseases such as RA are characterized by both inflammation and destruction 
Saidenberg Kermanac'h N (2002). Activated T cells within the rheumatoid synovium 
express and produce RANKL and IL-17. IL-17 and RANKL in the pathogenesis of 
chronic arthritis will contribute to improvement of current therapies. This study 
highlights the possibility that OPG may have therapeutic effects mediated by blockade 
of the RANKURANK system. 
Further studies are needed to elucidate the molecular mechanisms by which IL-17 
regulates the expression of RANKL. The affect of IL-17 on the production of RANKL, 
M-CSF and other osteoclastogenesis factors by connective tissue cells. In addition, 
study of the signal transduction pathways of IL-17, TNFa, and RANKL, and the cross- 
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talk between them may lead us to limit their affects on osteoclast formation and diseases 
exhibiting excessive bone destruction. 
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9 Appendix 
The following data has been included in order to give the reader a full account of the 
results presented in Chapter 5 and to allow investigation of the statistical analysis of the 
experiments. However, as previously described in Chapter 5, it is generally easier to 
follow the descriptives and Analysis of Variance (one way), with Tukey or Duncan 
post test. 
VARnAnnl 
Descriptives 
95% Confidence Interval for 
Mn 
N Mean Std Deviation Sid Error Lower Bound UpperBound Minimum Maximum 
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10 136000 4.29987 1.35974 10.5241 16.6759 Boo 20.00 50+25NG/ML 
? -RANKL 3ONG(ML 10 6.2000 1.87380 . 
59255 4.8596 7.5404 4.00 10.00 
M-CSF 25NGtML e 10 5.2000 1.93218 61101 3.817 a 65822 , 
200 8 '00 otat 
T 78 9 6 566718 40 
1 
8 17 10 9572 ()0 
1 
2 4 00 
Table Ape. 12. The descriptive statistical analysis for TRAP+ve multinucleated cells (MNCs) 
formed In vitro from PB1%1C as shown In Fig 6.3. 
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Dp. rAwvkwit VamNA, VAR(W=7 
MuMple Con"risons 
Mean 
Difference 99% Confid nee Inteml 
ROOOOI JV A A 0-3) Std Error SIG LowerBound Upper Bound 
. 
ý 
2. -5.4889* 1.48468 010 -109622 -. 0156 
3- L-1 5ONGM -9.2222* 1.52325 . 000 -148377 -3.6067 
4-RAN(L+M-CSF 
-14 4889' 1 48468 000 -199622 . 9.0156 30+25NC4& . . . 
5-IL-17+M-CSF 
5+25NGIR& -12 0889* 1.48468 . 000 -17.5622 . 4.6156 
6-IL-17+M-CSF 
50+25NGNL -114889* 1.48468 . 000 -169622 . 6.0156 
7-RANKL 3ONGAAL . 4.0889 1.48468 . 124 -9.5622 1.3844 8-M-CSF25NGA& -30889 148468 . 437 -85622 23844 2-IL-17 5 NC-A& I-CONT 5.4889* 1.48468 . 010 . 0156 10.9622 3- L-1 5ONG&L -3.7333 1.48468 . 207 -9.2066 1.7400 4-RANKL+M-CSF 
30+25NGIN& . 9.0000* 1.44508 . 000 -14.3273 . 3.6727 
5-L-17+M-CSF 
5+25NG&L -6.6000* 1.44508 . 001 -11.9273 . 1.2727 
6-IL-17+M-CSF 
50+25NG%L -6.0000* 1.44508 . 002 -11.3273 -. 6727 
7-RANKL 30NG&L 1.4000 1.44508 . 977 -3.9273 87273 S-M-CSF 25NCv%t 24000 1 "508 . 712 -2.9273 7.7273 3- IL-1 5ONG(ML I -CONT 9.2222* 1.52325 36067 14.8377 
2-IL-1 75 NGNL 3.7333 1.48468 . 207 -1.7400 9.2066 4-RANKL+M-CSF 
30+25NG(kt -5.2667 1.48468 . 015 -10.7400 . 2066 
5-IL-17+M-CSF 
5+25NCO& -2.8667 1.48468 . 535 -8.3400 2.6066 
6-IL-17+M-CSF 
50+25NG&t -2.2667 1.48468 . 790 -7.7400 3.2068 
7-RAWL 3ONCO& 5.1333 1.48468 . 020 -. 3400 10.6D66 8-M-CSF 25NG%L 6 1333* 148468 . 002 . 6600 116086 4-RANKL+ki-CSF 1-CONT 14.48891 1.48468 . 000 9.0156 19.9622 30+25NC, IM 2-IL-17 5 NGIM 9.0000, 1.44508 . 000 36727 U. 3273 3- IL-1 5ONCO& 5.2667 1.48468 . 015 -. 2066 10.7400 5-IL-17+M-CSF 
5+25NGIM 2.4000 1.44508 712 -2.9273 7.7273 
6-IL-17+M-CSF 
50+25NGUL 3.0000 1.44508 . 440 -2.3273 8,3273 
7-RANKL30NCO& 10.4000* 1.44508 . 000 5.0727 15.7273 8-M-CSF 25NGA& 114000* 144508 . 000 60727 187273 5-IL-17+M-CSF I-CONT 12.0689* 1.48468 . 000 6.6156 17.5622 5+25NGIM 2-IL-17 5 NG(M 6.6000* 1.44508 . 001 1.2727 li. 9273 3- IL-1 5ONGIML 28667 1.48468 . 535 -2.6066 8.3400 4-RANKL+M-CSF 
30+25NCdM . 2.4000 1.44508 . 712 -7.7273 2.9273 
6-IL-17+M-CSF 
60+25NC, lh& . 6000 1.44508 1.000 -4.7273 5.9273 
7-RANKL MGM 8.0000* 1. "508 . 000 2.6727 131273 8-M-CSF25NGIML 9 0000* 144508 . 000 1 3.6727 143273 6-IL-17+M-CSF I-CONT 11.4889' 1.48468 . 000 6.0156 16.9622 50+25NG&L 2-IL-17 5 NG%t 6.0000, 1.44508 . 002 . 6727 11.3273 3- IL-1 5ONGN& 2.2667 1.48468 . 790 -3.2066 7.7400 4-RAWL+M-CSF 
30+25NG%L -3.0000 1.44508 . 440 -8.3273 23273 
5-IL-17+M-CSF 
5+25NGIML -. 6000 1.44508 I. DDO -5.9273 4.7273 
7-RANKL 30NC.? & 7.4000* 1.44508 . 000 2.0727 U 7273 B-M-CSF25NGIML 840001 1.44506 . 000 30727 137273 7-RANKL 30NG(ML I-CONT 4.0889 1.48468 . 124 -1.3844 9ý5622 2-IL-17 5 NGIR& -1.4000 144508 . 977 -6.7273 3.9273 3- IL-1 SONGUL -5.1333 1.48468 . 020 -10,6066 . 3400 4-RokWL+M-CSF 
30+25NG, A& -10.4000* 1.44508 GW -15.7273 -50727 
5-IL-1 7+M-CSF 
5+25NG/ML -8. OGDG* 1.44508 . 000 -133273 -2.6727 
B-IL-17+M-CSF 
50+25NG(ML . 7.4000' 1.44508 ODO -12.7273 . 2.0727 
8-M-CSF 25NGNL I. ODOO 144508 997 . 43273 6.3273 
B-M-CSF 25NGI&L I. Cow- 3.0889 1.48468 . 437 -2.3844 6.5622 2-IL-17 5 NG&L -2.4000 1.44508 . 712 . 7.7273 2.9273 3- IL-1 5ONG&t -6.1333* 1.48468 . 002 -11.6068 -. 6600 4-RANKL+M-CSF 
30+25NG(ML . 11.4000' 1.44508 . 000 -18.7273 -6.0727 
5-IL-1 7+M-CSF 
5+25NGtý& -O. OODO* 1.44508 DDO -14.3273 -3.8727 
6-IL-1 7+M-CSF 
50+25NGAAL -8.4000* 1.44508 . 0m -13.7273 -30727 
7-RANKL 30NGtM -1.0000 144508 . 997 . -63273 43273 i no mean amerence is signtficant at the xi ievei. 
Table Ape. 1b. the statistical analysis (ANOVA) for TRAP+ve multinucleated cells 
(MNCs) formed in vitro from PBMC as shown In Fig 6.3.226 
Appendix 
Descriptives 
VA; Znnnn? 
95% Confidence Interval for 
Mean 
N Mean Std. Deviation Std. Error LowerBound UpperBound Minimum Maximum 
I=cont 21 2.0952 1.60950 . 35122 1.3626 2.8279 . 
00 6.00 
2=IL-1 75 ng/mI 21 5.1905 1.32737 . 
28966 4.5863 5.7947 2.00 7.00 
3-IL-17 50 mglrrd 19 9.8947 2.86540 . 65737 8.5137 
11.2758 5.00 14.00 
4=RANKL 30 ng/m 20 15.2500 3.65449 81717 13 5396 16 9604 10.00 24.00 
+ M-CSF 25 ng/ml . . . 
5= IL- 17 5 ng/ml + 20 12.2500 3.59642 80418 10 5668 9332 13 7.00 21.00 M-CSF25ng/mI . . . 
6= IL-17 50 ng/mI 20 12.5500 3.60519 . 
80614 10.8627 14.2373 8.00 20.00 
+M-CSF 25ng/ml 
7=RANKL 30 ng/m 20 4.5500 1.31689 . 
2W7 3.9337 5.1663 2.00 7.00 
8=M-CSF 25ng/ml 20 4.0000 1.52177 . 
34028 3.2878 4.7122 2.00 7.00 
Total 161 
, 
8.1553 5.24709 . 
41353 7.3386 8.9720 . 
00 24.00 
Table Ape. 1 a. The descriptive statistical analysis for TRAP+ve multinucleated cells (MNCs) 
formed In vitro from PBMC as shown In Fig 6.3. 
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P-A-0 %/Aonnnn7 
Multiple Comparisons 
Mean 
Difference 99% Confidence Interval 
(I)VAR00001 (I-J) Sid. Error Sin LowerBound Uooer Bound 
Tukey HSO 1-cont -3.0952* . 81162 . 005 -6.0159 
1740 
3-IL-1 7 50 mgtml -7.7995* . 83270 . 
000 -10.7960 -4.8030 
4-FtANKL 30 ng/ml 
-13 1548* . 82170 . 000 -16.1117 -10.1978 + M-CSF 25 ng/ml , 
5- IL-17 5 ng/ml + 
-10 1548* 82170 . 000 -13.1117 -7.1978 M-CSF 25 ng/ml . . 
6- IL-17 50 ng/ml S. -10 454 82170 . 000 -13.41ir -7.4978 +M-CSF 25ng/ml . . 
7-RANKL 30 ng/ml -2.4548 . 82170 . 063 -5AI 17 . 
5022 
8-M-CSF 25ng/ml . 1.9048 . 82170 . 
291 -4.8617 1.0522 
2-IL-17 5 ng/ml I -cont 3.0952* . 81162 . 005 . 1746 
6.0159 
3-IL-17 50 mg/ml -4.7043* a3270 . 000 -7.7008 -1.7077 
4-RANKL 30 ng/ml 
-10 0595* . 82170 . 000 -13.0165 -7.1026 + M-CSF 25 ng/ml . 
5- 11-47 5 ng/ml + 
-7 0595* 82170 . 000 -10.0185 -4.102G M-CSF 25 ng/ml . . 
6- IL-17 50 ng/ml 
+M-CSF 25ng/ml -7.3595* . 82170 . 
000 -10.3165 -4A028 
7-RANKL 30 ng/ml . 6405 . 82170 . 994 -2.3165 
3.5074 
B-M-CSF25ng/rnl 1.1905 . 82170 . 833 -1.7685 
4.1474 
3-IL-1 7 50 rngAnl I-cont 7.7995* . 83270 . 000 4.8030 
10.7960 
2-IL-17 5 ng/ml 4.7043* . 83270 . 000 
1.7077 7.7008 
4-FtANKL 30 ng/ml 
-5 3553* 84253 . 000 -8.3872 . 
2.3234 
+ M-CSF 25 ng/ml . . 
5- IL-17 5 ng/ml + 
-2 3553 84253 104 Q5 3872 . 678a M-CSF 25 ng1ml . . . . 
6- IL-W 50 ng/ml 
-2 6553 84253 040 -5.6872 . 3768 +M-CSF 25ng/ml . . . 
7-FLANKL 30 nglml 5.3447* . 84253 . 
000 2.3128 8.3766 
8-M-CSF 25ng/rnl 5.8947* . 84253 . 000 
2.8628 8.9266 
4-RANKL 30 nglml I-cont 13.1548* . 82170 . 000 10.1978 
16.1117 
M-CSF 25 ng/ml 2-IL-17 5 ng/ml 10.0595* . 82170 . 000 7.1026 
13.0165 
3-IL-17 50 mglml 5.3553* . 84253 . 000 2.3234 
8.3872 
5- IL-17 5 ng/ml + 
- 3 0000* 83166 010 0072 5.9028 , SF 25 ng/ml M4 . . . . 
6- IL-17 50 ng/ml 2.7000 . 83166 030 - 2928 5.6928 +M-CSF 25ng/ml . . 
7-PtANKL 30 ng/ml 10.7000* . 83166 . 000 7.7072 
13.6928 
B-M-CSF 25ng/ml 11.2500* . 83168 . 000 8.2572 
14,2428 
5- IL-17 5 nglml + I-cont 10.1548* . 82170 . 000 7.1978 13.1117 M-CSF 25 ng/ml 2-IL-17 5 nglml 7.0595* . 82170 . 000 4.1026 10.0185 
3-IL-1 7 50 mg/ml 2.3553 . 84253 . 104 -. 6766 5.3872 
4-RANKL 30 ng/ml 
+ M-CSF 25 ng/ml -3.0000* a3166 . 010 -5.0928 -. 0072 
6- IL-17 50 ng/ml 
+ M-CS F 25 n g/rn 1 -. 
3000 . 83166 1.000 -3.2928 2.6928 
7-RANKL 30 ng/ml 7.700G* . 83166 . 000 4.7072 10.6928 
8-M-CSF 25ng/ml 8.2500* . 83166 . 000 5.2572 11: 2428 
6- IL-17 50 nglml I-cont - 10.4548* . 82170 . 000 7.4978 13.4117 +M-CSF 25ng/ml 2-IL-17 5 ng/ml 7.3595* . 82170 . 000 4.4026 10.3165 
3-IL-1 7 50 mg/rn 1 2.6553 . 84253 . 040 -. 3766 5.6872 
4-RANKL 30 ng/ml 
+ M-CSF25 ng/ml -2.7000 . 
83168 . 030 -5.6928 . 2928 
5- IL-17 5 ng1ml + 3000 83168 1.000 -2 6028 2928 3 M-CSF 25 nglml . . . . 
7-RANKL 30 ng/rnl 8.0000* . 83166 . 000 5.0072 10.9928 
8-M-CSF 25ng/rni 8.5500* . 83166 . 
000 5.5572 11,5428 
7-PLANKL 30 ng/ml I-cont 2.4548 . 82170 . 
063 -. 5022 5.4117 
2-IL-17 5 ng/ml -. 6405 . 82170 . 
994 -3.5974 2.3165 
3-IL-1 7 50 mg/ml -SZ447* . 84253 . 
000 -a. 3766 -2.3128 
4-RANKL 30 ng/ml 
-10 7000* . 83166 . 
000 -13.6928 -7.7072 + M-CSF 25 ng/ml . 
5- IL-17 5 nglml + 
-7 7000* 83166 . 000 -10 6928 7072 -4 M-CSF 25 ng/ml . . . . 
6- IL-iT 50 nglml 0. -8 000 83166 . 000 -10.9928 -5.0072 +M-CSF 25ng/ml . . 
8-M-CSF 25ng/ml 
. 
5500 . 
83168 . 
998 -2,4428 3.5428 
8-M-CSF25ng/ml I -con t 1.9048 . 82170 . 
291 -1.0522 4.8017 
2-IL-17 5 ng/ml -1.1905 . 82170 . 
833 -4.1474 1.7885 
3-IL-i 7 50 mg1ml -5.8947* . 
84253 . 
000 -8.9266 2.8628 
4-PtANKL 30 ng/ml 
. 11.2500* . 
83166 . 
000 -14.2428 -8.2572 + M-CSF 25 ng/m 
5- IL-17 5 ng/ml + 
-8 2500* . 
83108 . 
000 -11.2428 -5.2572 M-CSF 25 nglml . 
6- IL-17 50 nglml 
-8 5500 . 
83160 . 
000 -11.5428 -5.5572 +M-CSF 25ng/ml . 
7-RANKL 30 mg/ml -. 5500 
1 
. 
83166 . 
998 -35428 24428 
'. The mean diffeience is significant at the . 01 level. 
Table Ape. lb. the statistical analysis (ANOVA) for TRAP+ve multinucleated cells 
(MNCs) formed in vitro from PBMC as shown in Fig 6.3. 
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Descrlptlves 
VAR(X=2 
95% Confidence Interval for 
Mean 
N Mean Std. Deviation Sid. Error Lower Bound Upper Bound Minimum Maximum 
1=OPG 16 1.6000 1.04115 . 26029 1.0452 2.1548 . 50 4.30 
2=IL-17 5 16 3.1938 1.10843 . 27711 2.6031 3.7844 1.50 
6.00 
3=IL-17 50 15 3.7667 1.78152 . 45999 2.7801 4.7532 . 60 7.90 
4--RANKLIM-CSF 16 4.9750 3.24459 . 81115 3.2461 6.7039 2.00 
12.50 
5=IL-17 5/M-CSF 16 4.1875 1.51959 . 37990 3.3778 4.9972 . 50 
6.60 
6--IL-17 501M-CSF 16 4.7688 2.15181 . 53795 3.6221 5.9154 1.30 
9.90 
7=IL-i7/OPG 16 1.6562 . 93093 . 23273 1.1602 
2.1523 . 40 
3.60 
8=RANKL/M-CSF/OP 16 2.3750 2.56502 . 64126 1.0082 3.7418 . 50 
10.80 
Total 127 , 
3.3118 2.27375 
. . 20176 2.9125 
3.7111 . 40 12.50 
Table Ape. 2a. The statistical description for the resorption area on Ivory slices In the 
cultures of PBMC alone as shown In Fig 6.5. 
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Denerldm9 VAARNAI VARnn002 
Multiple Comparisons 
Mean 
Difference 95% Confidence Interval 
)VAROMOI MAR (0001 1 
' -J) 
Sid Error Siq L&mer Bound Upper Bound 
-OPG L- 17 5 Tukey HSU 1 -1.5938 . 68967 . 297 47218 . 6343 3-IL-17 50 . 2.16671 . 70107 . 049 . 4.3299 -. 0035 4-RANKUM-CSF -3.3750* . 68967 . 000 -5.5030 -1.2470 5-fL-17 5/M-CSF -2.5875* . 68967 . 006 -47155 4595 6-IL-17 50WSF -3.1687* . 68967 . 000 -5.2968 -1.0407 7-fL-17/OPG -. 0562 . 68967 1.000 -2.1843 2.0718 8-RANKUM-CSF/OPG -. 7750 . 68967 . 950 -29030 1 3530 2-IL-17 5 11-OPG 1.5938 . 68967 . 297 -. 5343 
_ 3.7218 
3-IL-17 60 -. 5729 . 70107 . 992 -2.7361 1,5903 4-RANKUMZSF -1.7812 . 68967 . 173 -3.9093 . 3468 6-IL-17 51M-CSF 9937 . 68967 . 836 -3.1218 11.1343 B-IL-17 50/MZSF -1.5750 . 68967 . 311 4.7030 . 8530 7-IL-17/OPG 1.5375 . 68967 . 342 5005 3.6655 8-RANKL/M-CSF/OPG . 8188 . 68967 . 934 -13093 2.9468 3-IL-17 50 I. OPG 2.1667* . 70107 . 049 . 0035 4.3299 2-IL-17 5 . 5729 . 70107 . 992 -1.5903 2.7361 4-RANKUM-CSF -1.2083 . 70107 . 672 . 3,3715 . 9549 5-IL-17 WM-CSF 4208 . 70107 . 999 -2.6840 1.7424 6-IL-17 SOWSF -1.0021 . 70107 . 842 -3.1663 1.161 ll 7-IL-17/OPG 2.1104 . 70107 . 061 -. 0528 4.2736 8-RANKLA4-CSF/OPG 13917 . 70107 . 496 -. 7716 15549 4-RANKUM-CSF I-OPG 3 3750* . 68967 . 000 1.2470 5.5030 2-IL-17 5 1.7812 . 68967 . 173 -. 3468 3.9093 3-IL-17 50 1.2083 . 701107 . 672 9549 3.37115 5-IL-17 SIMZSF . 7875 . 68967 . 046 -1.3405 2.9155 6-IL-1760/M-CSF . 2062 . 68967 1.000 -11.9218 2.3343 7-IL-17/OPG 3.3188* . 68967 . 000 1.1907 5.4468 8-RANKUM-CSF/OPG 26000, . 68967 . 006 . 4720 47280 5-IL-17 5/"SF I-OPG 2.5875' . 68967 . 006 . 4695 4.7165 2-IL-17 5 9937 . 68967 . 836 . 1.1343 3.1218 3-IL-17 50 . 4208 . 70107 . 999 -1.7424 2.5840 4-RANKUM-CSF 7875 . 68967 . 946 . 2.9155 1.3405 B-IL-17 50/A&CSF -. 5812 . 68067 . 990 -2.7093 1.5468 7-IL-17/OPG 2.5313* . 68967 . 008 . 4032 4.0593 S-RANKLftA-CSF/OPG 18125 . 68967 . 156 -. 3165 39405 6-IL-17 50/M. CSF 1-OPG 3,1687* . 68967 . 000 1.0407 5.2968 2-IL-17 5 1.6750 . 68967 . 311 -. 6530 3.7030 3-IL-17 50 1.0021 . 70107 . 842 -1.1611 3.1653 4-RANKL/M-CSF -. 2062 . 68967 1.000 . 2.3343 1.9218 5-IL-17 &"SF . 5812 . 68G67 . 990 -1.5468 2.7093 7-fL-17/OPG 3.1125* . 68967 . 000 . 9845 5.2405 8-RANKL/M-CSF/OPG 2 3937* . 68967 . 018 . 2657 45218 7-IL-17/OPG I -OPG . 05e2 . 68967 1.000 -2.0718 2.1843 
2-IL-17 5 -1.5375 . 68967 . 342 . 3,6055 . 5905 3-IL-17 50 -2.1104 . 70107 . 061 -4.2738 . 0528 
4=RANKLIM-CSF -3.3188* . 68967 . 
000 -6.4468 -1.1907 
6=IL-17 5/M-CSF -2.5313' . 
68967 . 
008 -46593 -. 4032 
6-IL-17 601"SF -3.1125* . 
68967 . 
000 -6.2406 9845 
8-RANKL/M-CSF/OPG -. 7188 . 
68967 . 967 -28468 14093 
8-RANKL/"SF/OPG I-OPG 
. 7760 . 68967 . 
950 -1.3530 2.9030 
2-IL-17 5 -. 8188 . 68067 . 
934 -2 946a 1.3093 
3-IL-17 50 -1.3917 . 70107 . 496 -3.5649 . 7715 
4-RANKUM-CSF -2.6000* . 
68967 . 006 -4.7280 -. 4720 
5-IL-17 5/M-CSF -11.8125 . 
68967 A56 -3.9405 . 3155 
6-IL-17 50/M-CSF . 2.3937* . 
68967 . 016 -4.6218 -. 2657 
7-IL-17/OPG 7188 68967 . 067 q. 
'. The mean clifference is significant at the . 
05 level. 
Table Ape. 2b. The statistical analysis (ANOVA) for the resorption area formation on Ivory 
slices in the cultures of PBMC alone as shown in Fig 6.5. 
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Descriptives 
VAJZD0002 
95% Coniclence interval for 
Wan 
N Wan Std. Deviation Std. Error Lower Bound UpperBound Minimum Maximum 
I=CPG 38 12105 . 96136 . 15595 . 8945 1.5265 . 10 4.50 
2=L-17 5 38 3.5132 2.09712 34020 2B239 4.2025 30 10.30 
3=L-17 50 35 53229 2.93439 A9600 43149 6.3309 . 60 13.00 
4=1RANKLUýCSIF 39 62590 5.14821 B2437 5.1901 8.5278 50 18.00 
S=L-17 5MCSF 40 3.9725 2.52942 39994 3.1636 4.7814 30 12.20 
6=L-1750/M-CSF 39 5.6667 2.66294 A2641 4BO34 6.5299 1.60 Il 1.40 
7=L-1750/CPG 37 29162 1.87328 30797 22916 3.5408 . 80 7.30 
8=RANKLM-CSFOPC 40 1.7725 1.36288 21549 13366 2.2084 . 10 5.30 
9=M-CSF 40 1 ý9 775 1.10789 . 17517 1.6232 2.3318 30 
4.70 
Total 346 , 3B737 3.15045 , . 16937 33406 4.0068 . 10 
18.00 
Table Ape. 3a. The statistical description for the resorption area on Ivory slices In the co- 
cultures of PBMC and Synovial fibroblasts from RA as shown In Fig 6.8. 
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RopleconvNdsons 
W 99%Ovidi ncBtnOwd eence 
R MI A ool j Igjz_ Low BoIrd lkxerlgýh T J j W T, O" HSD -13026, 419443 . 004 -4.4571 , 
3-L4750 -4112r . 80703 . 000 -6.3125 
4.9122 
4-FfkNIGJMCSF -6. ""* . 59060 
ODD -7.7890 4. M79 
S-L47 5A4CSF -2.7w Am Doo 
6%6 
G-L4750MCSF .4 4561* _vm . 000 -6 5w 
413155 
? -L47501CPG -1.7w Mw . 105 -35748 
AW3 
8-F7ANKUMCSRMO -im Aam . 999 .2 6M 
1.56% 
9*ACSF '76M . 58095 
929 -2 am 1 NX 
24L-17 51 -CPG 2.3026' . 59"3 . 004 . 1482 
4.4571 
3-L4750 -1 aw W703 . 074 -4 OD95 
3904 
4-FANKLUCSF . 3.345r A= . 000 -GASU 
4252 
5-L475A4CSF 4593 . 5m . 997 -21M 
i. 6m 
G-L4750#ACSF . 2.1535* Agm OD9 -42941 '0129 
7-0-47 501 CPO . 5" SPU3 . 906 -i_lvm 
2.70% 
8-FANKLNACSRCPG 1.7407 Mm . 078 3867 
3.86M 
9-MCSF 15357 -58M . 184 -5917 " 
3 66M 
3-IL-17 50 1. (PG 4,1123' . 60703 . 000 
5 122 63125 
2-L475 1.8097 wm . 074 3904 
4 OOM 
4-R%NKJMCSF 4.5361 . 80329 
214 -3,722? s5m 
S-L475hiCSF 1.3504 M971 . 375 9? 32 
3.524D 
M47 50/MCSF 3435 wm 1.000 . 2.5304 1.843 
7-L4? 50/CPG 24(W . 61095 . 003 . 
1923 46210 
$-RkmaAhcspcpG 15504* M971 . 000 1.370B 
5.724D 
9-MCSF 334541 . 59971 000 11715 
5 5HO 
4, qkNOQA4CSF i -(PG 5.64W . 5ww OUO &5079 
7.750 
2-L4? 5 3,345V Mm . 000 U= 
SAM 
3-L4750 1.5361 . 80329 214 Imm 
V227 
5-L47 5A4CSF 2.886T -%" . 000 IM 
OM 
G-L4750MCSF 11923 . 58676 . 522 -. 9343 
3.316D 
T-L4? SOICPG 3.942r mm . 000 1.7875 
&OGM 
54*AKL/MCSRCPG &OBW . 5ow zgrs 
7.19M 
OýMCSF 4 OWS' W308 . 000 2 76M 
69" 
5-4L-17&WSF I-CPG 7 7W 58695 . 000 . 6346 
48893 
2-L475 . 4503 . 997 -1.66W 
2.5W 
3-L4750 4.3504 . 59971 . 375 . 
35240 A232 
4*WJAQJMCSF -Za8W . 58" . 
000 -4 OM M2 
G-L4750#ACSF -16942 . 55308 . 
091 -3.8075 A192 
7-L4? 50/CPG 1.0563 . 59100 . 
691 4.08M 3.19M 
a-FONIQJMCSRMG 22000' . 57MB . 
005 . 1001 
42am 
9-MCSF 19950 . 018 -1049 
4090. 
fplL-l7504ACW I-CPG C4561* . 5m . 
000 13155 a5w 
2-L475 Z15W . 59060 . 
009 
. 0129 
42M 
3-L4750 -Um AD329 
1.0m -1 am 2. W 
4-RVAQA4CSF 4.1923 -We 
m -3.3190 a343 
5-L475#ACSF IAQ sm . 091 4192 
38015 
7-L4750/CPG Z75W . 
59M . 000 JS953 
4,90eB 
S-RVA<LWSRCPG M42' . 5m . 
000 1.7" 6 OD75 
9-MCS F Mor . 000 Ism 58oz. 
74L-17 501 CPG I -CPG 1.7057 . 59W . 
105 4633 3.8745 
2-1.475 -zmo . 59843 . 
986 . 27650 1 572D 
3-L4750 -2.40W . 51095 
OD3 . 46210 1123 
4-F*J*QWSF . 3.942r . 59M . 
000 . 60990 4.7676 
5-L475#ACSF -1.0563 '59100 . 
091 . 31963 1.00S 
G-L47 50MCSF -2.75M* . 000 . 4.9056 5M3 
a-f*j4QjmcsRa, G 1.1437 Mloo m 9983 32M 
9-MCSF 9M7 . 5Dloo 
all -12033 308(a 
044%NPQAACSRCPG I -CPO iE-T An -i-MM 2.680 
2-L475 -1.7407 . 58M . 
078 48600 3867 
3-L4750 4-%W . 59971 
ODD . 5.7240 4.3768 
4-FANKLOACSF .5 oew . 000 . 7.19M 
41 W32 
5-L475#ACSF -22DO(r . 005 -429M 
ICDI 
6ý1.4730#ACSF -3 aw . 50308 . 
000 .6 OD75 4,7006 
7-L4750/CPG -11437 . 59100 . 
590 42858 9983 
9-MCSF -205D 579M I OOD .2 3D49 
i no 
9-MCSF i-CPG . 7670 . 58m . 
929 . 1.3604 Z890 
2-L475 -i_lw wm . 154 -3 MM 
591? 
3-L4750 &345e . 5N7i . 
5.5190 4,1718 
4-FANKLAACSF -4,8815' W" 
ODO 49M 4.7582 
5-L475A4CSF 4.9950 . 57938 . 
018 -4.0949 . 1049 
G-L4750MCSF -&6w W308 ODD . 8.8025 
4558 
7-L4750/CPG 9381 . 59100 . 
811 . 3.0800 12033 
6-4*, NKLIACSRMG I 2MMO 579M I low -18949 23M 
'- ThOmeandfw6ceialigifeedd to. (" IML 
Table Ape. 3b, The statistical analysis (ANOVA) for the resorption area on ivory slices in 
the co-mitures of PBMC and Synovial fibroblasts fmmRA as shown in FIg 6.8. 
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Descriptives 
vAnnnrm 
95% Confidence Interval for 
Mean 
N Mean Std. Deviation Std. Error LowerBound Upper Bound Minimum Maximum 
-OPG 19 2-5579 1.59559 . 36605 1.7888 3.3269 . 40 7.00 
3-L-1750r, 4M 17 4.1059 1.45794 . 353W 3.3563 4.8555 1.90 7.40 
4zRANI(1jU-CSF 17 5.3118 1.75103 . 42469 4.4115 6.2121 2.20 8.80 
S-L-17 SW3. U-CSF 17 5.0118 1.91764 . 46510 4.0258 5.9977 1.20 7.90 
6XIL-117 SONGU-CS1 16 &8500 1.34858 . 33714 5.1314 6.5686 3.80 8.30 
IToW 86 1 45058 1 1.98265 1 . 21379 1 4.0807 1 4.9309 1 . 40 1 8.80 
Table Ape. 4a. The statistical description for the resorption area on dentine 
slices In the co-cWtures of PB, '%IC and Synovial fibroblasts from RA as shown In Fig 6.10. 
Multiple Comparisons 
r%ar. arwtmod VurinWgo- VARMAY17 
Mean 
Difference 99% Confidence Interval 
(1) VAROMI (J)VAR00001 (I-J) Std. Error sio. LowerBound Upper Bound 
Tukey HSO -C+4ti 3- IL-1 7 bOng/n-d -1.5480 . 54392 . 043 -3.3790 . 2830 
4=RANKLIM-CSF -2.7539* . 54392 . 000 -4.5849 -. 9229 
SmIL-17 5NG/M-CSF -2.4539* . 54392 . 000 -4.2849 -. 6229 
6=11--l 7 5ONGIM-CSF -3.2921* . 55282 . 000 . 5.1531 -1.4311 
3=IL-1 I 50ng/" =OPG 1.5480 . 54392 . 043 -. 2830 3.3790 
4-RANKLA4-CSF -1.2059 . 55883 . 206 -3.0871 . 6753 
S=IL-17 5NGIM-CSF -. 9059 . 55883 . 489 -2.7871 . 9753 
6=[L-17 50NGIM-CSF . 1.7441 . 56749 . 023 -3.6545 . 1662 
4zRANKLM-CSF =OPG 2.7539* . 54392 . 000 . 9229 4.5849 
3= IL-1 7 50ng/ml 1.2059 . 55883 . 206 -. 6753 3.0871 
5=IL-17 5NG(M-CSF . 3000 . 55883 . 983 -1.5812 2.1812 
6=IL-175ONGIM-CSF -. 5382 . 56749 . 877 -2.4486 1.3721 
5-L-1 7 5NG(M-CSF =OPG 2.4539* . 54392 . 000 . 6229 4.2849 
3-IL-1 7 50nglrrd . 9059 . 55883 . 489 -. 9753 2.7871 
4=RANKLAA-CSF -. 3000 . 55883 . 983 -2.1812 1.5812 
6=[L-17 50NGIM-CSF -. 8382 . 56749 . 580 -2.7486 1.0721 - 6zIL-1 7 5ONGIM-CSF =OPG 3.2921 . 55282 . 000 1.4311 5.15i l 
3=IL-17 50ng/ml 1.7441 . 56749 . 023 -. 1662 3.6545 
4=RANKLJM-CSF . 5382 . 56749 . 877 -1.3721 2.4486 
S=IL-17 5NGIM-CSF . 8382 . 56749 . 580 -1.0721 2.7486 
*-The mean difference Is significant at the . 01 level. 
Table ApeAb. The statistical analysis (ANOVA) for the resorption area on dentine 
slices In the co-cultums of PB, '*IC and Synovial fibroblasts from RA as shown In Fig 
6.10. 
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Descriptives 
ARFAFRAr 
95% Confidence Interval for 
Mean 
N Mean Std. Deviation Std. Error Lower Bound UDDer Bound Minimum Maximum 
I-OPG 33 1.6848 1.57185 . 27362 1.1275 2.2422 . 30 8.40 
2-L-17 5r*hd 34 2.9588 1.26494 . 21694 2.5175 3.4002 
1.10 5.60 
3-L-1750nglrri 34 4.9912 1.86846 . 32044 4.3392 5.6431 1.90 
9.70 
4-RANKL+M-CSF 33 6.6273 2.86108 . 49805 5.6128 7.6418 1.30 13.10 100+30ngtrrd 
5--L-17+M-CSF 34 3.9794 1.90991 . 32755 3.3130 4.6458 . 80 9.40 5+30ng/rrJ 
6-L-17+WCSF 34 4.5294 1.51068 . 25908 4.0023 5.0565 
1.70 8.60 
50+30n" 
7zL. 17+OGP 34 2.1294 1.40853 . 24156 1.6380 
2.6209 . 30 5.20 5+100rghTg 
8=RMO 34 2A324 1.64993 . 28296 1.8567 
3.0080 . 40 6.30 
Total 270 3.6630 2.37422 . 14449 3.3785 3.9474 . 
30 13.10 
Table Ape. 5a. The statistical description for the resorption area on Ivory slices in 
the co-cultures of PBN1C and Synovial fibroblasts OA as shown In Fig 6.11. 
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Multiple Comparisons 
DeDendent Variable: AREAFRAC 
Mean 
Difference 99% Confidence Interval 
(I)TREATMEN (J) TREATMEN (W) Std. Error Sig. ower Bounc Jpper Bounc 
Tukey HS I =OPG 2=IL-17 5ng/ml -1.2740 . 44273 . 081 -2.8538 . 3058 3=IL-17 50ng/m -3.3063* . 44273 . 000 -4.8861 -1.7265 4=RANKL+M-C 
100+30ng/ml -4.9424* . 44602 . 000 -6.5340 -3.3509 
5=IL-17+M-CSF 
5+30ng/ml -2.2946* . 44273 . 000 -3.8744 -. 7147 
6=IL-17+M-CSF 
50+30ng/ml -2.8446* . 44273 . 000 -4.4244 -1.2647 
7=IL-17+OGP 
5+1 OOng/ml -. 4446 . 44273 . 974 -2.0244 1.1353 
8=RMO -. 7475 . 44273 . 695 -2.3273 . 8323 
2=IL-17 5ng/ml I=OPG 1.2740 . 44273 . 081 -. 3058 2.8538 
3=IL-17 50ng/m -2.0324* . 43942 . 000 -3.6003 -. 4644 
4=RANKL+M-C 
100+30ng/ml -3.6684* . 44273 . 000 -5.2483 -2.0886 
5=IL-17+M-CSF 
-1.0206 . 43942 . 285 -2.5886 . 5474 5+30ng/ml 
6=IL-17+M-CSF 5706* .1 . 43942 . 010 -3.1386 -. 0026 50+30ng/ml . 
7=IL-17+OGP 8294 . 43942 . 561 -. 7386 3974 2 5+100ng/Mi . . 
8=RMO . 5265 . 43942 . 932 -1.0415 2.0945 
3=IL-1 7 50ng/ml I =OPG 3.3063* . 44273 . 000 1.7265 4.8861 
2=IL-17 5ng/ml 2.0324* . 43942 . 000 . 4644 3.6003 
4=RANKL+M-C, 
.1 6361 * 44273 . 006 -3.2159 -. 0563 100+30ng/ml . . 
5=IL-17+M-CSF 
5+30ng/ml 1.0118 . 43942 . 296 -. 5562 2.5797 
6=IL-17+M-CSF 4618 43942 . 966 -1.1062 2.0297 50+30ng/ml . . 
7=IL-17+OGP 2 8618* 43942 . 000 1.2938 4.4297 5+1 OOng/ml . . 
8=RMO 2.5588* . 43942 1 . 000 . 9908 4.1268 4=RANKL+M-C. ' 1=OPG 4.9424* . 44602 . 000 3.3509 6.5340 100+30ng/ml 2=IL-17 5ng/ml 3.6684* . 44273 . 000 2.0886 5.2483 3=IL-17 50ng/m 1.6361 * . 44273 . 006 . 0563 3.2159 
5=IL-17+M-CSF 
5+30ng/ml 2.6479* . 44273 . 000 1.0680 4.2277 
6=IL-17+M-CSF 
50+30ng/ml 2.0979* . 44273 . 000 . 5180 3.6777 
7=IL-17+OGP 
5+100ng/ml 4.4979* . 44273 . 000 2.9180 6.0777 
8=RMO 4.1949*1 *44273 1 . 000 1 2.6151 1 57747 
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5=L-17+fACSF I=OPG Z2946* . 44273 . 000 . 7147 
3.8744 
5+30ngfml 24L-17 5rig/ml 1.0206 . 43942 . 2B5 -. 5474 
2.5886 
34L-1750ng/ml -ID118 . 43942 . 296 -2.5797 . 
5562 
4=R, ANKL+gCSF 
-2 6479* 44273 . 000 -4.2277 -1.0680 100+30ngkni . . 
64L-17+KCSF 
-. 5500 43942 915 -2.1180 1.0180 50+30rig/mi . . 
74L-17+OGP 1.8500* 43942 . 001 . 2820 
3.4180 
5+1 00rig/ml . 
8=RMD 1.5471 . 43942 . 012 -. 
0209 3.1150 
6--L-17+M-CSF 1=OPG Z8446* . 44273 . 000 1.2647 
4.4244 
50+30ng/ml 24L-17 5ng/ml 1.5706* . 43942 . 010 . 0026 
3.1386 
34L-17 50ngknl -A618 . 43942 . 966 -2.0297 1.1062 
4=RMKL+M-CSF 
-2D979* . 44273 . 000 -3.6777 -. 5180 100+30ngAmi 
54L-17+M-CSF 
. 5500 . 43942 . 915 -1.0180 
2.1180 
5+3OrKjml 
7=4L-17+OGP Z40DO* 43942 . 000 . 
8320 3.9680 
5+1 00rig/ml . 
8=RMO Z0971 * . 43942 . 000 . 5291 
3.6650 
7=L-17+OGP 1=OPG . 4446 . 44273 . 974 -1.1353 2.0244 
5+100nglml 24L-17 5ng/ml -B294 . 43942 . 561 -2.3974 . 7386 
34L-17 50ngtml -2B618* . 43942 . 000 -4.4297 -1.2938 
4=RPNKL+M-CSF 
-44979* 44273 000 -6.0777 -2.9180 100+30ng/ml . . 
54L-17+M-CSF 
-IB500* 43942 001 -3.4180 -. 2820 5+30ng(ml . . 
64L-17+h4-CSF 
50+30ng/ml -2AOOO* . 43942 . 000 -3.9680 -. 
8320 
8=RMD 
-3029 . 43942 
997 -1.8709 1.2650 
8=RMO I=OPG . 7475 . 44273 . 
695 -. 8323 2.3273 
24L-17 5rg/ml -5265 . 43942 . 
932 -2.0945 1.0415 
34L-17 50nglml -25588* . 43942 . 
000 -4.1268 -. 9908 
4=RANKLAýCSF 
-4 1949* . 44273 . 
000 -5.7747 -2.6151 100+30ng/ml . 
5=4L-17+M-CSF 
-15471 43942 . 012 -3.1150 . 
0209 
5+30ng(ml . 
64L-17+PACSF 
-2 0971* 43942 . 000 -3.6650 -. 
5291 
50+30rig/ml . . 
74L-17+OGP 
3029 43942 * 997 
1.2650 1.8709 
5+1 OOng/ml I I I I I 
*-The meandfferenceis s7igrificantatthe. 01 lewl. 
Table Ape. 51L The statistical analysis (ANOVA) for the resorption area on Ivory 
slices In the co-cultures of PBINJC and Synovial fibroblasts OA as shown in Fig 6.11. 
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